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Recent Development in Understanding Dengue Virus 
Replication 
 






Dengue is the most important cause of mosquito-borne virus diseases in tropical and subtropical regions 
in the world. Severe clinical outcomes such as dengue haemorrhagic fever and dengue shock syndrome 
are potentially fatal. The epidemiology of dengue has undergone profound changes in recent years, due to 
several factors such as expansion of the geographical distribution of the insect vector, increase in 
traveling, and demographic pressure. As a consequence, the incidence of dengue has increased 
dramatically. Since mosquito control has not been successful and since no vaccine or antiviral treatment is 
available, new approaches to this problem are needed. Consequently, an in-depth understanding ofthe 
molecular and cellular biology of the virus should be helpful to design efficient strategies for the control 
of dengue. Here, we review the recently acquired knowledge on the molecular and cell biology of the 




















aa, amino acid; ADE, antibody-dependent enhancement; C, capsid / coat protein; Cdc42, cell division 
cycle 42; cHP, capsid hairpin; CS, cyclization sequence; DAR, downstream of the AUG region; DC, 
dendritic cells; DC-SING, dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin; 
DENV, dengue virus; DF, dengue fever; DHF, dengue hemorrhagic fever; ds, double-stranded; DSS, 
dengue shock syndrome; E, envelope; eEF, eukaryotic elongation factor; eIF, eukaryotic initiation factor; 
ER, endoplasmic reticulum; FcgR, receptor of the Fc portion of IgG; GFP, green fluorescent protein; 
HLA, histocompatibility-linked antigen; HMEC, human microvascular endothelial cell; HSP, heat shock 
protein; IF, intermediate filament; IFN, interferon; IL, interleukin; LC3-II, light chain 3 form II of the 
microtubule-associated protein 1; LD, lipid droplet; M, matrix protein; MT, microtubule; MTase, 
methyltransferase; NC, nucleocapsid; NS, non-structural; nt, nucleotide; NTPase, nucleoside 
triphosphatase; ORF, open reading frame; PABP, poly(A)-binding protein; prM, precursor of M; Rab 5, 
Rabatin-5; Rac1, ras-related c3 botulinum toxin substrate 1; RC, replication complex; RER, rough ER; 
RdRp, RNA-dependent RNA polymerase; RTPase, RNA 5’-triphosphatase; siRNA, small interfering 
RNA; SL, stem-loop; sgRNA, subgenomic RNA; ss single-stranded; TGN, trans-Golgi network; TNF, 
tumor necrosis factor; UAR, upstream AUG region; UTR, untranslated region; V-ATPase, vacuolar 




Although dengue only became a major global medical concern within the last few decades, disease that 
might have been caused by dengue was reported in China as early as the VIIth century. Since then, 
epidemics that may have been caused by dengue have sporadically appeared with outbreaks in the XVIIth 
century in Central America and in Philadelphia in the XVIIIth century. In the XXth century epidemics 
were reported in Southeast Asia and the Pacific, favored by increased expansion of the dengue virus 
(DENV) mosquito vector, Aedes aegypti. This was accompanied by circulation of the four DENV 
serotypes (known as hyperendemicity) and the appearance of dengue hemorrhagic fever (DHF). By the 
1970’s, DHF had become a major cause of death among children in regions where DHF occurred. Since 
then, epidemics have become more frequent and more intense, and cover an ever increasing geographical 
area. Although before the 1980’s Africa had not experienced major epidemics, it now harbors all four 
DENV serotypes (reviewed in Gubler, 1998). DENV continues to be a public health problem in tropical 
and subtropical countries. With the recent increase in dengue epidemics, interest in attempts to control 
dengue has expanded. It has become urgent to control dengue because to date neither animal model, 
vaccine, nor therapeutic measures are available to counteract DENV and the disease. One of the control 
measures adopted had been vector control. However, although this strategy seemed to be highly 
promising, it was later neglected, resulting in renewed epidemics in various parts of the world. Safe and 
efficient strategies will need to be developed to control the vector, and will require the active participation 
of local communities. The aim of the present review is to bring together recent knowledge acquired on the 
molecular and cell biology of the life cycle of DENV in the hope that it might lead to a better 
understanding of dengue diseases. References to recent review articles related to the field of research 
presented here can be found throughout the present review.  
 
II. DENGUE DISEASE 
 
A. The agent  
 
Dengue is the most widespread arthropod-borne viral disease of humans and is caused by DENV. DENV 
is a spherical, enveloped virus with a monopartite single-stranded (ss) positive-sense RNA ssRNA(+) of 
the family Flaviviridae, genus Flavivirus (reviewed in Mukhopadhway et al., 2005). Four DENV 
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serotypes are recognized, DENV-1 to DENV-4 that possess 67-73% identity at the nucleotide (nt) level 
and 69-78% identity at the amino acid (aa) level. Three to six subtypes (genotypes) can be distinguished 
within each serotype (Diaz et al., 2006). Monoclonal antibodies made it possible to identify epitopes that 
are serotype-specific, DENV complex-specific and flavivirus group-reactive epitopes as well as 
intermediate categories. All serotypes have the same transmission cycles and cause similar clinical 
manifestations although serotype- and strain-related differences in virulence exist. Infection by one 




DENV is vectored by Aedes mosquitoes. Humans and A. aegypti are generally the only vertebrate 
reservoir and vector respectively, but forest and rural cycles involving nonhuman primates and Aedes 
species other than A. aegypti exist. A. aegypti breeds mainly in human-made containers and about 2.5 
billion people are at risk in regions where A. aegypti is endemic 
(www.who.int/mediacentre/factsheets/fs117/en/). A general tendency towards increased frequency and 
magnitude of dengue outbreaks has occurred recently. The reasons invoked are demographic, cultural, 
environmental and political (Guha-Sapir and Schimmeer, 2005; Wilder-Smith and Gubler, 2008). 
Prominent factors implicated are increase in global population and in air travel, and rapid and unplanned 
urbanization. This has resulted in the simultaneous circulation of multiple DENV serotypes, known as 
hyperendemicity. Other factors include the increasing use of disposable products that become mosquito 
breeding sites, decay in public health infrastructure, insecticide resistance, and global warming. 
 
C. Clinical manifestations 
 
Infection by DENV results in clinical outcomes ranging from asymptomatic to fatal. Traditionally, 
dengue cases have been classified as undifferentiated fever, dengue fever (DF) and DHF; DHF has been 
further divided in cases with or without shock, the first being designated as dengue shock syndrome 
(DSS). A more recent classification divides the disease into dengue (with or without warning signs) and 
severe dengue; the second category includes cases with significant plasma leakage, hemorrhage or organ 
impairment, comprising the old categories of DHF and DSS, as well as other severe forms of DENV-
induced disease that affect the brain, liver, heart or other organs [World Health Organization (WHO), 
2009]. Although this latter classification promises improved reporting of cases and better medical 
management, here we will often use the more familiar DF, DHF and DSS designations. 
At least half of the DENV infections are asymptomatic or mild. Yet DF is an acute disease characterized 
by fever and pains in the head, eyes, muscles and joints. Lymphadenopathy, rash, nausea and minor 
hemorrhages also occur. The course is usually benign and self-limited. A variable proportion of cases 
evolves into DHF, a condition defined by fever, thrombocytopenia (<100,000 platelets/mm
3
), 
hemorrhages (or a positive tourniquet test) and increased vascular permeability. DHF usually appears 
three to eight days after fever begins. It is often preceded by acute abdominal pain and is commonly 
characterized by hepatomegaly and bleeding from the skin, mucosae and the gastrointestinal tract. Most 
severe DHF cases develop hypotension and other signs of shock that characterize DSS, and can lead to 














No appropriate animal models exist to study DENV infections. Mice can be infected intravenously but 
neither viremia nor disease develops. Monkeys develop an infection but viremias are low and no disease 
is observed. Thus, human infections have supplied most of the information available.  
Human infection begins in the skin with the injection of DENV by the bite of an infected mosquito. 
DENV probably initially replicates in dendritic cells (DC) or macrophages (Wu et al., 2000; Markovich, 
2001) and then migrates to regional lymph nodes from where it spreads to other lymphoid organs through 
the blood stream. It is detected in the plasma and in peripheral blood mononuclear cells. Monocytes, 
macrophages and DCs are major targets of DENV replication, although Kupffer cells, hepatocytes and 
lymphocytes have also been implicated as target cells (Halstead et al., 1977; King et al., 1999). Antibody 
response to DENV infection is different in the first (primary) and subsequent (secondary) infections. In 
the former, a strong IgM response appears by the end of the febrile period, and lasts two to three months; 
IgG appears shortly after IgM, increases moderately and is maintained for years. These antibodies are 
predominant against the infecting serotype but a low titer cross-reactive (heterotypic) response is also 
observed. After a subsequent infection, IgG levels increase more rapidly and to higher levels than in 
primary infections; IgM response is weaker and declines rapidly; antibodies are mostly heterotypic and 
titers are usually higher against the first infecting serotype (Vaughn et al., 1997). Antibodies recognize 
both structural and non-structural DENV proteins, but only those reactive with the E (envelope), M 
(matrix) and non structural (NS) 1 proteins have neutralizing properties (reviewed in Pierson and 
Diamond, 2008). The duration of protection against re-infection with DENV remains unclear. Humans 
challenged with the homologous strain were completely immune to re-infection for as long as 18 months. 
Temporal cross-protection to challenge with a heterologous serotype was demonstrated two to nine 




 T cell immune responses. 
After primary infection, most circulating T lymphocytes are serotype specific, but following a second 
infection with a different serotype, cross-reactive memory T cells predominate and more frequently 




 T lymphocytes can lyse 
DENV-infected cells. DENV-specific lymphocytes release mostly Th1 cytokines, which could be 
important factors in viral clearance as well as in the pathogenesis of DHF (reviewed in Mathew and 
Rothman, 2008).Features of DHF/DSS are increased vascular permeability, bleeding and hepatic 
compromise. Fatal cases present bleeding in the viscera and mucosal membranes, liquid collection in 
serous cavities and midzonal necrosis in the liver. Although mostly a vascular illness, vascular endothelial 
damage is not observed in DHF, suggesting a functional rather than anatomical alteration in the 
endothelium (reviewed in Gubler, 1998; Guzman and Kouri, 2002; Trung and Wills, 2010). Severe forms 
of DHF/DSS are associated with young age, female gender, non-African ancestry and pre-existence of 
immunity against other serotypes. Most severe cases are associated with a heterotypic antibody response 
confirming secondary infection as the main risk factor for DHF/DSS (Sangkawibha et al., 1984; Burke et 
al., 1988; Kliks et al., 1989). The finding of pre-existing heterotypic antibodies in cases of DHF is linked 
to a phenomenon designated antibody-dependent enhancement (ADE). It consists in increased replication 
of certain viruses in cell culture by the addition of immune sera at dilutions beyond the neutralization 
endpoint. This led to the “immune enhancement hypothesis”, whereby non-neutralizing antibodies 
remaining after the first dengue episode bind to the new infecting serotype enhancing virion penetration 
into monocytes and macrophages by interacting with the receptor for the Fc portion of IgG, known as 
FcR (see Section IV. Cell Cycle of DENV. A. Entry and fusion complex formation: E protein and cell 
receptors). This phenomenon would lead to enhanced viral replication and release of soluble factors that 
would mediate increased vascular permeability and hemostatic disorder (Halstead and O’Rourke, 1977; 
reviewed in Halstead, 1981). In spite of considerable efforts, the mechanism involved in ADE remains 
unclear. Dejnirattisai et al. (2010) using monoclonal antibodies against the precursor of M (prM) showed 
that these antibodies even though they cross-react with the various DENV serotypes, are unable to block 
DENV infection, but on the contrary promote ADE. This interaction is likely due to some uncleaved prM 
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remaining on the virus surface of extracellular virions that would allow their recognition by the 
monoclonal antibody. Cellular immune factors are also involved: DENV-specific CD4
+
 cells release 
cytokines such as interferon (IFN)-, interleukin (IL)-2, tumor necrosis factor (TNF)- and TNF- 
(Gagnon et al., 2002). TNF- and IL-2 can induce plasma leakage, and IFN- enhances TNF- 
production by monocytes. IFN- also upregulates the expression of class II histocompatibility-linked 
antigens (HLAs) and of the receptor FcR (the Fc portion of IgG) in monocytes; this could enhance 
DENV antigen presentation and antibody-mediated uptake of the virus, respectively. Increased levels of 
TNF- IL-6, IL-8, IL-10, and of soluble IL-2 and TNF receptors occur in DHF (Hober et al., 1993; 
Chang and Shaio, 1994). Immunity against a different serotype is neither necessary nor sufficient for 
DHF/DSS development. Severe forms of DENV can occur in primary infections (Barnes and Rosen, 
1974; Morens et al., 1987), whereas in other settings DHF/DSS was never observed in spite of frequent 
sequential infections by different serotypes. Viral risk factors associated with severe forms of DENV-
induced disease include the infecting serotype, subtype and strain, the time lapse between infections and 
the order of the serotypes in successive infections. A compelling demonstration of the importance of the 
virus strain in the severity of dengue came from the Americas where epidemic DHF emerged abruptly in 
1981 when a Southeast Asian subtype of DENV-2 was introduced. This subtype then spread across the 
Caribbean, Central and South America displacing the prevalent “American subtype” of DENV-2, which 
had been associated with mild DF cases only (Gubler and Clark, 1995; Watts et al., 1999). The time of 
arrival of the Southeast Asian subtype coincided with the emergence of DHF/DSS in each of these 
regions. At the phenotypic level, certain DENV isolates are more infectious and are disseminated more 
efficiently by A. aegypti mosquitoes than other isolates (Gubler et al., 1978). At the genotypic level, 
consistent differences between isolates of two DENV-2 subtypes were detected in several viral genes 
involved in severity (Cologna and Rico-Hesse, 2003). Thus even minor differences at the molecular level 
can affect the clinical outcome. Yet the specific mechanisms involved are unresolved because the role of 
most viral proteins remains elusive. Elucidation of these roles is of utmost importance to understand the 
molecular basis of virulence and attenuation, which is fundamental to the design of the long-awaited safe 
and efficacious vaccines for dengue. This review will now focus on the molecular aspects of DENV 
replication to describe the viral and cell factors that could be modulating the clinical and epidemiological 
behavior of dengue. 
 
III. DENV GENOME AND DENV PROTEINS  
 
The ssRNA(+) of DENV (Figure 1B) acts directly as mRNA for the synthesis of the viral polyprotein 
(Figure 1C). The genome is approximately 11 kb, bears a type I cap structure (m
7GpppAmG) at its 5’ end, 
but lacks a 3’ poly (A) tail. It encodes a single open reading frame (ORF)flanked by highly structured 5´ 
and 3´ untranslated regions (UTRs) of about 100 and 400 nts respectively (Figure 1B); these regions are 
important for translation regulation, viral RNA replication (Figure 1A) and severity of infection 
(Leitmeyer et al., 1999; Edgil et al., 2003; Holden and Harris, 2004; reviewed in Markoff, 2003; 
Bartenschlager and Miller, 2008). The cap structure is added co-transcriptionally by the virus-encoded 
NS5 protein which contains in a single domain both (guanine-N7)- and (adenosine-2'-O)-
methyltransferase (MTase) activities, and an as yet unidentified guanylyltransferase domain  (Egloff et 
al., 2007; reviewed in Davidson, 2009). The RNA 5‘-triphosphatase (RTPase) domain of NS3 is also 
involved in capping the viral RNA; although the precise role of NS3 in this process has not been well 
characterized, several studies have shown that the NS3 RTPase and the NS5 MTase work together 
removing the terminal - phosphate and performing sequential guanine-N7 and adenosine-2’O 
methylation, respectively (Wengler and Wengler, 1993; Egloff et al., 2002). The cap structure presumably 
stabilizes the mRNA and allows efficient translation (reviewed in Furuichi and Shatkin, 2000). The ORF 
is translated as a single polyprotein of 3,387-3,392 aa that undergoes co- and post-translational cleavages 
by viral and host cell proteinases (Figure 1C). 
 
  




Figure 1. The DENV genome. A: schematic diagram of DENV genome circularization; B: organization 
of the 5’ and 3’UTRs; C: polyprotein. A and B. The viral ssRNA(+) genome is ~11 kb long. The 5’UTR 
contains the large stem-loop A (SLA) the promoter for NS5 the RNA-dependent RNA polymerase 
(RdRP), followed by stem-loop B (SLB) that contains the 5’ upstream AUG region (5’UAR) and the 
translation initiation codon (*). The 3’UAR is complementary to the 5’UAR. Another stem-loop hairpin 
structure (cHP) located within the C protein-coding region enhances selection of the 5’ initiation codon. 
The 3’UTR contains conserved sequences such as the 3’ stem-loop (3’SL) that includes the 3’UAR. The 
3’ cyclization sequence (3’CS) lies upstream of the 3’SL; it is complementary to the 5’CS present in the 
gene encoding the C protein. The predicted 5’-3’UAR and 5’-3’CS sequences are in grey, and 
hybridization between these regions is necessary for genome cyclization and RNA synthesis. C. The viral 
genome possesses one ORF coding for a polyprotein. The genes for the structural proteins are the capsid 
(C), the precursor of membrane protein (PrM) and E, followed by the genes for the NS proteins (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B and NS5). The polyprotein is processed in the cytoplasm by NS2B-
NS3 (closed circles), by a signal peptidase (small arrow), or by an as yet unknown proteinase (open 
triangle) in the lumen of the ER, and prM is processed by furin (closed triangle) in the cellular secretory 
pathway.  
 
In the region of the ORF encoding the capsid (C) protein, a stem-loop hairpin structure designated capsid 
hairpin (cHP) involved in codon start selection and viral RNA replication has been identified (Hahn et al., 
1987; Clyde and Harris, 2006), followed by a 5’cyclization sequence (CS) complementary to a 3’CS in 
the 3’UTR (Figure 1A and B) (Hahn et al., 1987).  
The ORF of over 10 kb comprises from its 5’ to 3’ end, information for the synthesis of three structural 
proteins C, prM and E, and the seven NS proteins (NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5) (Figure 
1C), a feature common to all members of the genus Flavivirus. Yet size heterogeneity exists between the 
non-coding regions, particularly in the 3´UTR (Wallner et al., 1995; Bryant et al., 2005; Mendeiros et al., 
2007). The 5´UTR (Figure 1A, B) bears the stem-loop (SL) A, and the SLB that ends with the initiator 
AUG codon (Brinton and Dispoto, 1988). The SLA acts as promoter element recognized by NS5, which 
contains an RNA-dependent RNA polymerase (RdRp) domain for RNA synthesis (Filomatori et al., 
2006). It harbors a side stem-loop and a top loop, in addition to a U bulge (Lodeiro et al., 2009) that are 
critical for DENV RNA replication. SLB contains upstream of the initiator AUG codon, a sequence 
known as 5′UAR (upstream AUG region), that is complementary to a sequence located at the 3′ end of the 
viral genome (Brinton and Dispoto, 1988; Alvares et al., 2005a).  
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The 3´UTR (Figure 1A, B) includes three regions, a variable region immediately after the termination 
codon of the ORF followed by a core region, and finally a 3´-terminal region. The latter includes a 
conserved 3´SL of ~96 nt (Grange et al., 1985; Brinton et al., 1986; Mohan and Padmanabhan, 1991). 
The 3’SL contains a conserved 3’UAR sequence that is complementary to the 5’UAR located in the 
5’UTR (Figure 1A) (Alvarez et al., 2005a); distal flavivirus-conserved  CACAG Box has also been 
described (Chen et al., 1997; Filomatori et al., 2006; reviewed in Markoff, 2003). The genome contains 
upstream of the 3’UAR, a conserved 3’CS (Hahn et al., 1987) complementary to the conserved 5’CS and 
which together with the 5’UAR and 3’UAR is involved in RNA cyclization (Hahn et al., 1987; Men et 
al., 1996; Clyde and Harris, 2006). Moreover, a sequence located downstream of the initiation codon, 
designated 5’ downstream AUG region (DAR) is involved in DENV replication (Friebe and Harris, 
2010). Co- and post-translational cleavage of the DENV polyprotein is achieved by the viral-coded serine 
proteinase NS2B-NS3, by the cell convertase furin a proteinase of the trans-Golgi network (TGN), and by 
a cell signal peptidase (Falgout et al., 1991; Cahour et al., 1992; reviewed in Lindenbach and Rice, 2003). 
Polyprotein cleavage sites, conserved and unique motifs, important cysteine residues and potential 
glycosylation sites have been characterized (reviewed in Gubler et al., 2007; Mukhopadway et al., 2005). 
Table 1 provides a summary of the major activities so far identified for the viral proteins.  
 
IV. CELL CYCLE OF DENV 
 
A. Entry and fusion complex formation: E protein and cell receptors  
 
Monocytes, macrophages, B and T lymphocytes, hepatocytes, endothelial cells, epithelial cells, DC and 
fibroblasts are all potential targets for DENV infection and replication, and viral antigens have been 
detected in liver, spleen, lymph node, thymus, kidney, lung, and skin cells (Upanan et al., 2008). Hence 
the virus can replicate in a wide spectrum of cells, which might explain its ability to enter via various 
receptors, as discussed below. Receptor binding and membrane fusion characteristics of DENV entry 
have been studied in living cells by real-time fluorescence microscopy, and by direct biochemical or 
genetic analyses. Yet, the reports published on virus entry and on the molecules involved in this process, 
are controversial and may vary with the cell model used. Considerable evidence suggests that the first 
step in a primary infection is attachment of the viral glycoprotein E which is present on the surface of 
mature virions as a homodimer, to cell receptors on the surface of permissive cells (Fig. 2, step 1). The E 
protein consists of three domains. Domain I is in the N-terminal region and provides an organizational 
structure. Domain II or central domain is involved in dimerization and that contains a hydrophobic fusion 
loop essential for fusion of E to the cell membrane. Domain III in the C-terminal region is believed to be 
the receptor recognition and binding domain and has an immunoglobulin-like fold (reviewed in Chin et 
al., 2007; Huerta et al., 2008). The interaction of the E protein with the receptor(s) leads to a series of 
events on the viral particle and in the cell membrane, and also in the cytoskeleton allowing entry of the 
virus. Two types of cell receptors appear to be involved in facilitating entry of DENV into the human 
target cell, depending on the cell (reviewed in Huerta et al., 2008). The first type corresponds to receptors 
of low affinity and specificity, including aminoglycan-type adhesion molecules such as heparan sulfate 
that are expressed in many cell types (Germi et al., 2002; Lin et al., 2002). The second type corresponds 
to lectin-type receptors such as DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-

















M  -N- and C-termini have charged residues 
-Central hydrophobic region that associates with 
-Membrane 
-C-terminal hydrophobic sequence that acts as a signal 
-peptide for translocation to ER 
– Has nuclear localization signal and is found in the 
cytoplasm and nucleus; its role in the nucleus is 
unknown 
– Forms NCs with viral RNA; its dimerization 
triggered 
by viral RNA is required for virus assembly 
– Interacts with the apoptotic protein DAXX inducing 
apoptosis 
– Interacts with human Sec3, a member of the exocyst 
complex, a transcription and translation repressor of 
flavivirus that can retard infection 
Wang et al. (2002), Ma et al. (2004) 
Ma et al. (2004) 
Markoff et al. (1997) 
Tadano et al. (1989), Wang et al. (2002), 
Bulich and Aaskov (1992), Tsuda et al. 
(2006), Sangiambut et al. (2008) 
Ma et al. (2004), Ku¨mmerer and Rice (2002), 
Kiermayr et al. (2004), Lopez et al. (2009), 
reviewed in Bartenschlager and Miller 
(2008) 
Netsawang et al. (2010) 
Bhuvanakantham et al. (2010) 
pr  Precursor of membrane protein M, cleaved into 
pr þ M (26 þ 8 kDa) by furin located in TGN; required 
for infectivity 
– Liberated from polyprotein by host signalase located 
in 
the ER 
– Importance of His39 in the morphology of virus, and 
secretion and entry of virus into cell 
Interaction with E forms spikes on the virus surface, 
and is required for proper folding and secretion of E 
– Interaction with V-ATPase required for proper egress 
of virus 
– pr leaves virions after secretion of particles and 
exposure to neutral pH 
– By interacting with E, the pr peptide prevents fusion 
of 
E to cell membranes 
– pr blocks membrane fusion by binding to virus at 
acidic pH 
– Binds to the claudin-1 tight junction membrane 
protein 
that protects cells from the environment; interaction is 




Elshuber et al. (2003) 
 
reviewed in Lindenbach and Rice (2003) 
 
Pryor et al. (2004) Duan et al. (2008), Li et al. (2008), 
reviewed in 
Lindenbach and Rice (2003) 
Duan et al. (2008) 
Li et al. (2008), Yu et al. (2008a) 
Zhang et al. (2003), Li et al. (2008), Yu et al. 
(2008a, 2009) 
Yu et al. (2009) 
Gao et al. (2010) 
E 50 Intracellularly linked to prM forming heterodimers 
that protect E from premature acidification during 
transit through Golgi 
– Forms outer glycoprotein shell of virus 
– Major target for neutralizing antibodies 
– Cleavage of prM produces reversible conformational 
change in E 
– Protected by pr retained on particle from premature 
fusion to cell 
– Interaction with chaperones (Bip, calnexin, 
calreticulin) required for virus production 
Guirakhoo et al. (1993), Konishi and Mason 
(1993), reviewed in Perara et al. (2008) 
reviewed in Lindenbach and Rice (1997, 
2003) 
reviewed in Halstead (1988), Green and 
Rothman (2006) 
Li et al. (2008), Yu et al. (2008a) 
Li et al. (2008), Yu et al. (2008a) 
Limjindaporn et al. (2009) 
  Specific amino acids determine hemorrhagic disease or 
encephalitis 
– Low pH in Golgi induces change in E structure 
important for formation of fusion complexes 
– Interacts with vacuolar-ATPase important for entry 
and egress of virus at low pH 
– E glycosylation decreases infectivity and increases 
virus release 
– Natural killer (NK) cell-activating receptor NKp44 
interacts with E, leading to activation of NK cells and 
destruction of virally infected cells 
Barker et al. (2009) 
reviewed in Heinz and Allison (2003) 
Duan et al. (2008) 
Lee et al. (2010), Duan et al. (2008) 
Hershkovitz et al. (2009) 
Limjindaporn et al. (2009) 
Hsieh et al. (2010) 
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– Interaction with chaperones in ER facilitates folding 
and assembly of DENV proteins 
– Its transmembrane domain is responsible for 
retention 
and assembly of E on ER 
NS1 46 In flaviviruses, proposed to act early in replication 
cycle 
– May define pathogenesis 
– Possibly interacts with NS4A, thereby participates in 
viral RNA replication 
Lindenbach and Rice (1997, 1999), Muylaert 
et al. (1997) 
Falconar (1997) 
Lindenbach and Rice (1999) 
NS2 22 With NS4A and NS4B, is involved in IFN resistance 
and blocks IFN-b signal 
 
NS2B 14 Cofactor of NS3, forming serine proteinase activity in 
trans; acts in cis to cleave NS2B–NS3 
– Required for proteolytic processing of DENV 
nonstructural proteins 
Westaway et al. (2010) 
Falgout et al. (1991) 
NS3b 70 Has N-terminal region with serine-proteinase acivity 
and C-terminal region with NTPase, RNA helicase, 
and 5’ RNA triphosphatase activities 
– Cleavage activity retained in NS2B–NS3 
heterodimer 
– NS5 stimulates NS3 activities 
– Required for proteolytic processing of DENV 
nonstructural proteins 
– Binds to La protein 
Wengler and Wengler (1993), Li et al. (1999), 
Sampath et al. (2006), Luo et al. (2008a,b) 
Leung et al. (2001), Bera et al. (2007) 
Yon et al. (2005) 
Falgout et al. (1991) 
Garcia-Montalvo et al. (2004) 
NS4 16 C-terminal region known as 2K fragment; involved in 
regulating membrane rearrangements 
– Associates with membranes through its hydrophobic 
regions 
– Probably involved in RNA replication 
– Induces membrane rearrangements resembling 
virus-induced structures 
Zou et al. (2009), Miller et al. (2007) 
reviewed in Lindenbach and Rice (2003) 
Miller et al. (2007) 
NS4B 27 Blocks IFN-induced signal-transduction cascade 
– Interacts with NS3 and dissociates it from ssRNA 
– Downregulates expression of STAT2 
– Participates in formation of RCs 
Munoz-Jordan et al. (2003) 
Umareddy et al. (2006) 
Jones et al. (2005) 
Miller et al. (2006) 
NS5 103 Has MTase (N-terminus) and RdRp (C-terminus) 
motifs 
– Possesses two nuclear localization signals for 
transport 
to nucleus 
– Is a nuclear phosphoprotein; only hypophosporylated 
NS5 is located in cytoplasm where it interacts with 
NS3 
– Modulates enzymatic activities of NS3 
– Possesses a nuclear export signal and interacts with 
CRM1 for export to cytoplasm 
– Participates in methylation of viral RNA cap 
structure 
– Binds to La protein 
– Its interaction with STAT2 required for IFN 
signaling, 
reduces level of expression of STAT2. Inhibits IFN-a 
signaling by binding to the STAT2 and inhibits its 
phosphorylation 
Ackermann and Padmanabhan (2001), Egloff 
et al. (2002), Yap et al. (2007); Selisko et al. 
(2010) 
Brooks et al. (2002) 
Kapoor et al. (1995) 
Rawlinson et al. (2009) 
Yon et al. (2005) 
Rawlinson et al. (2009) 
Egloff et al. (2002), Geiss et al. (2009) 
Garcia-Montalvo et al. (2004) 










Figure 2. Schematic representation of the DENV life cycle. The DENV E protein is the major component 
of the virion surface. 1. Attachment: The initial step in the viral life cycle is attachment of the E protein to 
a cellular receptor (forming a fusion complex) such as heparan sulphate, a mannose-speciﬁc C-type lectin, 
but a speciﬁc receptor for internalization of the virus into host cells has not been identiﬁed. 2. 
Endocytosis: Following receptor binding, the virus is internalized into the cells through clathrin-mediated 
endocytosis transporting the virus particles to endosomes 3. Fusion of membranes: In the cytoplasm, 
acidiﬁcation of the endosome lumen induces structural changes in E and promotes fusion between the 
virus particle and the endosomal membrane. 4. Uncoating: A fusion pore is formed, the nucleocapsid 
(NC) is delivered into the cytoplasm, and after uncoating the viral RNA (red) is released from the NC into 
the cytoplasm. 5. Translation: The RNA(+) is directly translated as a single endoplasmic reticulum (ER)-
bound polyprotein. The 5’ cap structure of the viral mRNA promotes assembly of eukaryotic initiation 
factors (eIFs) such as eIF4E and eIF4G and recruits ribosomes on the mRNA. In addition, in spite of the 
fact that the mRNA lacks a poly(A), the poly(A)-binding protein (PABP) interacts with the 3’UTR, 
suggesting that the viral genome is circularized though PABP-eIF4G interaction. The polyprotein is 
processed by viral and cellular proteases into three (then four) structural proteins and seven NS proteins 
(some of which are highlighted). 6. Replication: The NS proteins (highlighted) actively replicate the viral 
RNA(+) in replication complexes (RCs) associated with cellular membranes, producing complementary 
RNA(-), which in turn is used as template to produce RNA(+), that functions as genomic RNA. 7. 
Assembly: Following RNA replication and translation, virus assembly is achieved when one copy of 
RNA interacts with several copies of C protein forming NCs that are enveloped by the heterodimer prM-
E, to assemble into immature virus particles that bud into the lumen of the rough ER. 8 and 9. Maturation: 
Virus particles transit through the Golgi (G) and the trans-Golgi network (TGN) where prM is cleaved by 
cellular furin resulting in the formation of particles containing the pr, M and E proteins. 10 and 11. 
Exocytosis and Release: The mature virus particle migrates to the cell membrane and is released from the 
cell as is also the pr protein. N: nucleus. 
 
non-integrin) expressed in some antigen-presenting cells such as immature DCs (Tassaneetrithep et al., 
2003; Lozach et al., 2005). These molecules presumably concentrate viral particles on the cell surface 
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(Tassaneetrithep et al., 2003; Lozach et al., 2005; Reyes del Valle et al., 2005; reviewed in Huerta et al., 
2008), and facilitate recognition of the second type of receptors, such as the heat shock proteins (HSP) 70 
and 90 (HSP70 and HSP90). This interaction induces the formation of endosomes; this phenomenon 
designated “receptor-mediated endocytosis” (Fig. 2, step 2) allows virus entry into the cell (Reyes del 
Valle et al., 2005). However, the implication of HSP70/90 as receptors is still a matter of debate and 
could depend on the cell types examined (Reyes-del Valle et al., 2005; Cabrera-Hernandez et al., 2007; 
Chavez-Salinas et al., 2008). Both these proteins are associated with microdomains, whose interaction is 
important for DENV entry. Interestingly, HSP70/90 have been postulated to be implicated in the entry of 
other viruses such as Hepatitis E virus (Zheng et al., 2010) and flaviviruses (Lin et al., 2007; Ren et al., 
2007). Certain proteins known as adaptor proteins such as GRP78 are believed to also be part of the 
DENV entry complex but their functions remain undefined (Cabrera-Hernandez et al., 2007). 
Associations between E and adaptor proteins are designated here "fusion complexes". The presence of 
lipid rafts or coated pits in virus fusion complexes indicates that vesicle formation depends on cholesterol 
(in human cells) or clathrin (in mosquito cells) (Lee et al., 2008a; Acosta et al., 2008; van der Schaar et 
al., 2008). Together these results show that regardless of the receptor used, at least two mechanisms of 
flavivirus entry into insect and mammalian cells exist: virus entry can occur by direct fusion of the virus 
to the cell membrane or by clathrin-dependent endocytosis (Hase et al., 1989a; Hase et al., 1989b; Lim 
and Ng, 1999; Se-Thoe et al., 2000; Chu and Ng, 2004; Chu et al., 2006; Krishnan et al., 2007; 
Suksanpaisan et al., 2009). Based on experiments in which it was shown that ablation of clathrin-
mediated endocytosis only reduces virus entry (Chu and Ng, 2004; Chu et al., 2006; Krishnan et al., 
2007), another independent pathway of entry was proposed (Suksanpaisan et al., 2009). However, it 
should be stressed that different cell types were used in the various experiments referred to above.  
Another mode of entry for DENV is by ADE (see Section II. The dengue problem. D. Pathogenesis) (Kou 
et al., 2008). It has been demonstrated that infection of U937 monocytes is induced by ADE-mediated 
FcRI, as is also infection of K562 leukaemic cells by FcRII (Rodrigo et al., 2006). Although the role of 
FcRIII in ADE-DENV infection remains unclear, it was recently reported that the immune tyrosine 
activation motif of FcRIII RIIIA is essential to mediate ADE (Moi et al., 2010). Interestingly, in mature 
DCs but not in immature DCs expressing high levels of DC-SIGN, ADE requires the Fc receptor IIa 
(Boonnak et al., 2008). Finally, lipid rafts are necessary for AD-mediated infection of U937 cells by 
DENV (Puerta-Guardo et al., 2010).  
 
B. Virus adsorption and fusion to the endosome membrane  
 
Evidence obtained to date suggests that the pathway of DENV entry after attachment to the host cell is 
primarily by clathrin-dependent endocytosis (Fig. 2, step 2). At pH 6.2-6.4, homodimer dissociation is 
facilitated and the resulting E monomers present a fusion loop that anchors to the endosome membrane, 
catalyzing the formation of E protein homotrimers (Heinz et al., 2004). This association induces a bend in 
the endosomal membrane promoting formation of a bridge (hemifusion stalk) between the virus and the 
endosomal membrane, leading to fusion. Thus, the nucleocapsid (NC) is released into the cytoplasm (Fig. 
2, steps 3 and 4); how this occurs is largely unclear. After uncoating, the DENV genome is poised for 
translation by the host-cell machinery.  
Although the processes leading to fusion complex formation and to the E conformational changes 
involved in membrane fusion are established, no satisfactory agreement has been reached as to whether 
early and/or late endosomes are the site where viral fusion complexes form (Krishnan et al., 2007). Using 
HeLa cells, chemical inhibitors and small interfering RNAs (siRNAs), it was demonstrated that Rab 5 
(Rabaptin-5), a small GTPase protein that is a marker for early endosomes, showed that early endosome 
components are indispensable for virus amplification (Krishnan et al., 2007).  
 
C. Intracellular transport of the viral genome  
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Little is known about the mechanisms involved in the disassembly of the NCs, the transport of incoming 
genomes to the rough endoplamic reticulum (RER), or the recruitment of ribosomes by genome RNA. 
Intracellular transport of NCs/genomes is mediated by direct interaction with the cytoskeletal transport 
machinery (reviewed in Döhner and Sodeik, 2005; Kanlaya et al., 2009). The cytoskeleton is composed 
of actin and vimentin filaments, microtubules (MTs) and intermediate filaments (IFs) that are constantly 
modified during the cell cycle. These modifications include morphological changes and activation, i.e. 
maturation and rearrangements that can be enhanced by the viral pathogen (Chen et al., 2008). 
DENV can alter the components of the cytoskeleton, but how this is achieved is poorly understood; it 
requires actin-rich regions endowed with a dynamic reorganization mechanism (Chen et al., 2008; 
Talavera et al., 2004) and also affects vimentin filaments, MTs and IFs. In the presence of DENV the 
arrangement is modified and the vimentin filaments retract from the cell periphery and from around the 
nucleus (Chen et al., 2008). Other studies showed that infection of human microvascular endothelial 
cells-1 (HMEC-1) with DENV-2 promotes actin reorganization, regulated by the GTPase proteins, ras-
related c3 botulinum toxin substrate 1 (Rac1) and cell division cycle 42 (Cdc42); this is critical for the 
formation and function of filopodia, necessary for viral entry (Zamudio-Meza et al., 2009).  
Thus the cytoskeletal transport machinery may facilitate the transfer of the viral genome to the ribosomes. 
Yet the mechanism involved and the time necessary for capsid disassembly and RNA release are 
unknown. 
 
D. Genome expression  
 
Liberated from its structural proteins, the DENV genome (Figure 1) becomes accessible to perform its 
three major functions: 1) as mRNA for the synthesis of the viral polyprotein (translation), 2) as template 
for the synthesis of further RNA strands (replication), and 3) as genome incorporated into new viral 
particles (encapsidation). It is important to bear in mind that DENV genome translation is coupled to 
replication since the viral genome must be translated to synthesize the NS proteins required for RNA 
replication (reviewed in Harris et al., 2006). Translation of the DENV RNA(+) produces a single 
endoplasmic reticulum (ER)-bound polyprotein (Fig. 2, step 5). Synthesis of the viral polyprotein is 
initiated at the 5’ proximal AUG codon in the RNA. The cap structure of the viral mRNA facilitates 
assembly of eukaryotic initiation factors (eIFs) such as eIF4E and eIF4G and recruits ribosomes on the 
mRNA. Interestingly, the poly(A)-binding protein (PABP) can bind to the 3’UTR (Polacek et al., 2009b) 
even though the genome lacks a poly(A) tail, suggesting that circularization of the genome via interaction 
with the PABP-eIF4G complex could be required for efficient translation (Figure 2 step 5).  
Interestingly, initiation of DENV mRNA translation can also occur efficiently when cap-dependent 
translation is inhibited, such as when the cap-binding protein eIF4E is limiting (Edgil et al., 2006). 
Experiments performed in the presence of inhibitors of cellular capped mRNA translation, showed that 
DENV RNA or a reporter mRNA flanked by the DENV 5’UTR and 3’UTR was efficiently translated. 
Translation by a cap-independent initiation mechanism may facilitate amplification of viruses that 
multiply in divergent hosts (e. g. mosquitoes and humans), and may also help the virus accommodate to 
various intracelular environments. The highly conserved 3’SL structure present in the 3’UTR (Figure 1B) 
facilitates mRNA binding to polysomes and is a major player in promoting efficient DENV-2 mRNA 
translation (Holden and Harris, 2004); during the first round of translation it stimulates translation in the 
absence of viral proteins. Natural variants of DENV-2 that differ in their ability to multiply in primary 
human cells appear to vary in their ability to synthesize viral proteins in vivo and in vitro (Edgil et al., 
2003). These differences are linked to mutations in the 3’UTR and sugget that other regions than the 
coding sequence are important for efficient translation and could be activated by modifying either RNA-
RNA or RNA-protein interactions. Certain cell proteins bind to the 3’UTR. Indeed, in addition to certain 
translation initiation factors important for cap-dependent DENV RNA translation, the 3’SL binds several 
cell proteins such as the eukaryotic elongation factor (eEF) 1A enhanced viral RNA transcription (Davis 
et al., 2007). Other reports have shown that the La autoantigen, the polypyrimidine-tract-binding protein 
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and the Y-box-binding protein-1 bound to the 3’UTR (De Nova-Ocampo et al., 2002; Garcia-Montalvo et 
al., 2004; Davis et al., 2007; Paranjape and Harris, 2007), but the functional roles of these interactions in 
replication and/or translation have not been clearly established. Some results have proposed that 
translation and subsequent replication occur within intracellular membranes structures, whose origins are 
not well defined (reviewed in Clyde et al., 2006; Miller and Krijnse-Locker, 2008).  
 
E. Genome replication  
 
The association of the machinery for DENV negative-sense RNA RNA(-) synthesis with host 
intracellular membranes is poorly understood, but the membranes probably play a structural and 
organizational role in forming the replication complex (RC). However, it is known that following 
translation, viral NS proteins together with host factors form the RC responsible for the synthesis of 
RNA(-) complementary to the RNA(+), resulting in an intermediate double-stranded (ds) RNA. The 
complete DENV RNA replication cycle includes the synthesis of RNA(-), and of new RNA(+) that 
functions as mRNA (Fig. 2 step 6), and as genomic RNA to form new virus progeny. RNA synthesis is 
recgulated by sequences located in the 5´and 3´UTRs: the 5’-3’CS and 5’-3’UAR sequences (Fig. 1A, B) 
mediate Mg
2+
-dependent and cell protein-dependent circularization resulting in long-range RNA-RNA 
interactions important for DENV RNA replication (Khormykh et al., 2001; Lo et al., 2003; Alvarez et al., 
2005;. Circularization is further facilitated by the presence of a 6 nt-long 5’DAR sequence (Friebe and 
Harris, 2010). Although the specific role of NS3 in replication remains unclear, its helicase domain could 
be involved in unwinding RNA secondary structures present in the 3’UTR and assisting the first steps of 
replication. NS3 is a multifunctional protein with RNA-stimulated nucleoside triphosphatase (NTPase), 
ATPase/helicase, and RTPase (Yon et al., 2005; Sampath et al., 2006; Wang, et al., 2009a) activities that 
are essential for viral RNA replication and capping. SLA at the 5’ end of the 5’UTR is the promoter for 
the RdRp activity of NS5 and RNA synthesis (Filomatori et al., 2006). In transfected cells, NS5 interacts 
with the 5’ SLA, but surprisingly not with the 3’UTR (Filomatori et al., 2006). Various structures in the 
5’SLA (UAR, cHP and CS) are involved in circularization of the DENV genome and in promoting RNA 
synthesis (Friebe and Harris, 2010; Lodeiro et al., 2009). Despite sequence and structural differences 
between the 5’SLAs of DENV-1 and DENV-2, the RdRp of DENV-2 efficiently uses the 5’SLA of 
DENV-1 for RNA replication (Hahn et al., 1987; Filomatori et al., 2006; Yu et al., 2008b). Thus the 
requirement for the homologous 3´SL for viral replication is related to specificities of other viral NS 
proteins in addition to NS5 which not only functions as the RdRp, but also acts as the MTase implicated 
in capping of the viral RNA. Alternatively, the specificity of NS5 could be altered by its interaction with 
other NS proteins or with cell proteins. A single mutation within the 5’UAR can decrease RNA synthesis 
up to 3000 fold during DENV genome replication (Alvarez et al., 2008). In addition, genomes with 
disruption of the stem of SLB by mutations that still maintain complementarity with the 3’UAR, can be 
translated and replicated. Therefore, the 5’UAR sequence acts as a cis-element regulating DENV RNA 
replication. In the DENV genome, interaction between the 3’ and 5’ CSs also facilitates hybridization of 
the 5’-3’UARs, that form a 15 nt-long base-paired structure interrupted by a C bulge and a G-G mismatch 
(Fig. 1B) (Alvarez et al., 2008). Although hybridization between the 5´ and 3´UARs requires interaction 
between the 5’ and 3’CSs, interaction between the 5’ and 3’CSs does not depend on interaction between 
the 5’ and 3’UARs (Polacek et al., 2009a). Studies performed in vitro using viral subgenomic (sg) RNA 
templates containing the 5´ and 3´CSs showed that interaction between the two terminal regions is 
necessary for the synthesis of RNA(-) from RNA(+) (Ackermann and Padmanabhan, 2001; You et al., 
2001; Nomaguchi et al., 2004). Recently, the presence of a small sgRNA derived from the 3’UTR by cell 
nuclease digestion and essential for virus-induced pathogenicity, was identified in DENV-infected cell 
cultures and in animal tissues (Pijlman et al., 2008; Liu et al., 2010). Both the sgRNA and genomic RNA 
accumulated together during viral RNA replication. It will be interesting to define the function of this 
non-coding sgRNA in the virus life-cycle. The 3´UTR(-) could act as a promoter element for the synthesis 
of new RNA(+) as does the 3’UTR(+) for the synthesis of RNA(-). In addition, the 3’UTR(-) of DENV 
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interacts with La, a  nuclear protein that participates in cell mRNA transcription initiation, forming a 
ribonucleoprotein complex in association with other cell proteins such as calreticulin and the protein 
disulfide isomerase (Yocupìcio-Monroy et al., 2003).  
Circularization of the viral RNA favors coupling of translation and replication. This occurs in the 
cytoplasm on induced cell membranous structures probably derived from the ER, and in vacuoles induced 
by the virus and known as viral RCs. NS2A in addition to playing a direct role in viral RNA replication, 
could also be the viral protein that targets the viral RCs to membrane organelles (Mackenzie et al., 1998). 
NS4B which presents at its C-terminus a highly hydrophobic fragment (designated 2K) that function as a 
signal sequence, serves for the translocation of NS4B into the ER lumen, where it is a component of RCs 
(Miller et al., 2006). In the membrane-bound viral RCs, NS4B is associated with NS3 and dsRNA, a 
marker for replicating viral RNA. During this process, proteolytic removal of a 2 kDa peptide from NS4A 
is important for the induction of membrane alterations that may harbour the viral RCs (Miller et al., 
2007). Dissociation of NS3 from ssRNA by NS4B in vitro enhances the NS3 helicase activity, suggesting 
that NS4B can modulate DENV replication (Umareddy et al., 2006). Viral genome replication takes place 
in the RCs (reviewed in Bartenschlager and Miller 2008), although some replication activity has been 
detected in the nucleus (Uchil et al., 2006). The question however remains of how the RCs are formed. A 
role of authophagy in virus replication has recently become a new emerging field of investigation. 
Autophagy develops in an area of the cytoplasm where a membrane pre-exists, and expands the 
membrane to form double-membrane vesicles; it is part of a lysosomal degradation pathway that is 
important for cell remodeling and development, and that is also involved in various disease processes. 
DENV appears to also induce authophagy as a means of enhancing replication in the cell (Colombo, 
2005; Lee et al., 2008b), and viral RNA replication has been associated with double-membrane structures 
(Uchil et al., 2003; reviewed in Miller and Krijnse-Locker, 2008) that are hallmarks of autophagosomes 
(Dunn, 1990). Other studies showed that the induction of autophagy by DENV-2 and DENV-3 resulted in 
an increase in the titers of extracellular and intracellular virus (Khakpoor et al., 2009). Moreover, DENV-
2 triggers autophagy by increasing the expression of LC3-II (light chain 3 form II of the microtubule-
associated protein 1) and green fluorescent protein (GFP)-LC3 dot formation. In addition, LC3-II is 
associated with autophagosome membranes, and co-localizes with viral dsRNA, NS1, and the ribosomal 
protein L28 (Kuma et al., 2004; Panyasrivanit et al., 2009b). Inhibition of fusion of autophagosomes and 
amphisomes with lysosomes decreases DENV-3 production, suggesting a role for authophagosomes in 
the DENV life cycle (Panyasrivanit et al., 2009a). Based on results showing that DENV components 
colocalize with markers of autophagic and endosomal vesicles, it was proposed that amphisomes 
constitute a site of DENV genome replication and translation. The activation of the cell autophagy 
machinery to promote DENV RNA replication depends on the ATG5 protein, an initiator of 
autophagosome formation during autophagy progression (Kuma et al., 2004; Lee et al., 2008b). Inhibition 
of autophagy by ATG5 knockout or treatment of cells with lysosomes that inhibit fusion of 
autophagosomes and amphisomes, is associated with a decrease in DENV replication and reduced 
progeny virus particle formation (Limjindaporn et al., 2009; Khakpoor et al., 2009). Interestingly, there 
appears to be a link between DENV entry and replication/translation in terms of a continued association 
of the virus life cycle with membranes of an endosomal-autophagosomal lineage (Panyasrivanit et al., 
2009a). Thus, DENV replication/translation is coordinated by cis-acting genomic sequences, viral 
proteins and cell factors. Future studies should clarify how autophagic membranes and how DENV 
coordinates the authophagic processes.  
 
F. Maturation and release of DENV from the host cell  
 
After polyprotein synthesis and genome replication have occurred, the next step leading to viral particle 
formation is encapsidation. Although the first indications of interaction between the viral RNA and C 
were demonstrated over a decade ago (Khromykh et al., 1999), the precise mechanisms involved in RNA-
C complex (or NC) formation are unclear. Recently, Samsa et al. (2009) reported that mature C protein is 
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associated with lipid droplets (LDs), defined as ER-derived organelles located in the cytoplasm and that 
contain various proteins surrounded by a core of neutral lipids and a monolayer of phospholipids; this 
association is triggered by hydrophobic residues present in the center of C (Ma et al., 2004). Infection of 
cells by DENV stimulates the formation of LDs, and decreasing the number of LDs reduces virus 
replication. Strong evidence suggests that viral RNA-C protein assembly occurs in membrane structures 
derived from the ER (Fig. 2, step 7), forming NCs. In addition to its RNA-binding motifs, the N-terminal 
region (aa 21-100) of the C protein contains four hydrophobic α helices essential for association with the 
ER (Ma et al., 2004). Thus, the partially assembled virus NCs, bud from the lumen of the ER (Fig. 2, step 
7), and become enveloped by a lipid membrane that contains in addition to NCs, the two structural 
proteins, prM and E, in the form of prM-E heterodimers (Mukhopadhyay et al., 2005, Wang et al., 2009b) 
that are incorporated into immature virions by interaction with the NC; this step constitutes the assembly 
of immature viral particle. Yet NCs are not prerequisites for the formation and secretion of viral particles 
since sub-viral particles composed only of prM and E are also secreted from DENV-infected cells 
(Mukhopadhyay et al., 2005). The E protein undergoes reversible pH-dependent conformational changes 
during egress of virions through the secretory pathway. In the immature state the prM-E heterodimers are 
grouped as trimers, whereas in the mature particles there are E homodimers, and E forms homotrimers 
when the virus fuses with the host cell endosomal membrane (Bressanelli et al., 2004). During this 
transport process the virus particles pass through the trans-Golgi Network (TGN) where the prM protein 
is cleaved by the protease furin but the pr segment continues to be associated with the virion until the 
virion is released from the cell. The retention of the pr segment prevents premature binding of the E 
protein to the exosomal membrane during transit of the virus in the acidic enviroment of the TGN. These 
mature viral particles are released from the TGN into the cytoplasm and are transported to the outer cell 
membrane by exocytosis (Fig. 2, steps 10) (Yu et al., 2008a; Yu et al., 2009; reviewed in Perera and 
Kuhn, 2008). Finally the cleaved pr and virions are released into the extracellular medium upon particle 
secretion (Figure 2 step 11) (Yu et al., 2009). Virus maturation in the lumen of the TGN produces mature 
virions composed of one copy of RNA, 90 homodimers of E and 180 copies of prM. The transition from 
immature (spiky) to mature (smooth) particles due to the cleavage of prM occurs during transit of the 
particles through the Golgi into the TGN (Fig. 2, steps 8 and 9)(Wang et al., 2009b). Cleavage of prM to 
M by furin is essential for DENV infectivity (Zybert et al., 2008). Indeed, treatment of immature viruses 
with exogenous furin restores viral infectivity. Analyses performed with other flaviviruses suggest that 
prM cleavage is required for full maturity and infectivity of the virus particles (Wengler and Wengler 
1989). However, cleavage of DENV prM is inefficient, as various cell types infected with DENV-2 
release large amounts of virions with unprocessed prM (Elshuber et al., 2003). In addition to preventing 
fusion of E to the exosomal membrane (Yu et al., 2008a), pr retention could also 1) constitute a 
mechanism favoring flavivirus trafficking and stability in the cell secretory pathway, 2) be required for 
interaction with the vacuolar-ATPases (V-ATPases) whose silencing leads to reduction in DENV 
replication, and 3) establish a suitable pH environment for efficient virus secretion (Duan et al., 2008). As 
mentioned above, acidification of intracellular organelles such as components of the secretory pathway is 
crucial for infectivity (Yu et al., 2008a; Yu et al., 2009). Previous reports have shown that V-ATPases are 
multisubunit enzymes that acidify various organelles including lysosomes and components of the 
secretory pathway, facilitating protein processing and acid-dependent protein degradation during DENV 
infection (Duan et al., 2008). Residues 76 to 80 of prM participate in the interaction with V-ATPases, and 
the V-ATPase-virus interaction is critical for efficient virus entry and egress. Thus, the viral particles 
assemble and bud from the lumen of the ER, and virus maturation occurs in the TGN; finally the mature 
virus particles are released by exocytosis. In addition, it was recently demonstrated that the human 
immunoglobulin heavy chain binding proteins, calnexin and calreticulin, all ER-resident chaperones, 
interact with the E protein (Limijindaporn et al., 2009). Silencing of the three corresponding genes using 
siRNAs, affected the production of infectious DENV suggesting that these chaperones participate in the 
folding and assembly of the viral proteins. The E protein of DENV is glycosylated in the residues 67 and 
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153/154. Loss of either of the two E protein glycan enhanced infectivity of variants for mosquito cells and 
reduced virus releases in mammalian (Hanna et al., 2005; Lee et al., 2010). 
 
V. siRNAs AND NEW STRATEGIES TO CONTROL DENV REPLICATION 
 
Understanding the cellular cxomponents involved in DENV infection is imperative as it should allow 
better comprehension of dengue pathogenesis, and lead to the elaboration of gene-targeted inhibitor 
strategies. However, only a few reports of inhibitory factors of DENV infection have appeared. Lately, 
siRNAs have been used in vivo as a gene silencing approach to decrease DENV replication. dsRNA is 
cleaved by Dicer, an RNAse-III-type enzyme, into 21-25 nt-long siRNAs. siRNAs have been used as a 
knockdown mechanism to study cellular and viral genes involved in virus replication and constitute a new 
pathway for clinical treatment of various infectious diseases. Several reports have demonstrated the 
efficiency of the siRNA strategy to block DENV production (Ang et al., 2010; Mukherjee and Hanley, 
2010; Subramanya et al., 2010). The nucleotide sequence of the 3’UTR which is common to the genome 
of all four DENV serotypes, was used to design siRNAs and these siRNAs silenced DENV RNA 
replication. Adeno-associated virus encoding siRNAs targeted to the 3’UTR of the DENV RNA also 
reduced DENV infection in Vero cells and in human DCs in a dose-dependen manner (Zhang et al., 
2004). Moreover, infection of human dermal microvascular endothelial line-1 cells with DENV-2 induces 
high expression of 3 integrin, and pre-incubation of the virus with soluble  integrin or silencing of the 
3 integrin gene using siRNAs, drastically reduces virus entry (Zhang et al., 2007). In Huh7 cells, the use 
of siRNAs targeting genes implicated in clathrin-mediated endocytosis inhibited DENV entry into target 
cells (Ang et al., 2010). In HeLa cells, silencing of the gene encoding the V-ATPase, a proton pump that 
is key to establishing the low pH of endosomal compartments resulted in decreased DENV replication 
(Krishnan, et al., 2007), demonstrating the requirement of V-ATPase in endosomal DENV entry. 
Moreover, knockdown of the Rab 5 GTPase gene by siRNAs revealed that DENV infection requires the 
expression of Rab 5, a key regulator of transport to early endosomes. Cholesterol is an important element 
in DENV infection; its depletion with methyl-ß-cyclodextrin or its chelation with filipin III, a member of 
the polyene family of antibiotics, diminishes entry of DENV or Japanese encephalitis virus (Lee et al., 
2008a). Furthermore, selective silencing of enzymes involved in cholesterol biosynthesis using siRNAs 
inhibits DENV replication in A549 cells (Rothwell et al., 2009). Both studies suggest that cholesterol 
modulation affects DENV replication, although the mechanism(s) whereby this occurs is as yet unknown. 
DENV replication occurs in association with the ER, where the viral particles assemble; in a search for 
the role of host ER chaperones in these processes, it was demonstrated that siRNAs that separately silence 
three ER-resident chaperones, the immunoglobulin heavy chain-binding protein known as BiP, calnexin 
or calreticulin, significantly decreased the yield of infectious virus production (Limjindaporn et al., 2009). 
Moreover, using image-based immunofluorescence assays, inhibitors of the c-Src protein kinase were 
shown to be potent inhibitors of DENV replication (Chu and Yang, 2007), preventing virus assembly 
within the RC. The data suggest that siRNAs could be used to hinder DENV infection and could serve as 
therapeutic strategy.  
Interestingly, infection by DENV-2 of cultured A. aegypti cells, or DENV-2 administered orally to adult 
mosquitoes, led to the production of siRNAs specific for the virus, whereas impairing the siRNA 
machinery increased virus production in this vector (Sánchez-Vargas et al., 2009). Infection of 
Drosophila melanogaster S2 cells with any of the four serotypes of DENV induced siRNA production 
(Mukherjee and Hanley, 2010). Knockdown of one gene implicated in the RNA interference (RNAi) 
machinery led to enhancement of viral replication. Consequently, infection of insect cells activates an 










In recent years, new approaches such as transcriptomic/proteomic and microarray techniques to study 
integral aspects of virus life cycles have led to more profound knowledge concerning the relationship 
between virus and host. It was known that formation of infectious DENV requires the concerted action of 
viral structural proteins. More recently the importance for viral genome expression of viral NS proteins 
and cell proteins, and of regions of the viral genome that lie within the ORF are being recognized, as is 
also the coupling of viral RNA replication and virus assembly. These approaches have also demonstrated 
that NS proteins participate in the localization of active RCs and mediate formation of specialized 
assembly sites to regulate the release of RNA from the RCs and RNA packaging in the budding virus. 
Although replication occurs in the cytoplasm, NS5 has also been immunolocalized in the nucleus where 
its specific role in the virus life cycle appears to be to antagonize the antiviral response. However the 
functions of other DENV proteins that traffic between the nucleus and cytoplasm are unclear. Likewise, 
the function of the C protein in the nucleus is unknown. These observations nevertheless illustrate the 
essential roles of the viral proteins and their use as potential targets for genetic therapeutic strategies 
against DENV infection. The identification of host cell factors important for DENV infection remains an 
essential but largely unexplored area. Although the functions of the NS proteins in the production of 
infectious progeny are beginning to emerge, further studies should aim at elucidating their specific 
mechanisms of action so as to exploit this knowledge in the development of highly efficient antiviral 
drugs for dengue treatment. 
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Pattern recognition receptors are the main sensors of the innate immune response. Their function is to recognize 
pathogen-associated molecular patterns, which are molecules essential for the survival of microbial pathogens, but 
are not produced by the host. The recognition of pathogen-associated molecular patterns by pattern recognition 
receptors leads to the expression of cytokines, chemokines, and co-stimulatory molecules that eliminate pathogens, 
such as viruses, for the activation of antigen presenting cells and for the activation of specific adaptive immunity. 
Among the most thoroughly studied pattern recognition receptors implicated in viral infections, there are the toll-
like receptors (TLRs) and the RNA helicase-type retinoic acid- inducible gene-I receptors [or RIG-like receptors 
(RLRs)]. Moreover, other proteins such as PKR, 2’-5’ OAS, and ADAR also act as effector proteins in antiviral 
responses. The identification and characterization of pattern recognition receptors have contributed to our 
knowledge of the role of innate immunity in viral infections and has led us to better understand host-pathogen 
interactions. The most recent findings concerning the role of TLRs and RLRs in viral infections, the molecular 
mechanisms of viral ligand recognition through pattern recognition receptors, and the activation of their signaling 
pathways are discussed in this review 
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Innate immunity is the first protecting barrier of the host against foreign agents; its response and quality 
determine the development of adaptive immunity responses. The activation of the innate immune 
response involves a wide spectrum of cells and soluble factors that recognize and exert effector functions 
when challenged by pathogens that can enter the host. However, it was the description of pathogen 
recognition receptors (PRRs) and, particularly, of Toll-like  receptors (TLRs) that led to understanding 
Table 1 









Japanese encephalitis virus 
Hepatitis C virus 
Influenza virus 
West Nile virus 
MDA5 Encephalomyocarditis Virus 
Varicella-zoster Virus 
Extracellular/endosomal sensors 
TLR2 Lipoteichoic acid 
Lipophosphoglycan (LPG) 
Glycophosphatidylinositol (GPI) 
Hemagglutinin protein of the Varicella-zoster 
Virus 
herpes Simplex Virus-1 
Human Cytomegalovirus 
TLR4 LPS 
Syncytial Respiratory Virus 
Envelope protein of the Mouse Mammary 
Tumor Virus 
TLR3 Poly (I:C) 
murine cytomegalovirus 
vesicular stomatitis virus 
lymphocytic choriomeningitis virus 
reovirus 




Human Immunodeficiency Virus 
Vesicular Stomatitis Virus 
Dengue Virus 
Influenza Virus 
TLR9 Synthetic CpG-containing DNA 
Vesicular Stomatitis Virus 
Murine Cytomegalovirus 
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the prominent role that innate immunity plays in the recognition of microbial pathogens and in the 
regulation of the immune system1.One of the most interesting aspects of innate immunity is the wide 
range of molecules recognized by PRRs (C. A. Janeway Jr & Medzhitov, 2002). These receptors 
recognize diverse structural components or ligands (Table 1)2, essential for the survival of 
microorganisms, known as pathogen-associated molecular patterns (PAMPs) (Palm & Medzhitov, 2009). 
Recognition of PAMPs by PRRs stimulates an intracellular signaling cascade that involves the activation 
of diverse transcriptional factors involved in regulating expression of cytokines. Such cytokines play 
important roles in host protection, in the activation and migration of antigen presenting cells, and in the 
induction of the adaptive immune response.  
 
Figure 1. PRRs and antiviral proteins of the innate immune response. Viral nucleic acids and some viral 
proteins are recognized by TLRs, RLRs and DAI, which induce a signaling pathway that activates 
theproduction of cytokines and type-I IFN. IFN-mediated signaling through its cellular receptor 
IFNARinduces the expression of several proteins with antiviral activity. In addition, the IFN induced by 
virusinfection can bind to specific cell receptors and trigger the expression of different genes such as 
PKR. PKRis activated through homodimerisation after binding to viral dsRNAs via its dsRNA domain. 
Once active, as a kinase, PKR phosphorylates eIF2α (eIF2 αp) and blocks synthesis of both cellular or 
viral proteins. 2’5‘OAS and Mx GTPase are two additional effector pathways of the IFNmediated 
antiviral response. Thefirst is activated by dsRNA and specifically activates the latent form of RNase L 
leading to RNAdegradation, and the second is activated by viral proteins and blocks viral transcription. 
On the otherhand, TRIM 5α recognizes the viral capsid core and blocks HIV-1 infection at a post-entry, 
pre-integration stage in the viral life cycle. 
This review will focus on certain signaling PRRs that are potent triggers of inflammatory responses and 
play a very important role in viral infections. Among them there are the TLRs that can be either 
endosomal or extracellular (C. Janeway Jr & Medzhitov, 2000; Netea, van der Graaf, Van der Meer, & 
Kullberg, 2004), and retinoic acid-inducible gene- (RIG-) I/MDA5 (melanoma differentiation-associated 
gene 5), known as RNA helicase-like receptors (RLRs). Furthermore, Double-stranded RNA-dependent 
protein kinase (PKR), 2',5'-oligoadenylate synthetase (2’-5’OAS), and adenosine deaminase acting on 
RNA (ADAR), known as effector proteins, complement the function of PRRs1. All these proteins are the 
main sensors of viral components and induce pro-inflammatory cytokine expression or interferon (IFN) 
response factors (Figure 1). This review discusses recent new knowledge on the molecular mechanism 
and role of PRRs in the recognition of viral PAMPs, the signaling pathways activated by such 
recognition, as well as the strategies used by viruses to evade such response. 
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TLRs, adaptor molecules and their signaling pathways 
TLRs are the best characterized members of the PRR family and can recognize both intracellular and 
extracellular pathogens (Netea et al., 2004). Ten TLRs have been described in humans and all are type-1 
membrane glycoproteins, from which six (TLR2, 3, 4 7/8, and 9) recognize viral components (Table 1). 
Some TLRs form hetero (TLR2/TLR1, TLR2/TLR6) or homodimers (Kang et al., 2009). TLRs have an 
ectodomain or extracellular domain with leucine-rich repeats (LRRs), a transmembrane region and a 
cytoplasmic domain, homologous to the interleukin-1 (IL-1) receptor, known as Toll/IL-1R (TIR) (C. 
Janeway Jr & Medzhitov, 2000). Briefly, the signaling pathway induced by TLRs is as follows: each TLR 
is stimulated by its specific ligand, which is recognized through the ectodomain. This leads to the 
recruitment, through the TIR, of adaptor proteins like the myeloid differentiation primary response 
protein 88 (MyD88), the Toll/IL-1 receptor domain containing adaptor protein (TIRAP), the Toll/IL-1 
receptor domain containing adaptor inducing interferon-beta (TRIF), and the TRIF-related adaptor 
molecule (TRAM) (Figure 2).The IL-1R associated protein (IRAK) and tumor necrosis factor (TNF) 
receptor-associated factor 6 (TRAF6) then also participate in the signaling pathway. TRAF6 acts as an 
ubiquitin ligase E and activates the transforming growth factor (TGF) b-activated kinase 1 (TAK1) 
complex and its subunits the TAK1-binding protein-(TAB) 1 and TAB2/3, responsible for the 
phosphorylation of NF-kappaB essential modulator (NEMO), which results in the activation of the kinase 
complexes constituted by inhibitor of kappaB (IkB) and IkappaB kinase (IkK) and in the degradation of 
phosphorylated IkB6. Finally, the nuclear factor kB (NF-kB), the activator protein 1 (AP-1), and the IFN 
regulatory factors (IRFs) are released and translocated to the nucleus where regulate the expression of 
molecules that participate in the inflammatory response and in the initiation of innate immunity (Akira & 
Takeda, 2004; Netea et al., 2004) (Figure 2). The stimulation of TLR7 and TLR9 with their respective 
ligand results in the formation of a complex constituted by MyD88, IRAK-4, TRAF6, TRAF3, IRAK-1, 
IKK-k, and IRF7 responsible for the activation of IRF7, which once phosphorylated is translocated to the 
nucleus and regulates the expression of type-I IFN. TLR3, through TRIF as adaptor protein, can induce 
the phosphorylation of IRF3 translocated to the nucleus and activates NF-kB and the expression of type-I 
IFN, as described above (Akira & Takeda, 2004; Netea et al., 2004; Zhang & Ghosh, 2001). In summary, 
the stimulation of TLRs through viral PAMPs or another origin allows the recruitment of adaptor proteins 
responsible for activating the induction of signaling pathways that result in the activation of 
transcriptional factors involved in the activation of the expression of genes whose products are involved 
in antiviral responses. 
membrane.Recognition of viral components through TLRs. 
TLRs are components of a PAMP recognition system that act in concordance with other cellular factors to 
establish a bridge between the innate response and the adaptive immunity (Akira & Hemmi, 2003). Their 
activation is initiated by a signaling pathway that leads to the activation of some mitogen-activated 
protein kinases (MAPKs) and of transcription factors like AP-1, IRF, and NF-kB. These transcription 
factors are responsible for the activation of genes that encode pro-inflammatory cytokines, such as the 
tumor necrosis factor a (TNF-a), interleukins (IL-1, 6, 8, and 18), IFN-a/b, chemokines, leukotrienes, 
class II major histocompatibility molecules and co-stimulatory molecules like CD40, CD80, and CD86, 
necessary for adequate antigenic presentation. Initially, it was believed that the only TLRs involved in 
recognition of viral PAMPs were those recognizing nucleic acids like TLR3, TLR7/8, and TLR9, located 
in acid endosomes. However, certain authors and our unpublished results suggest that TLR2 and TLR4, 
located on the cell surface and known to recognize bacterial components, are also able to recognize viral 
PAMPs, mainly envelope glycoproteins (Compton et al., 2003; Sato, Linehan, & Iwasaki, 2006; Zhou et 
al., 2005). A study carried out using TLR2 and MyD88-deficient mice infected with Lymphocytic 
Choriomeningitis Virus (LCMV) demonstrated that the TLR2-MyD88 interaction is essential for the 
activation of astrocytes and microglia and for the production of TNF-a and the monocyte chemo-attractant 
protein-1 (MCP-1) (Zhou et al., 2005). TLR2 also recognizes PAMPs from measles virus (MV), hepatitis 
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C virus (HCV) and human herpes simplex virus type-1 and 2 (HSV1/2) (Bieback et al., 2002; Gaudreault, 
Fiola, Olivier, & Gosselin, 2007; Shehata, Abou El-Enein, & El-Sharnouby, 2006).  
 
Figure 2. Viral recognition through TLRs and the RIG-I protein. TLR2 and 4 recognize mainly viral 
envelope proteins and recruit MyD88 by an adaptor (Mal) protein; TLR7 and TLR9 interact directly with 
MyD88 following ligand recognition (viral ssRNA and viral DNA, respectively). In contrast, TLR3 
recognizes the presence of dsRNA through the recruitment of TRIF. Following MyD88 or TRIF 
recruitment, a signaling pathway is initiated via RIP1/TRAF6-NF-κB and TBK1/IKK-i-IRF-3/IRF-7, 
which ends with the expression of pro-inflammatory cytokines and type-I IFN. Recognition of dsRNA 
could also be mediated by RIG-I and occurs in the cytoplasm activating TBK1/IKK-i through the adapter 
protein IPS-1 located in the mitochondria 
 
In the case of HCV, it was demonstrated that an increase in the level of expression of TLR2 in individuals 
with chronic hepatitis is related to an increase in the level of circulating TNF-a, and to the development of 
hepatic lesions (Shehata et al., 2006). A study performed in HEK293 cells stimulated with Epstein-Barr 
Virus (EBV) showed that TLR2 is stimulated through NF-kB (Gaudreault et al., 2007; J. M. Lund et al., 
2004). Acute infection by varicella-zoster Virus (VZV) is characterized by the development of an 
inflammatory response due to high cytokine production, specifically IL-6 and IL-8, which is associated 
with increased expression of TLR2 in human monocytes exposed to the virus (J. P. Wang, Liu, Latz, 
Golenbock, Finberg, & Libraty, 2006a). TLR4 is stimulated by bacterial lipopolysaccharides (LPSs) and 
endogenous ligands that are inflammation products, such as fibrinogen, fibronectin, b-defensins, and heat 
shock proteins (Akira & Takeda, 2004). Studies performed using TLR4-deficient mice infected with 
vesicular stomatitis virus (VSV) showed decreased expression of IL-12 and a higher viral load in 
comparison to mice expressing this receptor (Haynes et al., 2001). The role of TLRs in modulating the 
replication of certain viruses has also been examined. Using mice transgenic for Hepatitis B virus and 
intravenously injected with specific ligands for TLR2, 3, 4, 5, 7, and 9 showed that all receptors, except 
TLR2, can inhibit virus replication in IFN-dependent manner (Isogawa, Robek, Furuichi, & Chisari, 
2005). In summary, TLR4 is stimulated by PAMPs from the respiratory syncytial virus (RSV), coxsackie 
B virus, HSV, and MV19-21. However, additional studies must be pursued to determine the role of TLR2 
and TLR4 in viral infections and in antiviral defense. All endosomal TLRs are activated by nucleic acids. 
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They also promote transcription of several cytokine and chemokine coding genes through the activation 
of NF-kB and MAPK, resulting in the expression of pro-inflammatory cytokines6. The main ligands of 
TLR3 are double-stranded RNA (dsRNA) genomes, and dsRNA replication intermediates of single-
stranded RNA (ssRNA) viruses like RSV, dengue virus, and encephalomyocarditis virus22. TLR3 is also 
activated by contact with synthetic molecules or viral dsRNA analogs [poly (I:C)]. The final product of 
TLR3 activation is the induction of a strong inflammatory response characterized by the secretion of IL-
12, TNF-a, IL-6, CXCL-10, IL-10, and IFN-a. The role of TLR3 in antiviral immune response was 
demonstrated in TLR3-deficient mice, which are more susceptible to murine cytomegalovirus (MCMV), 
given lower expression of IFN (Tabeta et al., 2004). TLR3-deficient mice infected with West Nile virus 
(WNV) develop higher viral loads (T. Wang et al., 2004). However, the mice are less susceptible to 
developing meningitis, suggesting that the entry of the virus to the brain, and its pathogenesis, could be 
mediated by TLR3 activation and the immune response developed upon viral infection. TLR7 is also 
involved in antiviral responses. In humans, TLR7 is mainly expressed by plasmacytoid dendritic cells 
(pDCs), which after stimulation, induce the activation of NF-kb and MAPK and trigger the expression of 
cytokines such as IL-6, IL-12 and IFN-a, and the activation of co-stimulatory molecules through the 
TLR7 pathway (J. M. Lund et al., 2004). TLR7 and TLR8 are tightly related endosomal receptors and 
their ligands are ssRNAs. Both receptors are also activated by guanine analogs and uridine or guanosine-
rich ssRNAs of either viral or cellular origin. Both receptors are crucial for the development of adaptive 
immune responses during viral infections, as is the case with influenza virus and dengue virus (J. M. 
Lund et al., 2004; J. P. Wang, Liu, Latz, Golenbock, Finberg, & Libraty, 2006b).Finally, the endosomal 
TLR9 is activated by at least three types of ligands with different biological outcomes (Kumagai, 
Takeuchi, & Akira, 2008): i) viral DNA, ii) conventional CpG-containing DNA that activates B 
lymphocytes and induces the production of inflammatory cytokines by macrophages, and iii) D/A-type 
CpG containing-DNA that also stimulates the production of cytokines by macrophages and B 
lymphocytes, besides stimulating high production of type-I IFN by pDCs. It has been reported that this is 
the mechanism used by pDCs to respond through TLR9 to the presence of DNA viruses, such as 
adenoviruses, HSV1/2 and MCMV (Iacobelli-Martinez & Nemerow, 2007; Krug et al., 2004; J. Lund, 
Sato, Akira, Medzhitov, & Iwasaki, 2003). However, besides the recognition of DNA by TLR9, a 
different TLR9-independent mechanism has been proposed allowing the recognition of dsDNA in the 
cytoplasm of macrophages and in non-immune cells, but also inducing activation of IRF3, NF-kb, and 
IFN-a (Ishii & Akira, 2006).Together, this shows that upon stimulation by nucleic acids or viral proteins, 
TLRs induce the expression of pro-inflammatory cytokines, whose function is to protect the host from 
viral infection. Thus, type-I IFN is one of the main components of innate immunity and is regulated by 
signals initiated at both intracellular and extracellular levels. 
RLRs, adaptor molecules and their signaling pathways 
The RIG-I and the MAD5 are two RLRs that recognize, respectively, short dsRNAs with 5’ triphosphate 
ends and long dsRNAs from viral genomic RNAs. Both proteins are cytoplasmic and members of the 
DExD/Hbox RNA helicases that are stimulated by dsRNAs. RIG-I/MDA5 have two recruiting domains: 
an RNA helicase domain and a caspase recruitment domain (CARD; also known as caspase recruiting 
domains). The first domain is responsible for the recognition of dsRNAs and for the recruitment of 
various proteins that activate signaling pathways, and the CARD domain recruits proteins implicated in 
type-I IFN expression (Kato et al., 2006). An adaptor protein has been described in this new signaling 
pathway. It is known as IFN-a promoter stimulator (IPS-1), [or anti-viral signaling protein (MAVS), 
virus-induced signaling adaptor (VISA) or CARD adaptor inducing IFN-a (Cardif)], and when it interacts 
with the CARD domain, allows the recruitment of dsRNA, which results in the expression of type-I IFN 
due to the activation and translocation of IRF3, IRF7 and NF-kB to the nucleus (Gitlin et al., 2006; Kato 
et al., 2005). RIG-I is up or down regulated by the ubiquitin ligase TRIM25 and by RNF125. This means 
that RIG-I/MDA5 recognizes viral dsRNAs in the cytoplasm, while TLR3 does so in the endosomes. 
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Recognition of viral components by RIG-I/MAD5: RNA helicase-like receptors (RLRs) 
Certain viral dsRNAs synthesized in the cytoplasm as viral life cycle intermediaries, or as part of viral 
genomes are not only recognized by TLR3, but also by RLRs such as RIG-I and MAD5, which induce the 
expression of type-I IFN through a signaling pathway independent of the signaling activated by TLR3. 
Working with RIG-I- (RIG-I-/) and MAD5- (MAD5-/-) deficient mice, it was demonstrated that RIG-I is 
essential in recognizing RNAs from paramyxoviruses, influenza virus, and Japanese encephalitis virus; 
MAD5 is essential in recognizing picornavirus RNA and for the expression of IFN (Heim, 2005; Hornung 
et al., 2006; Yoneyama et al., 2004). These results show that RLRs recognize different types of viral 
RNAs and activate a signaling pathway involved in the expression of IFN, different from the pathway 
used by TLRs. It was recently shown that cells over-expressing RIG-I and stimulated by Newcastle 
Disease Virus (NDV) or VSV present increased levels of expression of type-I IFN; in contrast, cells with 
low-level expression of RIG-I and stimulated by NDV, VSV, Sendai virus, HCV, or WNV show 
decreased levels of IFN (Loo et al., 2008). Because RIG-I/MAD5a induces antiviral responses, it has been 
suggested that the signaling pathways of both proteins have a common adaptor protein, but it is unclear 
whether they act in synergy when recognizing viruses. However, MDA5 not only participates in antiviral 
responses, it also inhibits the growth of tumor cells, through type-I IFN (Heim, 2005; Yoneyama et al., 
2004). Effector proteins involved in viral PAMP recognition. In the previous sections, the main PRRs 
involved in the induction of antiviral responses upon exposure to viral PAMPs were described. 
Nevertheless, it is also worth mentioning some proteins encoded by IFN-stimulated genes (ISGs). These 
proteins recognize virus structural components and through diverse mechanisms can activate antiviral 
responses. The first effector protein described with such characteristics was the PKR, which is an IFN-
inducible serine-threonine kinase, but in contrast to PRRs, its activation does not regulate transcription, 
but blocks protein synthesis (Langland, Cameron, Heck, Jancovich, & Jacobs, 2006). PKR possesses two 
dsRNA-binding motifs (dsRBMs) in its N-terminal region and a kinase motif in its C-terminal region. As 
a monomer, PKR is inactive, but its binding with dsRNA or highly structured RNAs induces its 
homodimerization and stimulates its autophosphorylation and auto-activation (Williams, 2001). Once in 
the active state, PKR is dissociated from the dsRNA and phosphorylates the a-subunit of the eukaryotic 
translation initiation factor 2 (eIF2a), resulting in the inhibition of cellular and viral protein synthesis. 
PKR can also be stimulated by pro-inflammatory factors, such as growth factors, cytokines (Langland et 
al., 2006), or the PKR-activating protein (PACT). In virus infected cells, most of the natural PKR 
activators are viral dsRNAs or viral life cycle replication intermediates. However, complex viruses with 
DNA genomes like Vaccinia virus (VV), Adenovirus, HSV-1, or HSV-2 have open reading frames 
(ORFs) in opposite orientation. This allows the production of overlapping mRNA transcripts that result in 
the production of dsRNAs that can in turn activate PKR. Interfering RNA (RNAi) used to silence PKR, or 
PKR knockout mice, has shown a reduction in their expression affects IFN production upon WNV 
infection, making the mice more susceptible (Langland et al., 2006; Samuel, 2001). The presence of viral 
RNA also activates 2’-5’OAS, also known as 2’5’ A synthetase. This enzyme is activated by IFN and was 
initially described as regulator of IFN synthesis, and, hence, as a key factor in antiviral responses (Leroy, 
Baise, Pire, & Desmecht, 2007; Samuel, 2001). 2´5´OAS promotes the degradation of viral RNA and 
catalyzes the synthesis of 2’5’ oligodenylates that activate the latent cellular RNase (RNAse L) (Leroy et 
al., 2007). ADAR1, 2, and 3 belong to another family of proteins known as adenosine deaminase acting 
on RNA (ADAR). ADAR1 is induced in response to IFN and has two different isoforms: ADAR1p150 
and ADAR1p110. Recently, it was described that, in infected cells, dengue virus 2 (strain TSV01) 
activates the expression of genes regulated by IFN, such as ADAR, PKR, and 2’5’OAS (Umareddy et al., 
2008). It has also been demonstrated that ADAR1 is responsible for editing the Hepatitis delta virus 
RNA, independently of IFN stimulation (Hartwig et al., 2006). However, one of the most interesting 
aspects of ADAR is its participation in the biogenesis of microRNA, which are non-coding RNAs 
implicated in the regulation of the expression of genes, whose products participate in various cellular 
processes. Additionally, it has been reported that ADAR1-induced modifications are necessary for the 
maturation of such RNAs (Faller & Guo, 2008). Recently, the stimulator of interferon gene (STING) 
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protein, a new adaptor molecule that induces the expression of type-I IFN and plays a role in antiviral 
response was described. STING has 5 possible transmembrane domains; if STING is present in the 
endoplasmic reticulum, it can activate both NF-kb and IRF3 and induce the expression of type-I IFN 
(Nakhaei, Hiscott, & Lin, 2010; Zhong et al., 2008). Studies made with mouse embryonic fibroblasts that 
do not express STING show that such cells are susceptible to infection by viruses with negative polarity 
RNAs, including VSV (Ishikawa & Barber, 2008). Another mechanism of host-virus recognition is 
through the Fv or [tripartite motif (TRIM)] protein. Many proteins with such motifs have been described. 
The different isoforms are produced by alternative mRNA splicing and each variant codes for a unique 
domain in its C-terminus. TRIM proteins, including TRIM5a that has in its C-terminal region the B30.2 
or SPRY motif, can down regulate replication of retroviruses, such as HIV-1 and Murine leukemia virus 
(Funderburg et al., 2008). On the other hand, some proteins members of the GTPase family, known as 
MX, are involved in recognition of viral proteins like the nucleocapsid, which after being recognized 
change their cellular location, affecting the production of new viral particles. All these mechanisms 
demonstrate the existence of a wide variety of strategies for pathogen recognition and host protection 
upon viral infections. In summary, effector proteins play antiviral roles through 4 different mechanisms: i) 
arrest of protein synthesis, ii) degradation of viral RNA, iii) adenosine deaminase enzymes play an 
important role in converting adenosines to inosines (AàI), inducing errors in translation, and iv) 
recognition of viral proteins. However, some of these processes can drastically affect cell viability and 
cause the induction of apoptosis (Umareddy et al., 2008). For this reason, the antiviral response induced 
by these types of proteins is immediate and observed only during the early stages of the infection, before 
the activation of the adaptive immune response. 
Role of TLRs in viral pathogenesis 
As described in this review, the aim of the recognition of viral PAMPs by PRRs is to control infection 
and/or contribute to the development of the adaptive immune response. However, prolonged activation of 
the innate immunity by TLRs can contribute to viral pathogenesis; for example, in WNV-infected mice in 
which the activation of TLR3 induces elevated production of TNF-a and IL-6 involved in the 
development of an inflammatory state, the permeabilization of the hematoencephalic barrier is induced, 
allowing viral entry and resulting in greater infection of the central nervous system24. Similarly, it has 
been described that RSV induces the over-expression of TLR3 and TLR4 that trigger an inflammatory 
state in the respiratory mucosa of the infected individual, who is rendered vulnerable to infections by 
other pathogens (Kurt-Jones et al., 2000). In cells stimulated in vitro with specific TLR2, 3, 4, 5, 7, 8, and 
9 ligands and infected with HIV-1, both naïve and memory T CD4+ and T CD8+ lymphocytes are 
activated. T CD8+ lymphocytes are activated and begin to express CD69, which promotes their own 
retention in lymphoid tissues, but T CD4+ cells lose the ability to express CD69. Despite these 
phenotypic changes, the cell population enters the cell cycle, but grows poorly, and can even undergo 
apoptosis. These results suggest that the systemic activation of TLRs through diverse ligands favors 
immune activation, effector cell sequestering, and T cell turnover. All these events can contribute to the 
immune dysfunction caused by HIV-1 and to the loss of T CD4+ lymphocytes in chronic HV-1 infections 
(Funderburg et al., 2008). 
Applications of TLRs in immunotherapies for viral disease control 
Because TLRs are important for the induction of the innate immune response, understanding the 
molecular mechanisms involved in their activation could contribute to the development of immune 
therapies of vaccines, not only for viral diseases, but also for sepsis, allergies, autoimmune diseases, and 
cancer. TLR activation induces several different effects in immune cells, such as cytokine production, the 
positive regulation of co-stimulatory molecules like CD40, CD80, and CD86; for pDCs, which when 
stimulated through TLR9, induce IFN-a production. In this instance, besides the antiviral effect of IFN, it 
also influences the transport and clustering of pDCs51. This phenomenon is indispensable for the 
stimulation of the adaptive immune response in lymph nodes (Asselin-Paturel & Trinchieri, 2005). Other 
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studies also carried out with pDCs have demonstrated that early stimulation (4 h post-stimulation) with 
TLR7 agonists activates the antiviral cell machinery. Furthermore, stimulation of TLR7 and TLR8 with 
imiquimod and resiquimod, specific agonist, respectively, have therapeutic effects in basal cell 
carcinoma, genital lesions, and other epithelial lesions, generally associated with chronic human 
papillomavirus (HPV) infections (Miller, Meng, & Tomai, 2008); these compounds induce apoptosis of 
HPV-infected cells and of other epithelial cells with dysplasic or neoplasic changes. 
Evasion of innate immunity by viruses 
As a consequence of the interaction between PRRs and PAMPs, the signaling pathways activated result in 
cytokine and IFN expression, or in the case of effector proteins, in inhibition of protein synthesis or 
degradation of viral dsRNAs. However, viruses has developed strategies to evade or take advantage of 
such immunological barriers for productive infections. Among the strategies already described is 
blockage of certain steps in the synthesis of IFN-a/b, inactivation of secreted IFN molecules, interference 
with signaling and/or blockage of the activity of effector antiviral proteins through their sequestration, 
production of viral homologous proteins, or competition. In the following paragraphs, we briefly describe 
some of the cell components manipulated by viruses to evade the innate immune response. Expression of 
type-I IFN depends on the activation of IRF3 and IRF7 via IKK epsilon and TBK1. The genome of 
Rabies virus, Borna disease virus, and Ebola virus code for the P phosphoprotein and VP35 that can block 
the antiviral response induced by IFN (Brzozka, Finke, & Conzelmann, 2005; Conzelmann, 2005; Feng, 
Cerveny, Yan, & He, 2007). In contrast, the human herpes simplex virus 8 encodes different analogs of 
IRF with negative dominant activity, allowing it to interfere with the activity of cellular IRFs56. The 
infected cell polypeptide 0 (ICP0) from Bovine herpes virus can interact with IRF3 and induce its 
proteasome-dependent degradation (Saira, Zhou, & Jones, 2007). Similarly, the V protein of 
paramyxoviruses interacts with MD5-a and inhibits IFN-a expression (Andrejeva et al., 2004). The 
genome of VV encodes two proteins (A46 and A52) that specifically inhibit the TLR-dependent signaling 
pathway. A46 interacts with the adaptor MyD88, TRIF and TRAM; while A52 interacts with TRAF and 
IRAK-2, inhibiting the formation of the complex implicated in the signaling pathway (Bowie et al., 
2000). During chronic infections, the NS3/4A protease of HCV degrades the TRIF adaptor of TLR3, 
resulting in an alteration of the antiviral response induced by dsRNA. There is also evidence regarding 
inhibition of PKR by viruses via several pathways: VV E3L, Influenza virus NS1, and Reovirus d3 
proteins can sequester dsRNAs and prevent PKR activation. Other viruses express dsRNA or highly 
structured RNAs that compete for binding to PKR. EBER-1 and EBER-2, expressed during the latent 
state of EBV and HCV IRES are some such examples40. Inhibition of PKR can also result from protein-
protein interactions, as is the case of the HCV NS5 and VV E3L that interact with PKR and inhibit its 
function (Feng et al., 2007; Langland et al., 2006; Samuel, 2001). The transcription factor NF-kB is 
essential in the induction of the IFN expression and of pro-inflammatory cytokines involved in antiviral 
response. However, it can also be beneficial for viruses, given that the promoters of some viruses, 
including HIV-1, CMV, and EBV have binding sites for NF-kb, which facilitates transcription of the viral 
genome. Hence, some viruses can up- or down-regulate the NF-kkb expression; for example, some 
proteins of the African swine fever virus are able to regulate its expression. In the early stages of 
infection, the early viral protein A238L inhibits NF-kb expression, but once the infection progresses the 
late viral protein A224L stimulates its expression (Tait, Reid, Greaves, Wileman, & Powell, 2000). 
Furthermore, besides the direct strategies inhibiting IFN expression, VV expresses the A52R protein, 
which contains a TIR domain that interacts with the cytoplasmic proteins IRAK-2 and TRAF6 involved 
in TLR  
HIV-1 infection at a post-entry, pre-integration stage in the viral life cycle. 
compartment as described for the PAMPs of other pathogenic agents. From this perspective, 
compartmentalization of the innate system has some similarity with the adaptive immune system because 
both systems use certain factors, depending on their cellular location. It is clear; however, as shown here, 
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that upon infection, the immune response is initiated with the recognition of viral PAMPs by PRRs, 
resulting in the up-regulation of IFN-a/b. Since the discovery of IFN, 50 years ago, knowledge about the 
signaling pathways that regulate its production has greatly expanded. The discovery of different PRRs has 
led to better understanding the interactions between the innate and adaptive immune responses and has 
favored the development of new therapies owing to the discovery that the stimulation of TLRs plays an 
important role in the protection from, or in the development of diseases. This highlights the importance of 
studies aiming to better understand the regulatory mechanisms and the signaling pathways associated with 
the PRRs in response to PAMPs.Other molecules that have also gained importance are the effector 
proteins, which inhibit protein synthesis, degrade RNA, or modify viral genomes and are also involved in 
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Scope of the thesis 
 
The work described in this thesis focuses on the early events associated with dengue virus (DENV) 
infection. DENV is transmitted to humans via mosquito bites and targets cells of the host immune system 
including monocytes/macrophages and dendritic cells (DCs) (Kurane & Ennis, 1988; Marovich et al., 
2001; Wu et al., 2000). There are 5 distinct DENV serotypes (ScienceInsider, 2013) and antibodies 
generated during a primary infection appear to have a dual role in controlling DENV re-infection. Upon 
re-infection, the pre-existing antibodies bind to the newly infecting virus and target the virus to Fc-
receptor (FcR) expressing cells, including monocytes/macrophages and DCs (Boonnak et al., 2008; 
Halstead & O'Rourke, 1977a; Halstead, 2003; Kliks et al.,1989). Viral entry is subsequently facilitated by 
antibody-FcR interaction (Boonnak et al., 2013). At high antibody titers, viral infectivity is neutralized 
and no specific disease symptoms develop. At sub- or non-neutralizing antibody concentrations, however, 
enhanced DENV infectivity is seen in monocytes, macrophages and DCs indicating that DENV can 
escape from degradation (Boonnak et al., 2008; Halstead & O'Rourke, 1977a). This phenomenon - also 
known as antibody-dependent enhancement (ADE) of infection– is associated with the development of 
severe disease (Burke & Kliks, 2006; Halstead & Simasthien, 1970; Halstead, 2003). Severe disease is 
predominantly seen in individuals with a heterologous secondary DENV infection and during primary 
DENV infection of infants born to dengue-immune mothers (Burke & Kliks, 2006; Halstead & 
Simasthien, 1970; Halstead & O'Rourke, 1977b; Simmons et al., 2007). Thus, during primary as well as 
secondary infection, the cells that are the primary sentinels of host immunity become viral factories. My 
objective was to unravel if and how DENV infection with and without antibodies influences the function 
of these cells, with emphasizes on DCs. To answer this, we characterized the activation status of cells 
targeted by DENV in ex-vivo and in vitro models. Additionally, we investigated the infectious potential 
of immature dengue virions and corroborated their importance in severe disease pathogenesis. 
 
Chapter 4 provides an ex-vivo analysis of monocytes and DCs isolated from dengue-infected patients in 
the acute and convalescent phase of the disease. Several in vitro and ex vivo studies revealed that Toll-
like receptor (TLR) signaling is altered by DENV infection (Azeredo et al., 2010; de Kruif et al., 2008; 
Modhiran, et al., 2010; Sun et al., 2009). Therefore, we here analyzed the expression of several TLRs and 
co-stimulatory molecules on monocytes and DCs from patients with different clinical outcomes. We 
found a link between lower expression of TLR3 and TLR9 and disease severity. In addition, DCs of 
severe dengue cases were observed to express lower levels of CD80 and CD86. Lastly, we demonstrate 
that interferon alpha production decreases in the presence of dengue virus after stimulation of PBMCs 
with TLR9 agonist.  
 
In Chapter 5, we evaluated if the presence of waning titers of anti-DENV-2 specific serum influences 
DENV-2 infection and activation of immDCs. In contrast to what has been previously described 
(Dejnirattisai et al., 2011; Nightingale et al., 2008), we found that only a small percentage of immDCs 
supports DENV infection. The vast majority of immDCs do internalize virus particles but apparently 
DENV fails to achieve a productive infection in most cells.  Furthermore, in line with a previous study 
(Boonnak et al., 2008), waning antibody titers do not enhance DENV infection in immDCs. Also, we 
show that while infection in the absence of antibodies impairs DCs activation, DCs acquire a fully mature 
state following infection at high antibody titers. Notably, infection of DCs at non-neutralizing serum 
conditions was found to trigger an intermediate, semi-mature phenotype.  
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ImmDCs proved to be relatively permissive to DENV infection in the absence of antibodies and fail to 
support ADE (Chapter 5, refs). On the other hand however, mature DCs are believed to be low/non 
permissive to DENV infection but do support enhanced infection in the presence of non-neutralizing 
antibodies (Boonnak et al., 2008). Therefore, in chapter 6, we evaluated the relative role of immature and 
mature DCs in DENV-2 infection in the absence and the presence of non-neutralizing antibodies. We 
investigated the specific infectivities of viruses produced in these two DC populations and show a striking 
difference in the quality of the viral progenies.  
 
DENV-infected cells secret virions that vary in maturation state from fully mature to fully immature 
particles (Cherrier et al., 2009; Junjhon et al., 2010). The latter are considered non-infectious, however 
their infectivity can be rescued by DENV-specific antibodies (Dejnirattisai et al., 2010; Yu et al., 2008; 
Zybert et al., 2008). Interestingly, partially immature particles of West Nile Virus (WNV) – like DENV a 
member of the flavivirus genus – was shown to infect cells expressing DC-SIGN (Mukherjee et al., 
2011). The glycan moieties on prM were found to interact with DC-SIGN, thereby facilitating virus 
binding and cell entry. Therefore in chapter 7, we revisited the infectious properties of immature DENV 
and tested its ability to infect immature DCs. We show that immature DENV exhibits low infectivity in 
immature DC, which is strictly dependent on its interaction with DC-SIGN receptor. Additionally, we 
demonstrate that, consistent with data on standard DENV preparations, macrophages but not immature 
DCs support ADE of immature virus infection.  
 
In chapter 8 we investigated the contribution of immature DENV particles in severe disease. We analyzed 
the capacity of acute DENV-2 sera from patients with DF, DHF and DSS to bind and enhance infection of 
immature DENV-2. We conclude that immature particles and antibodies recognizing these virions act as a 
co-factor in disease pathogenesis. 
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Differential Expression of Toll-like Receptors in Dendritic 
Cells from Patients with Dengue during Early and Late 
acute phases of the disease 
 
Silvia Torres, Juan Carlos Hernández, Diana Giraldo, Margarita Arboleda, Mauricio Rojas, Jolanda M 
Smit, and Silvio Urcuqui-Inchima 
 
Dengue hemorrhagic fever (DHF) is observed in individuals that have pre-existing heterotypic dengueantibodies and 
is associated with increased viral load and high levels of pro-inflammatory cytokines early in infection.Interestingly, 
a recent study showed that dengue virus infection in the presence of antibodies resulted in poor stimulation of Toll-
like receptors (TLRs), thereby facilitating virus particle production, and also suggesting that TLRs may contribute to 
disease pathogenesis.We evaluated the expression levels of TLR2, 3, 4 and 9 and the co-stimulatory molecules 
CD80 and CD86 by flow cytometry. This was evaluated in monocytes, in myeloid and plasmacytoid dendritic cells 
(mDCsand pDCs) from 30 dengue patients with different clinical outcomes and in 20 healthy controls. Increased 
expression of TLR3 and TLR9 in DCs of patients with dengue fever (DF) early in infection was detected. In DCs 
from patients with severe manifestations, poor stimulation of TLR3 and TLR9 was observed. In addition, we found 
a lower expression of TLR2 in patients with DF compared to DHF. Expression levels of TLR4 were not affected. 
Furthermore, the expression of CD80 andCD86 was altered in mDCs and CD86 in pDCs of severe dengue cases. 
We show that interferon alpha production decreased in the presence of dengue virus after stimulation of PBMCs 
with the TLR9 agonist (CpG A). This suggests that the virus can affect the interferon response through this signaling 
pathway.These results show that during dengue disease progression, the expression profile of TLRschanges 
depending on the severity of the disease. Changes in TLRs expression could play a central role in DC 
activation,thereby influencing the innate immune response 
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Author summary:  
Dengue is a public health problem worldwide and the most prevalent mosquito-borne viral disease affecting 
humans. Dengue virus (DENV) infections causes a broad spectrum of clinical manifestations, ranging from self-
limited fever to severe disease, such as dengue hemorrhagic fever (DHF), that can be fatal. The pathogenesis of 
severe dengue is associated with an inadequate immune response characterized by the over-production of cytokines 
and other inflammatory components. However, little is known about the role of the innate immune response in the 
progression to hemorrhagic manifestations. TLRs constitute one of the most important components of innate 
immunity and are responsible for initiating a response against a variety of pathogens, including viruses.  Recent 
studies suggest that TLRs may contribute to disease pathogenesis. Here we aimed to explore the role of these 
receptors in dengue disease progression. To this end, we examined the expression of several TLRs and of co-
stimulatory molecules in monocytes and DCs from dengue patients. A link between TLRs expression and severity of 
dengue was observed: patients with dengue fever express higher levels of TLR3 and TLR9 than patients with DHF. 
This could be crucial in host defense against dengue virus or disease progression. In addition, expression of CD80 
and CD86 was altered in DCs of severe dengue cases. We show that interferon type I production is also altered in 














































Dengue is the most widespread mosquito-borne viral disease worldwide. It is estimated that 50 million dengue 
infections occur each year, and that 2.5 billion people are at risk of acquiring dengue virus (DENV) infection 
(WHO, (2009)). It is caused by any of the four distinct, but closely related DENV serotypes (DENV-1 to 4), that are 
members of the Flaviviridae family (Lindenbach & Rice, 2003). DENV infection may lead to a febrile illness known 
as dengue fever (DF) but can also result in life-threatening complications defined as dengue hemorrhagic fever 
(DHF) and dengue shock syndrome (DSS) (WHO, 1997).  
Clinical and epidemiological studies have revealed that a secondary infection with a heterotypic serotype is a risk 
factor for the development of severe dengue disease (de Kruif et al., 2008; Halstead & Simasthien, 1970). 
Furthermore, infants born from dengue-immune mothers are at risk of acquiring severe dengue disease during a 
primary infection (Chau et al., 2008). The development of severe disease has therefore been linked to the presence 
of pre-existing antibodies. Although the mechanisms involved in immune-enhanced disease are still poorly 
understood, multiple in vitro studies have shown that antibodies promote viral entry and suppress antiviral 
responses, allowing a higher production of virus particles per infected cell (Boonnak, Dambach, Donofrio, 
Tassaneetrithep, & Marovich, 2011; van der Schaar, Wilschut, & Smit, 2009; Vaughn et al., 2000). The high 
infected cell mass and viral load seen early in infection together with an aberrant T cell response is believed to 
induce a cytokine storm which causes the hemorrhagic manifestations.  
The first line of defense towards pathogens is mediated by the innate immune system. Key players in the initiation 
of the innate immune response are Toll-like receptors (TLRs). TLRs recognize invaders through detection of 
pathogen-associated molecular patterns. To date, 10 TLRs have been described in humans, 6 of which (TLR2, 3, 4, 
7, 8, and 9) are implicated in recognition of viral components; namely viral nucleic acids and proteins (Takeda & 
Akira, 2007). TLRs are abundantly expressed on monocytes, macrophages and dendritic cells (DCs) (Jarrossay, 
Napolitani, Colonna, Sallusto, & Lanzavecchia, 2001; Zarember & Godowski, 2002), the main target cells of 
DENV, and trigger antiviral defenses such as the production of interferon and pro-inflammatory cytokines. 
Activation of TLR3 and TLR7 inhibits DENV replication in the monocyte cell line U937 and the human cell line 
HEK293, respectively (Tsai, Chang, Lee, & Kao, 2009), indicating that these TLRs possess antiviral activity 
towards DENV. Intriguingly, however, when DENV cell entry is facilitated by antibodies, activation of TLR-
negative regulators and down-regulation of TLR4 and genes associated with TLR signaling, have been observed in 
the monocyte cell line THP1 (Modhiran, Kalayanarooj, & Ubol, 2010). These results indicate that immune 
suppressive mechanisms are activated through this mode of viral entry. Similar results were found in peripheral 
blood mononuclear cells (PBMCs) from patients experiencing secondary DHF but not DF. Furthermore, and in line 
with the above observations, several clinical studies have indicated that alterations in pro-inflammatory cytokine 
production, as observed in DHF patients, can be attributed to recognition through TLRs (). Taken together, the 
recognition and subsequent activation of TLRs may be a contributing factor in dengue disease pathogenesis. In this 
study we examined the expression level of TLR2, 3, 4 and 9 and of the co-stimulatory molecules CD80 and CD86 
(CD80/CD86) in dengue patients experiencing distinct disease manifestations. TLRs and CD80/CD86 expression 
was evaluated in the acute and convalescent phase of the disease. The expression patterns of the different TLRs were 
assessed in each cell population as follows: monocytes (TLR2/4/9) (Hornung et al., 2006; Nguyen et al., 2010), 
plasmacytoid DCs (pDCs; TLR2/9) (Hemmi et al., 2002; Hernandez, Arteaga, Paul, Kumar, Latz, & Urcuqui-
Inchima, 2011a; Hernandez, Arteaga, Paul, Kumar, Latz, & Urcuqui-Inchima, 2011b) and myeloid DCs (mDCs; 
TLR2, 3, 4 and 9) (Kadowaki et al., 2001; Nguyen et al., 2010; Perrot et al., 2010). These cells represent important 
targets of DENV infection [22], and are key players in the innate immune response (Cella, Sallusto, & 
Lanzavecchia, 1997). Our data indicates there is a differential regulation of TLR expression profiles during the acute 
phase of DF and DHF disease. 
 




The protocols for patient enrollment and sample collection were approved by the Committee of Bioethics Research 
of the Sede de Investigación Universitaria, Universidad de Antioquia (Medellín, Colombia), as well as by the 
informed consent form, according to the principles expressed in the Declaration of Helsinki. All subjects read and 
signed an informed consent (including healthy donors). When the participant was a minor, the informed consent was 
signed by at least one parent.  
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Study populations and blood samples 
 
Thirty DENV-infected patients, 13 female and 17 male subjects between 12-72 years of age were enrolled in this 
study. Twenty healthy, 10 females and 10 males 13-52 years old, were included as healthy controls (HC). All HC 
were negative for DENV NS1 antigen and DENV IgM/IgG and have not been vaccinated against yellow fever virus. 
Dengue patients were enrolled from May 2009 to February 2010 in five healthcare centers located in Turbo and 
Apartadó, two municipalities of Antioquia, Colombia. 
Thirty ml of peripheral blood (PB) were taken and added to EDTA-containing tubes. Blood samples were collected 
three times, on the 3rd and 5th day after the beginning of symptoms (acute samples) and 15 days after admission to 
the hospital (convalescence samples). Infection with dengue was confirmed if one of the following tests were 
positive (1) Platelia™ Dengue NS1 Antigen kit (Bio-Rad Laboratories, Marnes La Coquette, France), (2) DENV 
specific real-time RT-PCR (Chutinimitkul, Payungporn, Theamboonlers, & Poovorawan, 2005), (3) DENV IgM 





Figure 1. Flowchart of enrolment, inclusion/exclusion criteria, diagnosis and classification of dengue patients.  
Inmunoensayo, Instituto Pedro Kourí, La Habana, Cuba) or (4) virus isolation and propagation in C6/36 mosquito 
cells (Singh & Paul, 1969). To determine whether the patient had a primary or secondary infection, the presence of 
dengue-specific IgM/IgG antibodies was evaluated, using the PanBio Dengue Duo Cassette System (PanBio Ltd, 
Queensland, Australia). Anti-dengue IgG levels were determined on day 3, on day 5 and on day 15 after the 
beginning of symptoms and if there was no rise in IgG titer over time it was classified as secondary infection. 
Dengue cases where classified as DF or DHF according to the guidelines of the World Health Organization (WHO) 
of 1997 (WHO, 1997), we applied the old guidelines as the new WHO guidelines published in 2009. The new 
guidelines are more focused on clinical practice and are not widely accepted for use in research (Srikiatkhachorn et 
al., 2011). Clinical characterization of DHF included the following criteria: fever, thrombocytopenia (platelet counts 
<100x103/mm3), hemorrhagic manifestations, positive tourniquet test, and hemoconcentration (20% changes in 
hematocrit value) or ascites as evidenced by plasma leakage. A flow chart explaining the in/exclusion criteria is 
depicted in figure 1. 
 
Flow cytometry  
 
PB samples were used to determine the frequency of mDCs, pDCs and monocytes and their expression of TLRs. All 
patients and healthy controls the proportion of mDCs, pDCs, and monocytes among blood mononuclear cells were 
0.5% (0.4-1.6%) 0.3% (0.1-1%), and 6% (4-12%), respectively. Peripheral blood was incubated with the appropriate 
antibodies at room temperature for 25 minutes. The whole blood was lysed with lysing Buffer BD Biosciences, San 
Jose, CA during 10 minutes at room temperature. Leucocytes were resuspended and washed in PBS containing 0.5% 
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BSA and 0.1% sodium, fixed with 2% formaldehyde and stored at 4ºC until analysis. For staining of intracellular 
receptors (TLR3 and TLR9), the cells were treated with fixation permeabilization buffer from (eBiosciences, San 
Diego. CA) following the manufacturer’s recommendations. All samples were evaluated within 2-4 h of staining and 
200,000 events were acquired per tube. Analyses were performed using the BD 
FACS Dive V6.1.1 (BD Biosciences), and the operating software on the FACS Canto II flow cytometer. TLR levels 
were expressed as mean fluorescent intensity (MFI) compared to the isotype-control. Logical gating was used to 
identify mDC, pDC and monocyte populations. The evaluation was done by single tube analysis. The acquisition 
gate (P1) was common for all the populations and was established based on forward scatter (FSC) and side scatter 
(SSC) corresponding to the gate of mononuclear cells (approximately 130,000-170,000 events). For phenotyping of 
each sub-population the following strategy was used: mDCs (Lin1-/CD11chigh) were gated as P3, Lin1 positive 
cells were excluded from analysis (gate P2), the pDCs (BDCA-2+/CD123high) were gated as P2 and monocytes 
(CD14+) were gated as P2 (Fig. 2A). Each speciﬁc sub-population was plotted as a histogram to show the 
expression of TLR2, 3, 4 and 9 (Fig. 2B). The data are presented as overall mean ﬂuorescence intensity (MFI) for 
toll-like receptors (TLRs) on the TLR+ subset, after subtraction of isotype staining background. The following 
monoclonal antibodies were used: Lineage 1 FITC (anti-CD3, anti-CD14, anti-CD16, anti-CD19, anti-CD20, and 
anti-CD56 cocktail), anti-CD123 PE-Cy5, anti-CD11c PE-Cy5, anti-CD80 PE and anti-CD86 PE (BD Biosciences, 
San Jose, CA). Anti-TLR2, 3, 4 and 9 were PE conjugates (eBiosciences, San Diego, CA). Anti-BDCA-2 FITC was 
from (Miltenyi Biotec, Auburn CA). Unstained cells and conjugated isotype antibodies were used as controls; all of 
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Figure 2. Gate strategy for identification of mDCs, pDCs and monocytes from PB samples and TLR staining. (A) 
Non duplets population was fractioned in mDCs  as mononuclear cells Lin
-
 and CD11c 
High 










(B) Representative examples of TLR2 expression in mDCs, pDCs, 
and monocytes. HC indicates healthy control and DF denotes for dengue fever. 
Virus stocks and titration 
 
The DENV-2 New Guinea C strain (NGC) was provided by the Center for Disease Control (CDC, Fort Collins, 
CO), and propagated in the C6/36 mosquito cell line. C6/36 cells were grown in L15 medium (Invitrogen, Carlsbad. 
CA) supplemented with 10% heat-inactivated fetal bovine serum, 1% vitamins, 1% L-glutamine and 1% non-
essential amino acids (Sigma-Aldrich Chemical Co, St. Louis, Mo), and incubated at 34°C without CO2 for 24 h. 
The cells were inoculated with DENV-2 at 0.01 multiplicity of infection (MOI) and incubated at 34°C for 5-6 days. 
The supernatants were collected and clarified by centrifugation (1500 g, 10 min). The virus titer was determined by 
conventional plaque assay in kidney rhesus monkey cells, (LLC-MK2), essentially as described (Srikiatkhachorn et 
al., 2011). Inactivation of the virus was achieved by exposure to UV light for 60 min.Influenza A virus (IAV) strain 
A/PR8/34 was kindly donated by Paula Velilla (Immunology Group, Universidad de Antioquia). Virus titration was 
performed by the limit dilution method, using 96-well microplates (Nunclon, NY). The virus titer was estimated by 
the cytopathogenicity of the cells and expressed as 50% tissue culture infectious doses/ml (TCID50/ml) of IAV ; 
1x104 TCID50/ml were used for the infection of PBMCs. The supernatant from IAV-infected PBMCs was used as a 
positive control to measure interferon concentration by ELISA (eBioscience, San Diego. CA). 
 
Preparation and infection of PBMCs 
 
PBMCs were isolated from  HC by density gradient centrifugation using Ficoll-Hypaque (Histopaque 1077, Sigma 
Aldrich Chemical Co., St. Louis, MO); all samples were processed within the first 8 h after collection. PBMCs were 
cultured at 1.0x106 cells/ml in 24-well polystyrene tissue culture plates at 37ºC in 5% CO2, using RPMI 1640 
medium (BioWhittaker, Walkersville, MD) supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml 
penicillin/streptomycin (Sigma Aldrich Chemical Co., St. Louis, MO) and 1% of L-glutamine (Sigma Aldrich 
Chemical Co., St. Louis, MO). Subsequently, the cells were challenged with wild-type DENV or UV-inactivated 
(iDENV), at a MOI of 5, for 2 h at 37°C in 5% CO2. The PBMCs were then washed and incubation was continued 
for another 24 h in the presence or absence of a TLR agonist: 50 μg/ml of polyinosinic:polycytidylic acid 
[poly(I:C)], 10 μg/ml of lipopolysaccharide (LPS), 5 μg/ml resiquimod (R848) and 5 μM oligonucleotides with 
motifs of unmethylated cytosine-phosphate-guanine (CpG) dinucleotides type A (CpG A); (Invivogen .San Diego. 
CA), for TLR3/TLR4/TLR7/8 and TLR9, respectively. To neutralize the stimulatory effect of CpG ODNs, 5 mM 
ODN TTAGGG was used (Invivogen .San Diego. CA). The supernatants were harvested after 24 h of culture and 
the interferon alpha (IFN-α) concentration was measured by ELISA according to the manufacturer’s protocol 




Statistical comparisons between the healthy donors and the dengue groups were performed using the Kruskal-Wallis 
test, with a confidence level of 95% followed by Dunn’s multiple comparison test. To compare TLRs expression 
according the severity of the disease, a Mann-Whitney test was employed. The critical value for statistical 
significance used for the analyses was P<0.05. All the analyses were carried out using the GraphPad prisma (Graph 
Pad, CA) software.




Characteristics of patients 
 
In this study, 45 patients were enrolled, 30 of which were positive for DENV infection. From the 30 dengue positive 
cases, 19 (67%) were classified as DF- and 11 as DHFpatients (Fig. 1), based on the guidelines of the WHO (WHO, 
1997). The patients were admitted to the hospital and PB samples were taken on days 3, 5, and 15 after onset of 
symptoms. Six patients (26.6%) developed ascites related to dengue infection; there were no patients with DSS nor 
mortal cases. The demographic and clinical information of the 30 dengue patients enrolled in this study are 
summarized in Table 1 
 
Demographic and clinical characteristics of 30 individuals with diagnosis of dengue and 20 healthy controls 
 Controls DF* DHF* 
 n=  20 n=  19 n=11 
Age, yr, mean ±SD                                                        32.61(16.41) 30.94(18.24) 33.09(12.56) 
Gender    
Male   10 11 6 
Female 10 8 5 
Severity criteria, no. (%)    
Thrombocytopenia*  3(15.78) 11(100) 
Hemoconcentration  8(42.10) 9(81.81) 
Ascites  2(10.52) 4(36.36) 
Spontaneous hemorrhage  4(21.05) 8(72.72) 
Positive tourniquet result   5(26.31) 9(81.81) 
Units specified in parenthesis are percentages; otherwise data are numbers 
(DF)*=Dengue fever; (DHF)*=Dengue Hemorrhagic fever. 
Thrombocytopenia* = Platelet counts <100000/mm3. 
Hemoconcentration*= Hematocrit level rising  ≥ 20%  
Ascites*=accumulation of fluid in the peritoneal cavity confirmed by abdominal 
ultrasound. 
Spontaneous hemorrhage=nose bleeding, gastrointestinal bleeding, ocular bleeding, 
and/or bleeding gums.  
Positive tourniquet= petechiae of ≥20 spots in a 2.5-cm2 area on the forearm after 
application of pressure at the midpoint between systolic and diastolic pressure for 5 min 
using a sphygmomanometer. 
 
TLR expression is up-regulated in mDCs and pDCs during the acute phase of dengue  
 
DCs are not only important target cells of DENV infection; they also play a central role in the innate antiviral 
response, through TLRs activation. Therefore, we evaluated the expression levels of TLR2, 3, 4 and 9 in mDCs, 
pDCs and monocytes of dengue patients, and compared them to HC. In mDCs of dengue patients, TLR3, TLR4 and 
TLR9 reached maximum expression on day 5 of illness (Fig.3A ).  
The MFI results showed that expression of TLR3 in mDCs was significantly higher in dengue patients than in HC, 
on days 3 and 5 of illness (P<0.05 and P<0.01, respectively).(Fig. 3A). For TLR4, only at day 5 a significantly 
higher expression  was observed (Figure 3A),. Expression of TLR9 in mDCs of dengue patients was significantly 
increased (P<0.05) on day 5 of illness compared to those of HC, while expression of TLR2 in mDCs did not differ 
between dengue patients and HC (Fig. 3A). Our results also show that on day 15, the level of expression of all the 
TLRs tested decreased to levels similar to those of HC (Fig 3A). 
Unlike in mDCs, in pDCs of dengue patients, only TLR2 expression was stimulated. The MFI of TLR2 reached 
maximum peaks at day 5 of illness. (Fig. 3B). On day 15, TLR2 expression was similar to that of HC (Fig. 3B), 
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suggesting that after DENV infection, TLR2 expression tends to normalize. In pDCs, the expression of TLR3, 4 and, 
9 did not differ between dengue patients and HC (Fig. 3B). In monocytes, no differences in TLR expression levels 
were detected between dengue patients and HC (data not shown). Similar results were obtained when the TLRs 
frequency was evaluated on the basis of absolute cell counts (data not shown).  
 
Differential expression of TLR2 in mDCs and pDCs of DF and DHF patients during the acute phase of infection 
 
The development of DHF is associated with an increased level of circulating pro-inflammatory cytokines and 
chemokines (Chang & Shaio, 1994; Gagnon et al., 2002; Lee et al., 2006), and several in vitro studies indicate that 
TLRs may contribute to this phenomenon (Azeredo et al., 2010; de Kruif et al., 2008). Therefore, we compared the 
expression profile of TLR2 and TLR4 in mDCs, pDCs and monocytes of patients with DF and DHF on different 
days of disease to that of HC. Similar TLR2 and TLR4 expression levels were detected in monocytes of DF, DHF 
patients and HC (data not shown). In contrast, there was a modulation in TLR2 expression in DCs of DF and DHF 
patients. On day 3 of illness, DF patients presented significantly lower TLR2 expression in mDCs, compared to HC 
and DHF (P<0.05; Fig. 4A). On days 5 and 15, the level of TLR2 expression was similar in patients with DF and 
DHF. In pDCs of DHF patients, a significant increase in TLR2 expression was seen on day 3 of illness, compared to 
HC (P<0.05; Fig. 4B). This increase reached a maximum on day 5 of acute infection (P<0.001). No differences were 
found in TLR4 expression levels in mDCs (data not shown). 
 
TLR3 and TLR9 expression is higher in DCs of DF than in those of DHF patients 
The effect of DENV on intracellular TLRs expression was evaluated in cell lines and in animal models (Nasirudeen 
et al., 2011; Wang et al., 2006). However, the effect of DENV infection on the modulation of intracellular TLRs 
expression in DCs of patients with DF or DHF has not been reported. The results show that on day 5 after the 
beginning of symptoms, mDCs of DF patients had a higher MFI for TLR3 and TLR9 than the mDCs of DHF 
patients (P<0.05) and HC (P<0.001 
  





Figure 3. Increased expression of TLRs in mDCs and pDCs of dengue-infected patients. Expression profile of 
TLR2, 3, 4 and 9 in mDCs and pDCs of dengue patients isolated at different times after the onset of disease 
symptoms (day 3, 5 and 15) (n = 30)  and of healthy controls (n = 20). The evaluation of TLR expression was 
performed by flow cytometry based on mean fluorescence intensity (FMI) analysis. Data are presented as the 
median and 25–75 interquartile ranges Statistical analysis was performed by using the Kruskal-Wallis test followed 
by the Dunn’s Multiple comparisons Test. *p< 0.05,  ** p< 0.01 and ***p< 0.001 
 
and P<0.01), respectively; Fig. 5A and B). On day 3 of illness, mDCs from DF or DHF showed a higher MFI for 











































































































































































































A Myeloid dendritic cells B Plasmacytoid dendritic cells




Figure 4. Increased TLR2 expression in pDCs of patients with severe disease. Analysis of TLR2 expression by flow 
cytometry of PB mDCs and pDCs cells in DF patients (n= 19) and DHF patients (n=11) at different times after the 
onset of symptoms (days 3, 5 and 15). Data are presented as the median and 25–75 interquartile ranges. Statistical 
analysis was performed by the Mann Withney test.*p< 0.05, ** p< 0.01 and ***p< 0.001. 
convalescent phase, the expression levels of TLR3 and TLR9 decreased to similar levels as in HC. The MFI results 
for TLR9 in pDCs of DF patients showed higher expression levels on day 3 of illness compared to those of DHF 
patients (P<0.05; Fig. 5A ). Taken together, our results are consistent with recently published in vitro data 
(Nasirudeen et al., 2011; Tsai et al., 2009; Wang et al., 2006), and suggest that the increase in TLR3 and TLR9 
expression in DF patients could act as an antiviral factor. 
Down-modulation of CD80/CD86 in mDCs of DHF patients 
 
Infection of mDCs with DENV has been reported to induce DC maturation and activation, albeit to lower levels than 
observed in uninfected DCs (Libraty, Pichyangkul, Ajariyakhajorn, Endy, & Ennis, 2001; Palmer et al., 2005). Since 
the effect of DENV on DC maturation is unclear in vivo we here assessed the maturation state of the mDCs and 
pDCs by examining the expression profile of the co-stimulatory molecules CD80 and CD86 in DF and DHF 
patients.Because the co-stimulatory molecule CD80 appears to be expressed in resting unstimulated mDCs (Velilla 
et al., 2008), we quantified the expression level of CD80 in mDCs of patients with DF and DHF and compared it 
with the expression in mDCs of HC. Analysis of the MFI showed that the mDCs of DHF patients express 
significantly lower levels of CD80 (P<0.05) and CD86 (P<0.001), when compared to HC (Fig. 6A and 6B). Also in 
pDCs, a significant decrease in the expression level of CD86 was seen in patients with DF and DHF (P<0.05 and 
P<0.01, respectively), compared to HC. No differences were found in the expression of CD80 in pDCs (data not 
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Figure 5. TLR3/TLR9 in 
mDCs and TLR9 in pDCs have different expression levels depending on disease severity. Analysis of TLR 
expression levels was performed as described in the legend of Figure 3. 
 
 
Figure 6. Expression of the co-stimulatory molecules CD80 and CD86 is affected in mDCs of DHF patients. 
Expression of CD80 and CD86 was evaluated by flow cytometry based on the FMIanalysis in mDCs and pDCs of 
DF and DHF patients on day 3 of illness and compared to that of healthy controls (HC). Data are presented as the 
median and the statistical analysis of the expression of CD80 and CD86 was performed by the Mann Withney 
test.*p< 0.05, ** p< 0.01 and ***p< 0.001 
Type I IFN production through TLR9 is impaired in DENV infection of PBMCs in vitro 
 
It is known that DENV is a weak inducer of type I IFN production after infection of human DCs. Several possible 
mechanisms have already been proposed to explain this observation (Mazzon, Jones, Davidson, Chain, & Jacobs, 
2009; Munoz-Jordan, Sanchez-Burgos, Laurent-Rolle, & Garcia-Sastre, 2003). The differential expression profiles 
of TLR3 and TLR9 in DF and DHF patients presented here may also influence type I IFN secretion. However, 
whether recognition of viral components by TLRs triggers IFN production in DENV-infected cells or, whether 
DENV infection affects the function of TLRs is largely unclear. To expand our knowledge on this subject, we tested 
the ability of PBMCs to respond to the TLR3, 4, 7/8 and 9 ligands, and trigger the IFN-α pathways, after challenge 
with wild-type DENV or iDENV at a MOI of 5 2 hours after the infection. We decided to use PBMCs for these 
studies to mimic natural infection thereby allowing cross talking between cell subsets. PBMCs only treated with the 
TLR3, 7 and 9 agonists and challenged with DENV showed a variable but enhanced IFN-alpha production when 
compared to that of non-treated cells, except for the TLR4 agonist LPS, which produced similar levels of IFN-α as 
the control (Fig. 7). PBMCs infected with DENV in presence of the TLR3, and 7/8 agonists further stimulated IFN 
production (P<0.05). The observation that iDENV produces a more robust IFN-α response than wild-type DENV is 
in line with prior published data indicating that the, NS2B, NS4B and NS5 proteins are responsible for inhibition of 
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led to a significant decrease of IFN-α expression (P<0.05), compared to PBMCs treated with CpG A only. In 
addition, PBMCs were treated with TTAGGG ODN, a compound that can neutralize the stimulatory effect of CpG 
A and consequently the production of IFN-α. After the treatment INF-α production was evaluated and a strong 
decrease (p<0.05) in IFN-α realease was observed compared with the mock without antagonist (Fig. 7). Were the 
cells were treated with CpG A, the antogonist and DENV, the IFN-α production was also decreased, suggesting a 
possible synergistic effect between DENV and the antagonist, in the IFN-α reduction.  
 
 
Figure 7. IFN-α production by PBMCs in response to TLR9 ligand is impaired by DENV infection. PBMCs from 
healthy controls were challenged with wild type DENV or iDENV at a MOI of 5 and then stimulated with agonists 
for TLR3 (poly:IC), TLR4 (LPS), TLR7 and TLR8 (R848)  and TLR9 (CpG A). The production of  IFN-α was 
measured by ELISA after 24 h pot stimuli. The antagonist of TLR9 (TTAGGG ODN) was used to neutralize the 
stimulatory effect of GpG A in the presence of DENV or iDENV. The supernatant from C6/36 cells were used as 
mock and Influenza virus was used as positive control for IFN-α production.Data are presented as the mean of 
values of at least two independent experiments performed in triplicate; error bars indicate standard deviation. 
Statistical comparisons among groups were carried out using the Kruskal-Wallis  test comparing between groups. 
*p<0.05 and** p<0.01. 
Discussion 
 
An immune response with loss in the homeostasis of cytokine secretion has been proposed as the central event in the 
development of DHF (Pang, Cardosa, & Guzman, 2007). TLRs are important initiators of cytokine production and 
in this report we show that DENV can modulate/alter TLRs expression in DCs. We observed an increased 
expression level of TLR3 and TLR9 in mDCs and of TLR2 in pDCs during the acute phase (days 3-5 after onset of 
symptoms) of DENV infection. When dengue patients were classified according the clinical outcome, a higher 
expression level of TLR2 was seen in DHF patients when compared to DF patients. In contrast, mDCs of DF 
patients expressed higher levels of TLR3 and TLR9 than those of DHF patients especially at day 5 of illness. In 
pDCs, this difference was also observed for TLR9 on day 3 of illness.  
The mDCs and pDCS are both important players of the innate immune system but vary with respect to their origin, 
phenotype and functional features (Dudziak et al., 2007; Steinman & Cohn, 1974). Previous studies have also 
indicated that these cells differ in permissiveness to DENV infection. Whereas mDCs are readily infected with 
DENV, pDCs are essentially non-permissive to infection (Sun et al., 2011).Interestingly, we observed changes in 
TLR expression in both mDCs and pDCs during the early acute phase of illness. TLR3 expression was increased in 
mDCs and this is likely related to infection of these cells since TLR3 is known to recognize dsRNA (Sun et al., 
2011). Cell surface-expressed TLR2 was up-regulated in pDCs, presumably due to sensing of the virus at the cell 
surface. Indeed, even though pDCs do not support a full replicative cycle of DENV, these cells do respond to 
infection since phenotypic and functional changes have been described upon addition of DENV to these cells 
(Steinman & Cohn, 1974). This phenomenon has also been previously reported for HIV-1, where in vitro studies 
showed up-regulation of TLR2 and TLR4 in pDCs (Hernandez, Arteaga, Paul, Kumar, Latz, & Urcuqui-Inchima, 
2011b; Hernandez, Stevenson, Latz, & Urcuqui-Inchima, 2012).  
Notably, we also found an up-regulation of TLR9 in mDCs. Basal expression of TLR9 has not been previously 
reported on mDCs, but a recent study showed that mDCs respond to the TLR9 agonists CpG A and CpG B thereby 
increasing the expression levels of CD80 and of human leukocyte antigen (HLA-DR9) molecules on the cell 
(Nguyen et al., 2010). These findings suggest that the expression of TLR9 can be enhanced after stimulation with its 
agonist. We show here that IFN-α production was significantly affected in PBMCs exposed to DENV in the 
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presence of the TLR9-agonist, suggesting that TLR9 responds to DENV infection.However, how TLR9 is activated 
in DENV infection is unclear,as TLR9 is known to recognize pathogen-associated DNA (Alexopoulou, Holt, 
Medzhitov, & Flavell, 2001; Hemmi et al., 2002; Krieg, 2002). One could speculate that the increased TLR9 
expression is due One could speculate that the increased TLR9 expression is due cross-talking between different 
receptors or adaptor proteins from different signal pathways as this has been described to occur in a pro-
inflammatory environment (Yoshida, Jono, Kai, & Li, 2005). 
Monocytes have also been reported to represent target cells of DENV replication (Sun et al., 2011). Moreover, 
Azeredo et al. (Azeredo et al., 2010) showed an increase of TLR2 expression in monocytes CD14+ of dengue-
infected patients. Subsequent in vitro studies revealed an increased frequency of TLR2 in pro-inflammatory 
monocytes (CD14+ and CD16+) and it was proposed that overexpression of TLR2 in CD16+ cells could contribute 
to DHF. We also assessed TLR2/TLR4 expression in monocytes but no effect of DENV infection on TLR2 and 
TLR4 expression was detected. This discrepancy is probably related to differences in the analysis and classification 
of the cell populations. 
TLR3 is specifically up-regulated in mDCs in patients with acute DF since no TLR3  up-regulation is seen in 
patients that develop DHF. Previously, Tsai and co-workers (Tsai et al., 2009) reported that TLR3 induces an anti-
dengue response in HEK293 cells. Furthermore, there is evidence that the type I IFN response initiated by TLR3 
contributes to the elimination of Hepatitis C virus (Kanda, Steele, Ray, & Ray, 2007). Based on the above 
observations, we postulate that TLR3 is associated with antiviral responses towards DENV. by TLR3 could promote 
the production of pro-inflammatory cytokines and IFN. This inhibiting DENV replication and therefore could 
prevent the development of severe manifestations. Indeed, and in line with our results, a recent report showed down-
regulation of TLR3/4/7 in PMBCs of patients experiencing secondary DHF but not DF (Modhiran et al., 2010). 
TLR2 expression was up-regulated in pDCs and mDCs of DHF patients but not of DF patients. Recent studies 
suggest that TLR2 is an important promoter of pro-inflammatory cytokine release, reviewed in (Mangada & 
Rothman, 2005; Marshall, Heeke, Gesner, Livingston, & Van Nest, 2007; Yoshida et al., 2005). Increased pro-
inflammatory cytokine production is one of the hallmarks of severe disease (Mangada & Rothman, 2005; Suharti et 
al., 2003). Therefore we postulate that individuals with a higher response to DENV through TLR2 may be more 
likely to develop severe manifestations, whereas patients who express TLR3 and TLR9, may have some degree of 
protection and may probably be less likely to develop DHF. 
TLRs not only promote cytokine release; they also  promote the up-regulation of co-stimulatory molecules such as 
CD80 and CD86 to favor cell maturation and efficient antigen presentation to T cells (Akira & Takeda, 2004). We 
found that mDCs of DHF patients have lower expression levels of CD80 and CD86 than HC suggesting inefficient 
maturation of mDCs in these patients. This may be explained by the low  TLR3 and TLR9 expression levelin 
patients with DF or DHF. In pDCs, a significant down-regulation of CD86 was observed in both DF and DHF 
patients. This could have important consequences in the development of a specific immune response able to induce 
memory T cells to control future infection. This hypothesis is supported by the observation of lower CD80/CD86 
expression levels in DHF patients, compared to DF patients (in mDCs) and healthy donors (in DCs). Libraty et al. 
(Libraty et al., 2001) reported lower expression of CD80 and CD86 in DCs in DENV infection in vitro. Sun et al. 
(2009) observed that in purified pDCs and mDCs the presence of the virus promotes the expression of CD80 and 
CD86 in mDCs but not in pDCs suggesting that DENV can down regulate the co-stimulatory molecules CD80 and 
CD86 (Sun et al., 2011). However, further studies are required to elucidate the mechanisms involved in this 
phenomenon. 
In conclusion the differential expression of TLRs in dengue may influence the clinical outcome of the disease. 
Future research is necessary to fully understand the participation of the innate immune response in dengue 
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Dendritic cells (DCs) play a dual role in DENV infection. They are the major initiators of antiviral 
immune responses and also susceptible to be infected. Previous observations named DCs as major targets 
in DENV infection, and show that infected cells can undergo maturation and cytokine productions under 
infection conditions. We evaluate the maturation profiles of DENV in immDCs infected with DENV in 
the presence or absence of DENV-immune serum. We found that DENV infection hampers the ability of 
DCs to unregulated cell surface expression of the co-stimulatory markers CD83 and CD86, and the major 
histocompatibility complex molecule HLA-DR when assessed by flow cytometry. Low concentrations of 
IL4, IL6, IL10 and TNF-α were found in supernatants from cells infected unaided to antibodies when 
compared to the cells infected in neutralizing conditions, Suggesting that the presence of immuno-
complexes activates signalization and cytokine production.These results demonstrate that DENV  impairs 
response by DCs an suggest that the extra stimuli by high concentrations of antibodies can works as 
compensatory mechanism to restore the DCs response, highlighting the protective role of antibodies 
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Author summary:  
DCs have been proposed as major targets in DENV infection and are, without doubt, a critical component 
of the initiation of antimicrobial response. Here we evaluated the susceptibility and response of DCs in 
the presence and, in the absence, of DENV-immune serum. We found that the internalization of viral 
particles detected by flow cytometry was not always indicative of the production of infective particles. 
Thereafter, when we evaluated the effect of antibodies in the phenotype and function of DCs we found 
that DENV infection, unaided to antibodies, blocked the maturation and cytokine production of immDCs. 
In contrast, the presence of DENV-antibodies complexes induced maturation of the cells, as well as 
cytokine production. We concluded that direct infection by DENV blunted the innate immune response. 
The upregulation of maturation and cytokine productions, carried out in the presence of immune-
complexes formed during neutralizing conditions, could play a crucial part in the host’s defense against 





























With an estimated 400 million infections each year, dengue virus (DENV) is the most important 
mosquito-borne viral disease world-wide. There are 5 serotypes of DENV (DENV1—5) and infection 
with each serotype can be asymptomatic or lead to a wide range of clinical symptoms ranging from a flu-
like illness to severe and potentially fatal disease (Bhatt et al., 2013; ScienceInsider, 2013; WHO, 1997). 
Primary infections are often asymptomatic and provide life-long protection against homotypic re-
infection and short term (approx. 9 months) protection against heterotypic re-infections (revised in 
(Murphy & Whitehead, 2011)). Intriguingly, individuals that are re-infected with a heterologous virus 
serotype after the cross-protection period are at risk of developing severe disease (Halstead, 2003; 
Halstead, 2007). Severe disease is also seen during primary infections in infants with low numbers of 
circulating maternal dengue antibodies (Simmons et al., 2007). Thus, antibodies appear to play an 
important role in controlling DENV infection. Indeed, in vitro and in vivo studies demonstrated that 
DENV infectivity depends on the concentrations and/or avidity of antibodies present during infection. 
DENV infection is contained in the presence of neutralizing antibody titers (de Alwis et al., 2011; Endy et 
al., 2004; van der Schaar et al., 2009). At sub- and non-neutralizing antibody concentrations, however, 
enhanced infection of immune cells is seen by facilitating viral entry via FcR-antibody interaction 
(Halstead, 2003).  
Dendritic cells (DCs) are the front line of defense invading pathogens. Upon antigen recognition 
immature DCs (immDCs) acquire a mature phenotype (matDCs), which is characterized by high cell 
surface expression of co-stimulatory molecules, major histocompatibility complex II molecules (HLA-
DR), as well as secretion of pro- and anti-inflammatory cytokines (Banchereau & Steinman, 1998; Cella 
et al., 1997). Activation of DCs is crucial for shaping the innate responses as well as for initiation of 
adaptive immunity (Banchereau & Steinman, 1998; Cella et al., 1997). DCs also represent the primary 
targets for DENV replication during primary and secondary infections (Marovich 2001; Wu et al., 2000). 
In the absence of antibodies (direct infection), immDCs have been shown to be particularly permissive to 
DENV infection (Boonnak et al., 2008; Boonnak et al., 2011; Nightingale et al., 2008) and viral 
replication was shown to blunt their maturation cytokine production (Chang et al., 2012; Munoz-Jordan et 
al., 2003; Munoz-Jordan, 2010). In the presence of high antibody titers, immDCs were shown to 
neutralize viral infection (Boonnak et al., 2008). ImmDCs do not support enhancement of infection at 
decreasing antibody concentrations (Boonnak et al., 2008).  Notably, the effect of DENV-specific 
antibodies on the activation of DCs upon infection remains unknown.  
In the present study, we evaluated the infectious properties of DENV in immDCs in the absence and 
presence of dengue-specific antibodies and investigated the effect antibodies on immDCs activation. We 
show that immDCs are only moderately permissive to DENV infection as the majority of the internalized 
virions do not induce a productive infection. We show that in the absence of antibodies DENV replication 
inhibits the ability of immDCs to undergo maturation and produce cytokines. On the contrary, depending 
on the antibody titers, DENV-immune complexes triggered fully or partially mature DCs phenotypes with 
distinct cytokine profiles, suggesting yet another mechanism by which pre-existing antibodies may 
influence DENV infection. 
Methods  
Virus and cell lines 
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DENV-2 strain 16681 was propagated in the Aedes albopictus cell line C6/36 as described before 
(Rodenhuis-Zybert et al., 2010). In summary, C6/36 cells were inoculated with DENV-2 at a multiplicity 
of infection (MOI) of 1. DENV particles were harvested at 72 hours post-infection (hpi) and cleared from 
cell debris by low speed centrifugation. The specific infectivity of DENV-2 was determined by measuring 
the number of infectious units by plaque assay on BHK-15 cells and the number of genome containing 
particles (GCPs) by quantitative PCR (qPCR) analysis, as described previously (van der Schaar et al., 
2007; Zybert et al., 2008). To generate UV-inactivated (UVi) virus, 1mL of DENV-2 was placed in a 
petri dish and exposed to UV light for 1 hour. The reduction in specific infectivity of UVi-treated virus 
was confirmed by plaque assay and qPCR, as described before (van der Schaar et al., 2007; Zybert et al., 
2008). 
Antibodies and DENV-immune serum 
Intracellular DENV staining was done by using the murine anti-DENV 3H5 (Millipore) or the rabbit anti-
DENV orb1707 (Biorbyt). A well-characterized convalescent DENV-2 immune serum (kindly provided 
by G. Comach Biomed-UC, Lardidev, Maracay, Venezuela; and T. Kochel, U.S. Naval Medical Research 
Center Detachment, Lima, Peru) was used as a source of polyclonal antibodies. The serum was obtained 
from a 12 year old boy with a primary DENV2 infection and was collected at 28 days after the onset of 
disease symptoms.  
Monocyte-derived dendritic cells 
Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats by density 
centrifugation using Ficoll-Paque™ Plus (GE Healthcare). The buffy coats were obtained with informed 
consent from healthy volunteers, in line with the declaration of Helsinki (Sanquin Blood bank). PBMCs 
were adhered to tissue culture dishes and after 90 minutes, monocytes were isolated by gelatin adherence, 
as described before (Miller et al., 2008). Next, monocytes were allowed to differentiate in complete 
RPMI medium (CM) with 20% fetal bovine serum (FBS), 500 U/ml recombinant granulocyte 
macrophage colony-stimulating factor (rGM-CSF), and 250U/ml recombinant human interleukin-4 (rIL-
4) (both from Prospec-Tany). The CM was replaced every second day for 6 days to generate immDCs. 
After 6 days of culture at 37°C, the phenotype of the cells was confirmed using flow cytometry analysis, 







. To generate mature dendritic cells (matDCs), the immDCs were further 
stimulated with monocyte-conditioned medium mimic (MCMm) containing recombinant human 
interleukin 6 (rIL-6), recombinant human interleukin 1β (IL-1β), tumor necrosis factor alpha (TNF-α), 
and prostaglandin E2 on day 6, as described in (Boonnak et al., 2008). Maturation of DCs was verified on 
the basis of an increase of the intensity of expression of CD40, CD83, and CD86 surface markers. 
Representative dot plots of the phenotype of immDCs and matDCs can be found in supplementary figure 
1. 
Infection assays 
DENV-IC were pre-formed by incubating the virus for 1 hour at 37°C with 10-fold sequential dilutions of 
DENV-2-immune serum. Then, the DENV-immune complexes were diluted with cell culture medium 
containing 2% FBS and added to immDCs. DENV infection was performed at a multiplicity of infection 
(MOI) of 0.1, 1, and 10 in the presence or the absence of the diluted DENV immune serum. At 1 ½ hpi at 
37 ⁰C, the inoculum was removed, cells were washed, and medium was added. At 24 hpi, cells and 
supernatants were harvested and separated by low-speed centrifugation. Cell viability was evaluated using 
LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen). The phenotype of the cells and viral titers were 
analyzed using flow cytometry as mentioned below. Virus production was assessed by plaque assay on 
BHK-15 cells and qPCR analysis (van der Schaar et al., 2007; Zybert et al., 2008).  
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Flow cytometry  
Staining of infected and mock-infected immDCs was performed 24 hpi. In parallel, typical DCs surface 
markers (including maturation markers) were analyzed. To this end, aliquots of (5 × 10
5
) cells were 
placed into cytometry tubes with FcRs block buffer True Stain FcX (Biolegend) and incubated for 10 min 
at room temperature. Cells were subsequently washed in a staining medium containing EDTA, saponin, 
and 2% FBS, all of which were provided by Sigma. Cells staining was performed with a panel of DCs 
markers (Lineage cocktail Lin-1 FITC, CD11c A PC, and HLA-DR V450) and a maturation panel (CD 40 
alexa fluor, CD83 PECy7and CD86 V500) for 30 minutes at 4°C. Cells were washed twice with staining 
medium and ﬁxed prior to acquisition. Additionally, a second aliquot was used for intracellular DENV 
staining. The cells were treated with intracellular fixation buffer in conjunction with the permeabilization 
buffer (eBioscience). Then, murine anti-DENV 3H5 (Millipore) was added followed by a secondary anti-
mouse Alexa-647 labeled antibody. As an additional strategy for viral detection, a rabbit anti-DENV orb 
1707 (Biorbit) was used. Isotype controls mAbs were used in every experiment to establish background 
staining and to set quadrants before analysis. The multi-color FACS analysis was performed on a LSR-II 
instrument (BD Biosciences) and the analysis was performed using Flow-jo software (Tristar). 
Measurement of cytokine levels 
Cytokines were measured in cell-free supernatants by using the cytometry bead array Human Cytokine 
Kit (BD Biosciences) per the manufacturer's instructions. Briefly, multiscreen 1.2μm hydrophilic filter 
plates (Millipore) were pre-wet with wash buffer and aspirated. Capture beads for each of the four 
examined cytokines (IL-4, IL-6, IL-10, TNF-α) were combined with 50 μl of supernatant obtained from 
the infectivity experiments. After 1 hour incubation at room temperature, phycoerythrin detection reagent 
for each cytokine was pooled and added to the wells. Incubation was continued for 2 hours at room 
temperature, after which the plate was washed and the beads were re-suspended in wash buffer. Data 
collection was done on a BD FACS canto cytometer. Calculations were performed using BD Biosciences 
CBA software.  
Statistical analyses 
Mann-Whitney U test was applied to the data with Prism software (GraphPad Software Inc). Differences 
were considered statistically signiﬁcant when p<0.05(*), p< 0.01 (**), p<0.001(***).  
Results 
Permissiveness of immDCs to DENV infection in the absence and presence of antibodies 
ImmDCs were generated from human monocytes, as described in the methods section. The obtained cell 






, confirming the differentiation of the 
cells from monocytes into DCs (Supplementary Figure 1A). To evaluate the ability of the cells to undergo 
maturation, immDCs were stimulated with monocyte-conditioned medium mimic (MCMm) and stained 
for surface expression of maturation markers (CD40, CD83, CD86, HLA-DR). At 24 hours post-
stimulation, DCs showed increased expression of these maturation markers when compared to non-
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Figure 1. DENV infection of immDCs in the absence and presence of DENV-immune serum. (A) 
ImmDCs were infected with standard (std) or UV inactivated (UVi) DENV at MOI 1 or MOI 10. Direct 
denotes DENV infection in the absence of DENV-immune serum. Neutr denotes DENV infection in the 
presence of serum at dilution 10
3
. Non-neutr denotes DENV infection at serum dilution 10
8
. Cells and cell 
supernatants were harvested at 24 hours post-infection (hpi). The frequency of DENV-positive cells was 
determined using MAb 3H5. DENV-positive populations are designated as DENV+ and DENV++. 
Representative dot plots of three independent experiments are shown. (B) Quantitative analysis of the 
infectious properties of DENV in immDCs. Dashed line: percentage of DENV ++ cells; grey bars: 
number of infectious particles (Log10 PFU/ml); black bars: number of genome-containing particles (log10 
GCPs/mL). Results are representative of at least 10 experiments with 3 donors. 
First, we assessed the permissiveness of immDCs to DENV infection (Figure 1). The cells were infected 
with DENV at MOI 10, 1, 0.1 with or without prior opsonization with increasing dilutions of DENV-2 
immune serum. At 24 hpi, the percentage of dengue antigen-positive cells was evaluated by using two 
distinct DENV-specific mAbs, 3H5 and orb1707. In addition, virus progeny production was measured by 
plaque assay on BHK-15 cells and qPCR to obtain both the number of infectious (plaque forming units- 
PFU) and physical particles (genome containing particles -GCPs) titers, respectively. A representative dot 
plot of immDCs infected at MOI 10 and MOI 1 and stained with DENV-E-specific 3H5 mAb is shown in 
Figure 1A. Note that two distinct DENV-positive populations (designated DENV+ and DENV++) were 
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detected following infection at MOI 10 and 1. We detected on average 3 % DENV++ immDCs following 
infection at MOI 1, which is considerable less than described in literature (Figure1 A and 1B, (Boonnak et 
al., 2008; Boonnak et al., 2011; Marovich et al 2001; Nightingale et al., 2008)). We did not detect 
DENV++ cells following infection at MOI 0.1 (data not shown).Since pathogen recognition and antigen 
presentation is an important feature of DCs, we inferred that the DENV+ population corresponded to cells 
that internalized the virus but aborted infection, while DENV++ population represented cells that were 
productively infected. To validate this, we exposed the cells to UVi-DENV at MOI 10 and 1 (inactivation 
of the virus was confirmed by PFU and GCP titration; data not shown). As shown in Figure 1A and 1B, 
we could only detect DENV+ cells following exposure of the cells to UVi-DENV (UVi direct panels). 
This indicates that the population identified as DENV+ populations indeed corresponds to cells that have 
internalized the virus, whereas the DENV++ populations indicate cells that are actively infected with 
DENV.  
In order to test the effect of DENV-immune serum on the permissiveness of immDCs to DENV, the cells 
were infected with DENV-2 pre-opsonized with increasing dilutions of the serum at MOI 1. The DENV-







 dilution is shown in Figure 1A and 1B). We used immDCs derived 
from 3 different donors and in none of them we detected PFU or GCP titers (detection limits are 20 
PFU/ml and 400 GCP/ml) following infection with DENV pre-opsonized with a 10
3
 serum dilution. 





led to a recovery of DENV PFU titers to the levels similar as direct infection. 
In line with a previous report (Boonnak et al., 2008), no enhancement of infection was observed, even at 
further dilutions of the serum (data not shown). Importantly, as in case of UVi virus, we did detect 
DENV+ cells under neutralizing conditions (Figure 1A). This finding further corroborates that the 
DENV+ population represents DCs that internalize the virus but abrogate viral replication. The 
identification of DENV+/++ populations upon infection of immDCs has not yet been described and we 
wondered whether this was related to the staining antibody used. Therefore, we also evaluated DENV 
infection by using a rabbit anti-DENV orb1707.  With this antibody, the DENV+ and DENV++ 
populations were not clearly separated (Supplementary Fig. S2), however, the total percentage of DENV 
positive cells detected by rabbit anti-DENV orb1707was similar to the sum of DENV+ and DENV++ 
populations detected by the murin anti-DENV 3H5 Ab (Table 1). Thus, the percentage of DENV positive 
cells detected by the rabbit anti-DENV orb1707  did not represent active infection but cells that 
internalized and/or replicated the virus, and implies that immDCs are not so permissive to dengue 
infection as previously considered.  
Changes in DCs phenotype following DENV infection with and without antibodies 
The effects of direct DENV infection on the maturation and activation of immDCs has been studied 
extensively (Boonnak et al., 2008; Boonnak et al., 2011; Ho et al., 2001; Libraty et al., 2001; Nightingale 
et al., 2008; Sun et al., 2009). In the majority of these studies, activation of DCs was measured at 48 hpi, 
which translates to 2 rounds of DENV replication. However, to directly assess the effect of antibodies on 
DCs maturation it is important to evaluate the expression markers after  
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Figure 2. Differences in DC phenotype following direct DENV infection and infection in the 
presence of antibodies. ImmDCs were infected with std virus or UVi DENV at MOI 1 in the absence 
and presence of DENV-immune serum. The mean fluorescence intensity (MFI) of the expression of co-
stimulatory markers CD83 and CD86 and the major histocompatibility complex molecule HLA-DR was 
assessed by flow cytometry at 24 hpi. As a control mock-infected matDCs were used (white bars).  A 
representative analysis of at least three independent experiments ± SD is shown. Statistical analysis was 
done by use of Mann-Whitney U-test (*P< 0.05 ** P < 0.01). Stars above the bars indicate differences 
when compared to mock-infected cells. 
 
1 round of replication. Therefore, we here measured the surface expression of CD83, CD86, HLA-DR 
and CD40 at 24 hpi. Mock-infected (with and without the addition of dengue-immune serum) and 
MCMm-stimulated matDCs were added as negative and positive controls, respectively. CD40 was found 
to be equally up-regulated in all infection conditions (data not shown). CD83, CD86, or HLA-DR were 
not up-regulated following direct DENV infection when compared to mock-infected cells (Figure 2). A 
significant increase in the surface expression of CD83, CD86 and HLA-DR molecules was however 
observed following exposure of the cells to DENV pre-opsonized with neutralizing serum titers. At 
neutralizing conditions, the expression levels of the maturation markers were similar to that of MCMm-
stimulated matDCs. To investigate, whether the up-regulation of the maturation markers was solely due to 
the blockage of replication, we compared the expression of the maturation markers in cells infected with 
DENV at neutralizing conditions with that of cells exposed to UVi-DENV (UVi direct). As depicted in 
Figure 2 and Supplementary Table S1, there were no clear differences in the expression levels of CD83, 
CD86 between these two conditions. Expression of  HLA-DR was only up-regulated following infection 
in the presence of neutralizing antibody titers, suggesting that HLA-DR up-regulation is triggered by the 
DENV-immune complex. To verify this, we next compared the expression profile of maturation markers 
upon direct infection and infection at non-neutralizing conditions. At these conditions, a similar number 
of infected cells is seen (Fig.2). Notably, only DENV in complex with antibodies triggered significant up-
regulation of HLA-DR, CD83 and CD86 in DCs. Accordingly, it appears that antibody opsonization of 
DENV provides an extra signal that is essential for immDCs to acquire a fully mature phenotype under 
neutralizing and an incomplete/semi-mature phenotype under non-neutralizing conditions. 
 
Expression of maturation markers increased only in DCs that internalized the virus. 
Previous studies reported differences in the maturation profile of DENV positive and bystander cells 
(Palmer et al., 2005). Therefore, we sought to evaluate the expression levels of surface molecules in cells 
that internalized (DENV+),  replicated the virus (DENV++) and DENV negative cells (DENV neg). 
However, all the antibodies available to determine the maturation profile of DCs are generated in mice, 
and therefore the detection pair comprising murine anti-DENV 3H5 clone and anti-mouse Ab could not 
be used. As primary labeling of this Ab proved not efficient enough to visualize the DENV+ and 
DENV++ cell populations, we used the rabbit anti-DENVE orb1707 Ab (Table 1).  As demonstrated in 
Figure 3, in all infection conditions DENV antigen-positive DCs expressed higher levels of maturation 
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antigen-positive cells (black bars) detected following exposure to abortive infection (neutr. and UVi 
conditions) expressed  
 
 
Figure 3. DENV antigen-positive and negative cells differentially express maturation markers. 
Experimental conditions and subsequent analysis are similar as described in the legend to Figure 2. 
DENV infection was done at MOI 1. Cells were stained with a rabbit anti-E antibody. White bars: DENV 
antigen-negative cells; black bars: DENV antigen-positive cells. The data is representative of three 
independent experiments ± SD. Statistical analysis was done by use of Mann-Whitney U-test (*P< 0.05).  
Stars above the bars indicate differences when compared between DENV positive and negative cells in 
each condition tested 
 
relatively higher levels of maturation markers than those exposed to successful infection(direct and non-
neutr. conditions). This suggests that cells that actively replicate DENV express lower levels of 
maturation markers when compared to cells that only internalized virus. In line with the data from the 
total DCs population, significantly higher expression of HLA-DR was found in DENV antigen-positive 
cells exposed to DENV in complex with antibodies, than in those exposed to direct infection (Figure 
3).This strengthens the idea of a distinct DCs activation pathway in the presence of immune-complexes. 
 
Presence of specific antibodies during DENV infection alters the profile of cytokines released from 
DCs. 
Activated DCs release soluble immune modulators including cytokines, which play an essential role in 
shaping the immune response (Banchereau & Steinman, 1998). Accordingly, we next investigated 
whether differences in the level of DC maturation induced after DENV infection in the absence and the 
presence of antibodies translated to a particular cytokine expression profile. Herein, we evaluated the 
levels of pro- (IL-6, TNF-α), and anti-inflammatory cytokines (IL-10, IL4), in the supernatants of DCs 
infected at different conditions (Figure 4). Upon direct infection, no change in maturation markers was 
observed and in line with this, no increased levels of cytokine production were seen when compared to 
the mock-infected cells. Furthermore, immDCs exposed to DENV under neutralizing conditions did 
mature and secreted significantly higher amounts of TNF-α, IL-4, IL-10 and IL-6.  It has been reported 
that ligation of FcγRIIa is required for production of IL-6 and TNF-α following infection of matDCs 
under ADE conditions (Boonnak et al., 2008). Therefore, we blocked FcγRIIa in immDCs and infected 
the cells with DENV pre-opsonized with a neutralizing serum dilution. Indeed, blocking FcҮRIIa 
inhibited the production of cytokines as similar levels were observed during mock infection (Figure 4), 
indicating that FcγIIa ligation triggered the cytokine production. Interestingly however, blocking of 
FcγRIIa had no effect on the neutralizing capacity of the antibodies (data not shown), suggesting that 
neutralization and activation depend on the engagement of different Fc receptors and that this occurs 
simultaneously. At non-neutralizing infection conditions, higher levels of IL-6, IL-4  and TNF-α were 
found when compared to direct infection. As the addition of the serum alone did not trigger cytokine 
response (data not shown), these results suggest that opsonization of DENV with non-neutralizing 
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Figure 4. DENV-immune complexes stimulate cytokine secretion by DCs. DENV infection (MOI 1) 
was performed as described in the legend to Figure 2. When indicated, anti-FcγRIIa was added to 
immDCs prior infection. At 24 hpi, TNF-α, IL-4 IL-6, and IL-10 production was measured by a Cytokine 
Bead Assay (CBA). White bars: mock-infected cells; grey bars: DENV-infected cells. The data shown are 
representative of at least three independent experiments ± SD. Statistical analysis was done by use of 
Mann-Whitney U-test (* P< 0.05; ** P < 0.01, *** P <0.001). Stars above the bars indicate differences 
when compared to mock. 
 
Discussion  
In the present study, we investigated the susceptibility of immDCs to DENV in the absence and presence 
of DENV-immune serum and evaluated their response to infection. By a combinatory approach of 
different titration methods we showed that many immDCs internalize DENV particles but only a 
relatively small fraction of cells is productively infected. This indicates that the majority of immDCs 
aborted viral infection. DENV-immune serum, depending on the serum dilution, neutralized DENV 
infection or had no effect. Yet, we found substantial differences in the maturation and response of 
immDCs infected with DENV at neutralizing or non-neutralizing antibody conditions. In the absence of 
antibodies, DCs were not activated. In contrast, however, at conditions of antibody-mediated 
neutralization of DENV infection, immDCs matured and a balanced inflammatory response was seen. At 
non-neutralizing antibody conditions, DENV replication proceeded and resulted in partial DCs maturation 
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It is generally believed that immDCs are highly susceptible to DENV infection (Boonnak et al., 2008; 
Dejnirattisai et al., 2011; Ho et al., 2001; Marovich et al., 2001; Nightingale et al., 2008; Wu et al., 
2000). However, the percentage of DENV positive cells described by the different groups is wide ranging, 
and this is likely due to differences in the genetic background of the DCs donors, the viral strains used, 
and the time-post infection at which the analysis is performed (Boonnak et al., 2008; Dejnirattisai et al., 
2011; Ho et al., 2001; Marovich et al., 2001; Nightingale et al., 2008; Wu et al., 2000). Interestingly, we 
herein demonstrate that the majority of immDCs that internalized the virus successfully aborted infection. 
Only a small fraction of immDCs is productively infected. Flow cytometry was used previoulsy to assess 
DENV infectivity but only a distinction between DENV antigen-positive and DENV antigen-negative 
cells was made (Boonnak et al., 2008; Dejnirattisai et al., 2011; Ho et al., 2001; Marovich et al., 2001; 
Nightingale et al., 2008; Wu et al., 2000). Antibodies binding to DENV structural proteins detect a higher 
(Marovich et al., 2001; Wu et al., 2000) or lower (Dejnirattisai et al., 2011) percentage of DENV antigen-
positive cells than Abs that bind DENV nonstructural proteins.  Thus, apparently, the epitope specificity 
of the anti-dengue antibody used is of a high importance when analyzing the permissiveness of immDCs 
to infection. Indeed, only one of the DENVE- specific antibodies that we tested was able to distinguish 
between an abortive and an active infection. Therefore, based on our results, we believe that the general 
perception of high susceptibility of immDCs may be overestimated. 
The main role of DCs is to sense, process and present antigens of invading pathogens to cells of the 
adaptive immune system (Banchereau & Steinman, 1998). Yet, many viruses such as HIV-1, measles, 
vaccinia and  DENV target DCs for infection (Boonnak et al., 2008; de Witte et al., 2006; Dejnirattisai et 
al., 2011; Ho et al., 2001; Liu et al., 2001; Nightingale et al., 2008; Rinaldo, 2013; Wu et al., 2000). 
Interestingly, despite this dual role of DCs, thus far none of studies claimed the ability of DCs to abort 
DENV infection. However, close examination of the results from Nightingale and co-workers revealed 
that exposure of DCs to UVi DENV leads to a shift in the antigen-specific fluorescence intensity of the 
cells when compared to mock-infection (Nightingale et al., 2008). Regrettably, although their data 
strongly suggests that the authors could distinguish between abortive and productive infection, this 
observation was not discussed. Further studies should define the mechanisms by which immDCs abort or 
support viral infection.  
Table1. 










DENV + : cells that internalized the virus; DENV++: cells that are productively infected with 
DENV. 











% DENV pos. 
Direct 61.0± 
9.84 





54.0 ±3.0 0.1 ±0.4 54.0 ± 2.64 52.x±24.0 
Neutr 44.03 
±7.0 





3.3 ±0.2 51.5 ±10.0 57.0±12.2 
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Given the pivotal role of DCs in promoting adaptive immune responses, it is not surprising that many 
viral pathogens employ immuno-modulatory effects to impair the ability of the infected DCs to initiate 
adaptive immunity (reviewed by (Lilley & Ploegh, 2005). Importantly, however, conflicting reports have 
been published with regard to the effect of DENV on DC maturation (Ho et al., 2001; Libraty et al., 
2001; Nightingale et al., 2008).  
A few studies (Ho et al., 2001; Libraty et al., 2001) reported that DENV replication is essential for the 
induction of cytokine production by DCs whereas others show that DC maturation is blunted upon 
DENV infection (Chang et al., 2012; Munoz-Jordan et al., 2003; Rodriguez-Madoz et al., 2010). In 
agreement with the latter groups, we found that DENV replication inhibits DCs maturation. Along with 
the lack of phenotypic DCs activation, we did not observe an increase in the production of pro- (TNF-α, 
Il-6) or anti-inflammatory (Il-4, Il-10) cytokines. This suggests infection of immDCs with DENV-2 
alone does not trigger the immune responses that are required to develop adaptive immunity. 
Importantly, direct infection did not trigger production of pyrogenic cytokines including TNF-α and IL-
6, what might explain why the majority of primary infections are asymptomatic. In addition, we 
presented that dengue-specific antibodies may exert distinct immuno-modulatory effects during DENV 
infection in immDCs. At conditions of antibody-mediated virus neutralization, the expression of HLA-
DR, CD83 and CD86 was up-regulated to levels found in matDCs stimulated by MCMm cocktail. 
Indeed, previous studies showed that loading DCs with antigen-IgG immune complexes (ICs) leads to 
efficient antigen uptake and maturation of DCs (den Dunnen et al., 2012; Regnault et al., 1999; 
Schuurhuis et al., 2006).Interestingly, at conditions of DENV neutralization, we also observed increased 
production of pro-inflammatory (IL-6, and TNF-α) and anti-inflammatory (Il-4 and Il-10) cytokines. The 
simultaneous production of TNF-α and IL-10 following neutralized infection may suppress 
overstimulation of the inflammatory responses that contribute to the pathogenesis of severe dengue 
(Costa et al., 2013; Pang et al., 2007; Soundravally et al., 2013). 
 
Ligation of FcγRIIa was required for the activation of cytokine production by immDCs exposed to DENV 
pre-opsonized with neutralizing antibody titers. This finding was particularly interesting since FcγRIIa 
blockage did not abrogate virus neutralization. To date, engagement of FcγIIa in matDCs has been 
associated with induction pro-inflammatory responses following antibody-mediated enhancement but not 
during neutralization of infection in mature DCs (Boonnak et al., 2008). Interestingly, recently a study by 
Chawla et al showed that FcγRI binds antibody-opsonized DENV more efficiently than FcγRIIa, however 
FcγRI is only preferentially engaged by neutralizing, but not non-neutralizing antibody concentrations 
(Chawla et al., 2013). This may explain our observation that blockage of FcγRIIa had no effect on virus 
internalization and neutralization. Although our study is the first to infer the importance of FcγRIIa in the 
induction of DCs activation during likely FcγRI-mediated neutralization, further studies will be needed to 
substantiate this notion.  
 
Remarkably, exposure of immDCs to DENV at non-neutralizing conditions triggered an significant 
increase of HLA-DR expression but not that of the co-stimulatory molecules. Moreover, TNF-α, IL-6, 
and IL-4 but not IL-10 were released at this condition. The presence of IL-4 is known to inhibit IL-10 
production by DCs (Yao et al., 2005). Therefore, it is possible that the lack of IL-10  production is due to 
the significantly elevated levels of IL-4 released from DCs exposed to non-neutralizing conditions, when 
compared neutralizing conditions. Furthermore, the ability of DENV in complex with non-neutralizing 
immune sera to increase cytokine production suggests that additional viral entry mechanisms (e.g., 
mediated by FcR) are used with different signaling components and downstream functional effects. 
Herein we showed that presence of antibodies during DENV infection of DCs has consequences for the 
maturation of DCs and activation of the cytokine responses.  Our results corroborate earlier findings that 
DENV-2 can blunt the maturation and activation of exposed DCs (Palmer et al., 2005). Additionally, we 
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show that in the presence of high concentrations of antibodies  DENV infection in DCs is not only 
neutralized but it also rescues the ability of DCs to mature and induce cytokine production. Also, our data 
reveals that this dual effect of neutralizing antibodies is governed by different Fcγ receptors. On the other 
hand, infection in the presence of non-neutralizing antibody titers may induce a phenotype of DCs that 
while will lack the ability to initiate adaptive immunity, triggering mainly pro-inflammatory responses. 
Further studies should investigate whether this partially impaired DCs phenotype contributes to the 
aberrant T responses and exacerbation of inflammation that hallmark the severe disease (Green & 
Rothman, 2006; Mangada & Rothman, 2005; Rothman, 2011).  
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Supplementary figure 1. Phenotypic analysis of immDC and matDC. (A) Flow cytometry evaluation of 
monocyte-derived immDC. A total of 1.5x10
5
 cells were gated as immDC. Histograms show the 
fluorescence intensity of typical dendritic cell markers: Lin-1
-
, HLA-DR and CD11c. Dashed line: isotype 
control; normal line: Ab-stained cells. (B) MFI of the co-stimulatory markers CD40, CD83, and CD86 of 




Suplementary figure 2. Comparison of the percentage of DENV positive cells between the Murine α 
DENV (3H5) and Rabbit α DENV -2 (orb1707 Biorbit). (A) Immature DC were infected with standard 
(std), UV inactivated (UVi) DENV at MOI 1. After 24 hours of infection, the frequency of DENV-
positive cells was determined using the Murine α DENV (3H5) and Rabbit α DENV -2 (# orb1707 
Biorbit). DENV-positive populations are designated as DENV+ and DENV++ for a. Representative dot 
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Dendritic Cells as DENV factories: Immature Vs mature 
cells 
 
Silvia Torres, Heidi van der Ende- Metselaar Jolanda Smit and Izabela Rodenhuis-Zybert 
 
 
Dengue virus (DENV) predominantly targets cells of the host immune system for replication. Immature dendritic 
cells (immDCs), potent sentinels of host immunity, are generally considered to be the most important target cells 
during DENV infection. ImmDCs have been shown to be highly permissive to DENV infection due to abundant 
expression of the DENV receptor molecule DC-SIGN at the cell surface. On the contrary, mature DCs (matDCs) 
express lower numbers of DC-SIGN molecules and hence are believed to be less permissive to direct infection. 
Interestingly, the decrease in DC-SIGN expression is thought to confer matDCs susceptible to antibody-dependent 
enhancement (ADE) of DENV infection. ADE is generally believed to underlie the pathogenesis of severe disease 
following heterologous secondary DENV infections. In this study, we evaluated the infectious potential of DENV 
particles released from immDCs and matDCs in the absence and presence of antibodies. We show that immDCs, 
although somewhat more permissive to DENV than matDCs, produce a large number of non-infectious virus 
particles. Conversely, matDCs support enhanced DENV infection in the presence of non-neutralizing antibodies and 
produce highly infectious virus. In conclusion, we observed that quantity does not always translate to quality 
signifying that determination of the specific infectivity of DENV is required to prevent misinterpretation of the 
importance of different DCs subsets as dengue factories. 
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Dengue is the most important human viral disease transmitted by mosquitoes worldwide (WHO, 2009). The five 
DENV serotypes are predicted to cause 390 million human infections each year (Bhatt et al., 2013; ScienceInsider, 
2013). Approximately 100 million of these individuals present clinical symptoms ranging from an uncomplicated 
fever to severe hemorrhagic manifestations and/or fatal disease (Bhatt et al., 2013). Mild illness is frequently seen 
following primary as well as secondary infections (WHO, 1997; WHO, 2009). Heterotypic re-infections and primary 
infections of infants born to dengue-immune mothers confer a risk for the development of severe disease (Burke & 
Kliks, 2006; Halstead & Simasthien, 1970; Halstead & O'Rourke, 1977; Simmons et al., 2007).These observations 
underscored the essential role of antibodies in controlling DENV pathogenesis and led to the widely accepted 
hypothesis of antibody-dependent enhancement (ADE) of infection (Halstead, 2003). According to the ADE theory, 
antibodies at sub-neutralizing conditions contribute to enhanced DENV infection by directing the virus to Fcγ 
receptor-expressing immune cells including dendritic cells (Boonnak et al., 2008; Boonnak et al., 2013; Huang et 
al., 2006; Moi et al., 2011). The higher infected cell mass is believed to explain the higher viremia titers found in the 
blood of patients that eventually develop severe disease. 
Dendritic cells (DCs) and macrophages are considered to be main factories of DENV particle production (Marovich 
et al., 2001; Sun et al., 2009; Wu et al., 2000). When an infected mosquito takes a blood meal, its saliva containing 
the virus is injected into the skin, where skin-resident immature DCs (immDCs) are believed to be primary targets. 
At the same time, a substantial number of mosquito-derived DENV particles are delivered directly into the blood, 
where immDCs, macrophages, and mature DCs (matDCs) are preferentially infected (Blackley et al., 2007; Jessie et 
al., 2004; Marovich et al., 2001; Wu et al., 2000). DENV has been shown to efficiently infect immDCs due to 
abundant expression of the DENV receptor molecule DC-SIGN at the cell surface (Boonnak et al., 2011; 
Tassaneetrithep et al., 2003). Maturation of immDCs leads to down-regulation of DC-SIGN molecules at the cell 
surface and therefore matDCS are considered less permissive to DENV infection (Boonnak et al., 2008; Boonnak et 
al., 2011; Wu et al., 2000). Interestingly, the decrease in DC-SIGN expression is thought to confer matDCs 
susceptible to ADE of DENV infection in the presence of non-neutralizing antibodies (Boonnak et al., 2008). 
Indeed, immDCs do not support ADE unless the expression of DC-SIGN is dowregulated (Boonnak et al., 2008). 
 
A                                                                       B 
  
Fig.1. Direct DENV-2 infection in immature and mature DCs. DCs were infected with DENV-2 16681 strain at 
the multiplicity of infection (MOI) of 1 or 10. At 24 hours post infection cells where fixed and stained intracellularly 
with an DENV-E- 3H5 mAb; cell-free supernatants were analyzed by qPCR and plaque assay.  A) Typical flow 
cytometric analysis, DENV+ gate denotes DCs that internalized DENV, DENV++ gate comprises DCs actively 
infected with DENV; (B) number of physical and infectious particles expressed in genome-containing particles 
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Cells of the innate immune system potently inhibit replication of invading viruses mainly via production of type-I 
IFN. In fact, DCs are one of the key participants in type-I IFN mediated suppression of virus spread (Scheu et al., 
2008). Due to their phagocytic ability, immDCs act as the sentinels of immune system. Phagocytosis of the viral 
pathogen triggers antiviral responses and drives the transformation of immDCs to antigen presenting matDCs. 
Paradoxically however, inhibition of viral replication limits the amount of antigen that can be presented to the 
adaptive immune system. Indeed, it has been recently shown that a specific population of spleen residing 
macrophages, which filter viral pathogens from the blood stream, produce little IFN I thereby locally allowing non-
restricted viral replication (Honke et al., 2011).  This mechanism appeared to be crucial for the stimulation of potent 
adaptive responses as well as increased presentation of antigen to the key IFN I producers such as plasmacytoid DCs 
(Asselin-Paturel & Trinchieri, 2005). 
Interestingly, immDCs produce little to no IFN alpha in response to DENV infection (Mazzon et al., 2009; Munoz-
Jordan, 2010; Rodriguez-Madoz et al., 2010). Thus, analogically to the abovementioned spleen macrophages, one 
may expect unrestricted replication in these cells. Yet, we (chapter 5) found that only a small fraction of immDCs 
support DENV infection. Furthermore, another study showed that DC-derived virus cannot re-infect DCs, which 
suggests that DCs may not be as important during DENV infection as previously considered (Boonnak et al., 2008; 
Libraty et al., 2001; Marovich et al., 2001; Nightingale et al., 2008; Palmer et al., 2005). Remarkably, upon close 
examination of the current literature we noticed that the quality of DENV particles produced by DCs has never been 
analyzed in detail. The majority of the studies evaluated DENV susceptibility on the basis of intracellular staining of 
the viral antigens, or by quantification of the physical particles, or infectious particles released (Boonnak et al., 
2008; Libraty et al., 2001; Marovich et al., 2001; Nightingale et al., 2008; Palmer et al., 2005); rarely all three 
measurements have been demonstrated. Considering this lack of knowledge, we herein aimed to re-evaluate the role 
of DCs as DENV factories during primary and secondary infection.  
To this end, we assessed i) the percentage of infected cells; ii) the quality of DENV-2 released by immDCs and 
matDCs following infection in the absence and presence of potentially enhancing antibody concentrations. ImmDCs 
and matDCs were cultured and analyzed as described elsewhere (Boonnak et al., 2008; Boonnak et al., 2011), 

















. Throughout the study, unless indicated otherwise, the mean of 6 
experiments with at least 3 cell donors are shown.  Cells were infected with mosquito C6/36 cell-line derived 
DENV-2 strain 16681 at a multiplicity of infection of 1and 10. At 2 hpi the inoculum was removed and incubation 
was continued for another 22 hrs. Subsequently, the cells and their supernatants were harvested and analyzed for the 
frequency of infection and progeny virus production, respectively. The frequency of DENV-infected cells was 
determined by flow cytometry, as described before (Rodenhuis-Zybert et al., 2010). For staining, DENV-E-specific 
3H5 mAb was used. As described in Chapter 5, a unique feature of mAb 3H5 is that it discriminates between 
antigen internalization (referred to as DENV
+
) and active infection (DENV
++
). As shown in Fig. 1A, direct infection 
(without antibody) led to a higher infection rate in immDCs than in matDCs, 12 % and 16 % vs 0.5 % and  8% of 
DENV++ cells for MOI 1 and 10, respectively. Surprisingly, however, we observed that many DCs internalize 
virions but apparently only a limited number of particles is able to escape from degradation and initiates viral 
replication. At MOI 1, 25-30% of immDC and matDC cultures internalized the virus but failed to induce a 
productive infection. At high MOI immDCs were more potent in DENV internalization than matDCs, which is in 
line with the lower endocytotic activity observed in these cells (Boonnak et al., 2008). Next, we examined the 
quality of the released virus progeny (Fig.1B). Cell-free supernatants from infected immDCs and matDCs were 
subjected to standard plaque assay on BHK-15 cells (Zybert et al., 2008) for infectious titer determination as well as 
to qRT-PCR analysis for quantification of the number of genome-containing particles (GCP) (van der Schaar et al., 
2007). Surprisingly, despite the marked difference in the frequency of infected cells at MOI 1, we found that both 
DC phenotypes released the same number of infectious virions (PFU/ml in order of 10
5
). Interestingly however, 
immDCs produced substantially higher levels of viral particles (in order of 10
9
 GCP/ml) than matDC (in order of 
10
7 
GCP/ml), indicating that a large fraction of immDCs-derived virus is non-infectious. Similar results were found 
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following infection at MOI 0.1 and MOI 10 demonstrating that the effect seen is MOI-independent   (data not 
shown). Thus, DENV-infected immDCs and matDCs, despite the differences in the number of infected cells and 
secreted physical particles, release an equal number of infectious virions and therefore both cell populations may 
play an important role in virus dissemination.  
The presence of antibodies during natural re-infection is believed to influence DENV infectivity (Boonnak et al., 
2008; Endy et al., 2004; Halstead, 2003; Huang et al., 2006). At non- or sub-neutralizing concentrations, pre-
existing antibodies are thought to enhance the infected cell mass by facilitating virus cell entry through Fc receptors 
(Boonnak et al., 2013). To evaluate the role of antibodies on DENV infectivity in the context of DC maturation, we 
infected the both phenotypes of DCs in the absence and presence of DENV-2 immune-serum. To this end, we first 
determined the ADE profile of DENV-2 in matDCs.. Therefore in Fig. 2A, a total DENV positive population 
(DENV+ and DENV++) is shown for both DCs phenotypes. Optimal ADE was observed at a serum dilution of 10
8
 
and led to a 2- to 3-fold increase in infection rate when compared to direct infection, depending on the donor used. 
Furthermore, this serum dilution failed to neutralize DENV infection in immDCs (Fig. 2A).  The increase in 
infected matDCs mass as compared to direct infection also led to 2- to 4- fold higher virus titers (Fig. 1B /2B). 
Interestingly, in presence of enhancing concentrations of antibody, matDCs produce higher numbers of PFUs than 
immDCs in the absence and presence of non-neutralizing conditions of antibody. This may suggest that during 
heterologous secondary infection, matDCs but not immDCs contribute to the increased viral load observed in 
patients that develop severe dengue. 
 
Fig. 2. Effect of non-neutralizing antibody concentration on the susceptibility of DCs to DENV infection. Cells 
were infected with MOI 1 of DENV-2 alone or DENV-2 pre-incubated with dengue-immune serum at non-
neutralizing concentration. A) Frequency of DENV-positive (a sum of DENV+ and DENV++) immDCs and 
matDCs. Each dot represents average of 3 experiments  with 1 donor; B) number of physical and infectious particles 
expressed in genome-containing particles (GCP) and plaque forming units (PFU) titers, respectively. 
To summarize the effects of DC maturation and/or the presence of DENV-antibodies on the quality of the progeny 
virions, we compared the GCP/PFU ratios of viral particles produced by immDCs and matDCs per individual donor. 
Figure 3 clearly demonstrates that the specific infectivity (inverted GCP/PFU ratio) of matDC-derived virus is 10- 
to 300-fold higher than that of virus released from immDCs. In other words, immDCs although highly permissive to 
direct DENV infection secrete a large fraction of non-infectious virus particles. Furthermore, the presence of 
antibody at non-neutralizing concentrations has no substantial effect on the infectious properties of DC-derived 
virions. Of note, the GCP/PFU ratio of DENV-2 produced in commonly used mosquito and mammalian cell lines 
varies between 20-100 (Zybert et al., 2008). It is not known why immDCs secrete a large fraction of non-infectious 
particles. It is however tempting to speculate that specific mechanisms in immDCs exist that support the production 
of non-infectious particles. Whether the production of poorly infectious virus by immDCs is a phenomenon that is 
specific to DENV or whether it hallmarks their role as potent innate sentinels remains to be evaluated. 
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Fig. 3. Specific infectivity of DC-derived DENV. Summary of GCP and PFU titers of DENV-2 released from 
immDCs and matDCs per analyzed donor. 
Secretion of poorly infectious DENV can be controlled by factors associated with the characteristics of the virus 
and/or cytokines present in the cell supernatant. These include maturation state of the virus, viral envelope 
glycosylation, and levels of IFN in the supernatant. Furthermore, the cell line used for titration may affect the 
specific infectivity found. In this study, we have used the same cell to titrate the C6/36- and DC-derived viruses 
indicating that the observed differences are not related to the cell line used for titration. Furthermore, considering 
that DENV maturation is more efficient in immDCs than in mosquito-cells (Dejnirattisai et al., 2010)  and the lack 
of IFN I production in immDCs following DENV infection (chapter 5, (Rodriguez-Madoz et al., 2010). We 
hypothesize that the level of DENV-2 protein glycosylation may play a role in the observed differences in GCP/PFU 
ratio of immDCs and matDCs-derived DENV. DENV- E protein has 2 potential N-linked glycosylation sites at 
positions 67 and 153  and both glycosylation sites play important roles in viral infectivity and replication (Mondotte 
et al., 2007). For example, Dejnirattisai et al demonstrated that immDC-derived DENV has a lower infectivity than 
insect or tumor-cell derived DENV due to changes in viral envelope protein glycosylation (Dejnirattisai et al., 
2011). Interestingly, maturation of DCs results in upregulation of N-glycosyltrasferases, enzymes responsible for N-
glycosylation of Asn-67 and Asn-153 on DENV- E (Bax et al., 2007) and therefore, increased glycosylation of the 
viral envelope protein may contribute to the lower GCP/PFU ratio of matDCs-derived virus. We are currently 
investigating this hypothesis. In summary, herein we showed that immDCs, produce a large fraction of non-
infectious virus particles. Conversely, matDCs are less permissive to direct infection but do support enhanced 
infection in the presence of antibodies. Importantly, matDCs produce highly infectious virus. In conclusion, even 
though immDCs seem to be a more productive DENV factory than matDCs, the quantity of the product does not 
always translate to its quality. The ability of matDCs to produce higher numbers of infectious virus in the absence 
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Dengue Virus (DENV) is the most common mosquito-borne infection worldwide. Important target cells during 
DENV infection are macrophages, monocytes, and immature dendritic cells (immDCs). DENV-infected cells are 
known to secret a large number of partially immature and fully immature particles alongside mature virions. Fully 
immature DENV particles are considered non-infectious, but antibodies have been shown to rescue their infectious 
properties. Therefore, immature DENV particles are thought to only contribute to DENV pathogenesis during 
secondary infection. In this study, we investigated the infectious properties of fully immature particles on primary 
immature dendritic cells (imDCs) and a macrophage-like cell line in absence and presence of anti-DENV human 
serum. We show that immature DENV, although non-infectious in multiple cell lines, exhibits low-level infectivity 
in imDCs via interaction with DC-SIGN. Furthermore, we demonstrate that imDCs, in contrast to macrophage-like 
cells, do not support antibody-dependent enhancement of immature DENV. Our data shows that immature DENV 
can infect imDCs, suggesting that immature DENV particles may contribute to dengue pathogenesis during primary 
infection. Furthermore, since antibodies do not further stimulate DENV infectivity on imDCs we propose that 
macrophages/monocytes rather than imDCs are responsible for the increased viral load observed during severe 
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Author summary:  
 
Dengue Virus (DENV) is a mosquito-transmitted virus common in the tropical and sub-tropical regions of the world. 
There are four serotypes of DENV, and each of these viruses can cause disease ranging from a mild fever to a more 
severe hemorrhagic fever and hypovolemic shock. Severe forms of disease are often seen during heterotypic 
secondary infections, due to a complex immunopathological reaction including antibody-dependent enhancement 
(ADE) of infection. Cells infected with DENV secret virions that vary in maturation state from fully mature to fully 
immature particles. The latter are considered non-infectious, however several studies have shown that their 
infectivity can be rescued by anti-DENV antibodies. In this study, we investigated the infectivity of immature 
DENV in immature dendritic cells (imDCs) and macrophage-like cells, which are known to be important during 
natural infection. We found that immature DENV exhibits low-level infectivity in imDCs due to interaction with the 
cell surface receptor DC-SIGN. Furthermore, we show that DENV infectivity cannot be stimulated by antibodies in 
imDCs. This study expands our knowledge on the role of immature DENV particles and imDCs during primary and 














































Dengue virus (DENV), a flavivirus within the Flaviviridae family, is the most common mosquito-borne viral 
infectious agent worldwide. According to new estimates, 390 million cases occur annually, of which about 100 
million are symptomatic (Bhatt et al., 2013). There are five different serotypes of DENV. Each of them can cause 
disease ranging from rather mild dengue fever to more severe dengue hemorrhagic fever and dengue shock 
syndrome (Martina et al., 2009; ScienceInsider, 2013; WHO, 2009). Pre-existing heterotypic antibodies represent a 
major risk factor for the development of severe disease via antibody-dependent enhancement (ADE) of disease 
(Halstead, 2003; Halstead, 2007; Kliks et al., 1989). In ADE, pre-existing antibodies are hypothesized to bind to the 
newly infecting virus serotype and facilitate efficient replication in Fcγ-receptor-expressing cells, thereby increasing 
the infected cell mass and viral load. A high viral load is often a prelude for severe disease development (Vaughn et 
al., 2000). 
DENV-infected cells secrete a heterogeneous population of virions that vary in maturation state (Cherrier et al., 
2009; Junjhon et al., 2008; Junjhon et al., 2010). Earlier studies revealed that the precursor membrane (prM) protein, 
the hallmark of immature virus particles, caps the envelope (E) protein. Fully immature particles are considered non-
infectious, as functional analysis in multiple cell lines indicated that prM affects virus-receptor interaction and 
membrane fusion activity (Li et al., 2008; Yu et al., 2008; Yu et al., 2009). Indeed, furin-dependent cleavage of prM 
to M is a prerequisite for membrane fusion activity and infectivity (Elshuber et al., 2003; Elshuber & Mandl, 2005; 
Moesker et al., 2010; Yu et al., 2008; Zheng et al., 2010; Zybert et al., 2008). Interestingly, antibodies have been 
found to rescue the infectivity of fully immature DENV particles by Fcγ-receptor-mediated binding and cell entry of 
DENV-immune complexes. Upon cell entry, the prM protein is cleaved by furin to render the particle infectious 
(Zheng et al., 2010)(Flipse et al., 2013; Rodenhuis-Zybert et al., 2010). This suggests that fully immature particles 
are only infectious in presence of antibodies and therefore contribute to the viral load observed in secondary DENV 
infections.  
Immature dendritic cells (imDCs) represent important target cells for DENV replication (Marovich et al., 2001). 
Virus-cell binding is facilitated through interaction of the glycan moieties that are linked to the DENV’s E 
glycoprotein with the receptor molecule Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-
integrin (DC-SIGN) (Tassaneetrithep et al., 2003). Interestingly, a recent report has shown that partially immature 
particles of West Nile Virus (WNV) – like DENV a member of the flavivirus genus – can infect cells that are 
engineered to express DC-SIGN (Mukherjee et al., 2011). The glycan moieties on prM were found to interact with 
DC-SIGN, thereby facilitating virus binding and cell entry. In view of the above studies we here assessed the 
infectivity of fully immature DENV in primary human monocyte-derived imDCs in the presence and absence of 
anti-DENV antibodies and compared it with the infectivity of immature DENV in macrophage-like cells. 
 
 




Human peripheral blood mononuclear cells (PBMCs) were isolated by standard density centrifugation using Ficoll-
Paque™ Plus (GE Healthcare, Sweden) from buffy coats obtained with written informed consent from healthy, 
anonymous volunteers, in line with the declaration of Helsinki (Sanquin Bloodbank, Groningen, the Netherlands). 
Monocytes were isolated by gelatin adherence (Miller et al., 2008) and allowed to differentiate in RPMI (Life 
Technologies) supplemented with 20% fetal bovine serum (FBS), 500U/ml granulocyte-macrophage colony-
stimulating factor (GM-CSF), and 250U/ml recombinant human interleukin-4 (rIL-4) (both from Prospec-Tany, 
Israel). The medium was replaced every second day till day 6 to generate imDCs. P338D1 cells, a macrophage-like 
cell line expressing Fcγ-receptors, was maintained in DMEM (PAA Laboratories, Austria) supplemented with 10% 
FBS, 100U/ml penicillin, 100mg/ml streptomycin, 0.75% sodium bicarbonate (Invitrogen) and 1 mM sodium 
pyruvate (Gibco) at 37°C / 5% CO2. Vero-WHO cells were maintained in DMEM supplemented with 5% FBS, 100 
U/ml penicillin and 100 mg/ml streptomycin. Human adenocarcinoma LoVo cells were maintained in Ham’s 
medium (Life Technologies) supplemented with 20% FBS at 37°C/5% CO2. C6/36, an Aedes albopictus cell line, 
was maintained in minimal essential medium (Life Technologies) supplemented with 10% FBS, 25 mM HEPES, 
7.5% sodium bicarbonate, 100U/ml penicillin, 100mg/ml streptomycin, 200 mM glutamine and 100 mM 
nonessential amino acids at 30°C/ 5%.  
 
Flow cytometry 
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The phenotype of the cultured primary imDCs was confirmed at day 6 using flow cytometry analysis, essentially as 
described before (Boonnak et al., 2011). The cells were analyzed using the primary labeled antibodies Lineage1-
FITC, CD11c-APC, HLR-DR-V500, CD80-PE, CD83-PECy7 and CD86-V50 (Becton Dickinson). DC-SIGN levels 
were determined using an anti-DC-SIGN antibody and a secondary PE-labeled antibody (both R&D systems, MN, 





For the functional experiments, standard (std) DENV-1 (strain 16007), DENV-2 (strain 16681), DENV-3 (strain 
H87) and DENV-4 (strain H241), were produced in the Aedes albopictus cell line C6/36 essentially as described 
before (Rodenhuis-Zybert et al., 2010). Briefly, an 80% confluent monolayer of cells was infected at multiplicity of 
infection (MOI) of 0.1. Depending on the serotype, 72 to 168 hours post infection (hpi), virus was harvested. 
Immature DENV-1, DENV-2, DENV-3 and DENV-4 were produced in furin-deficient LoVo cells as described (de 
Alwis et al., 2011). Briefly, an 80% confluent monolayer of cells was infected at MOI 2 and 72 hpi immature 
DENV was harvested. Preparations for determining specific infectivity were prepared in a similar way, however 
monolayers were infected with MOI 2 and virus was harvested 72 hours after infection for both immature and std 
virus and all serotypes.  
 
Infectivity assays  
 
ImDCs were infected at a multiplicity of genome-containing particles (MOG) of 1,000 of either immature DENV-2 
or std DENV-2. At 1.5 hpi, fresh medium was added to the cells. The supernatant was harvested at 43 hpi and the 
number of produced infectious particles was measured by standard plaque assay on BHK-21 clone 15 cells (Zybert 
et al., 2008). The detection limit of this assay is 20 PFU/ml. The role of DC-SIGN was studied by incubating imDCs 
1 h before and during infection with 25µg/ml of either an anti-DC-SIGN antibody or a non-specific isotype control 
(both R&D systems, MN, USA). To test if viral infectivity could be enhanced by antibodies, immature DENV-2 
(MOG 1000) or, as a control, std DENV-2 (MOG 100) was pre-opsonized with 10-fold sequential dilutions of 
human serum before infection. We used convalescent serum (28 days following infection) from a DENV-2 immune, 
hospitalized patient (kindly provided by Dr. G. Comach Biomed-UC, Lardidev, Maracay, Venezuela; and Dr. T. 
Kochel, U.S. Naval Medical Research Center Detachment, Lima, Peru). Infectivity assays on the macrophage-like 
cell line P388D1 were performed under the same conditions as for imDCs. For antibody-dependent enhancement 
studies, P3881D1 cells were infected with human serum-opsonized immature DENV-1 and 4 at MOG 1000 or, as a 
control, non-opsonized std DENV-1 and 4 at MOG 1000.  
 
Quantitative PCR  
 
The number of genome-containing particles (GCPs) was determined by quantitative PCR (qPCR) according to an 
earlier published protocol based on DENV-2m (van der Schaar et al., 2007). Briefly, the DNA was amplified for 40 
cycles of 15s at 95°C and 60s at 55°C (DENV-3) or 60°C (other serotypes). Determination of the number of RNA 
copies was performed with a standard curve (correlation co-efficient >0.995) of quantified DENV plasmids 
constructed with standard DNA techniques. For DENV-1: pcDNA3 encoding the M protein sequence of DENV-1 
strain 16007; DENV-3: pcDNA3 encoding the E protein sequence of DENV-3 strain 16562; and DENV-4: pcDNA3 
encoding the E protein sequence of DENV-4 strain 1036 was used. The details of the primers and probes used for 




To assess the specific infectivity of immature and std DENV of the different serotypes, the number of infectious 
particles was determined by an adapted protocol for immunofocus assay (Midgley et al., 2012). One day before 
titration, 1.3×10
4 
Vero-WHO cells were seeded per well in a 96-well plate. Prior to infection, the medium was 
removed and cells were infected with 10-fold serial dilutions of the virus. After 1.5 h incubation at 37°C, MEM/2% 
FBS and 1% carboxymethylcellulose (Sigma-Aldrich, Steinheim, Germany) was added as overlay. Cells were fixed 
and stained after 2 days (DENV-4), 3 days (DENV-2 and DENV-3) or 4 days (DENV-1) of incubation at 37°C/5% 
CO2. Prior to the staining procedure, cells were fixed with 10% formaldehyde in phosphate-buffered saline (PBS). 
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Subsequently, cells were washed with PBS and permeabilized with 2% Triton-X. For detection, 4G2 antibody 
(Millipore, Temecula, CA) was used as a primary antibody and goat anti-mouse HRP-labeled antibody (Southern 
Biotech, Birmingham, AL) as a second antibody. Cells were stained with Trueblue Peroxidase Substrate (KPL, 
Gaithersburg, MD). The foci were counted manually. The limit of detection for immunofocus assay is 20 infectious 




Monocyte-derived immature dendritic cells are susceptibility infection of immature DENV 
 
Human primary imDCs were obtained upon culture of PBMC-derived monocytes in the presence of GM-CSF and 
rIL-4. Six days after culture, the phenotype of the cells was determined by flow cytometry. Figure 1 shows that the 
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low
 and DC-SIGN. 
Importantly, and as expected, imDCs were found to express high levels of DC-SIGN. The  
 
Figure 1. Phenotypic analysis of monocyte-derived immature dendritic cells. Expression profile of different 
cell type markers by flow cytometry, details are provided in the text. One representative analysis is shown. 
White curve area: control antibody. Black curve area: specific staining antibody.  
 
differentiated imDCs were infected with  a multiplicity of genomeme-containing partcilces (MOG)  of 1000 of 
either immature DENV-2 or std DENV-2. Immature DENV was produced on furin-deficient LoVo cells. The 
specific infectivity of immature DENV was ~100,000 fold reduced compared to that of std DENV-2, demonstrating 
that immature DENV-2 is essentially non-infectious in BHK-21-15 cells. The genome-containing particle GCP, as 
determined by quantitative PCR (van der Schaar et al., 2007) to PFU ratio was 8.4×10
6 
for immature DENV 
compared to 73
 
for std DENV. Although we never detected infectivity of immature DENV in monocyte and 
macrophage cell lines or human (da Silva Voorham et al., 2012; Rodenhuis-Zybert et al., 2011), we did observe a 
low-level infectivity of immature DENV (prM) in imDCs (Figure 2A). At 48 hpi, approximately 1.8×10
3 
PFU/ml 
were produced following infection with immature DENV, while for std virus a titer of 1.4×10
6 
PFU/ml was 
obtained. Similar results were observed in cells of another blood donor (data not shown). Furthermore, to test 
whether immature DENV infects imDCs due to interaction with DC-SIGN, we treated imDCs with either an anti-
DC-SIGN antibody or a non-specific isotype control. Indeed, blockage of the DC-SIGN receptor completely 
abrogated infection of imDCs with immature DENV (Fig. 2B), indicating that DC-SIGN acts as an entry receptor 
for immature DENV particles. 
 
 
Antibody mediated enhancement of immature DENV-2 infectivity on imDCs  
 
The result that immature DENV particles are infectious in imDCs prompted us to also investigate if viral infectivity 
can be enhanced by anti-DENV serum. Earlier reports performed with std DENV preparations showed that high 
expression of DC-SIGN is inversely correlated with ADE (Boonnak et al., 2008; Boonnak et al., 2011). However, it 
is not known if this holds true for infection with immature DENV. Therefore, we performed infectivity assays with 
immature DENV-2 and, as a control, std DENV-2. Before infection, the virus was 
 




Figure 2. Fully immature DENV-2 particles exhibit basic infectivity on immature dendritic cells. imDCs were 
infected with MOG 1000 of standard (std) or immature DENV-2 (prM). Supernatant was harvested 43hpi 
and analyzed. (A) DENV-2 infectivity on imDCs. (B) Role of DC-SIGN on immature DENV-2 infectivity in 
imDCs as tested by DC-SIGN blockage. Data are expressed as means of at least two independent experiments 
performed in triplicate; error bars represent standard deviation. N.d. denotes for “not detectable”.  
 
pre-opsonized with human serum of a DENV-2 immune individual. As shown in Figure 3A, none of the serum 
dilutions tested enhanced the basic infectivity of immature DENV in imDCs. Furthermore, and in line with the prior 
results, no enhancement of std DENV infection was observed (Figure 3B). At lower dilutions (≤104 for immature 
DENV and ≤103 for std DENV), neutralization of viral infectivity was detected. Furthermore, no enhancement of std 
DENV infectivity was seen upon infection of the cells at lower MOGs (0.1, 1 or 10; data not shown). This shows 
that the absence of ADE at higher MOG values was not due to saturation of virus particle production capacity in the 
absence of serum. We achieved comparable results in all donors tested (at least two different donors for each 
experiment, data not shown), indicating that the outcomes are donor-independent. To test whether the serum 
possesses inherent enhancing activity, we next performed infectivity assays in P388D1 cells, a macrophage-like cell 
line expressing Fcγ-receptors. Indeed, and in line with previous published data REF, viral infectivity of immature 




. At low serum dilutions, neutralization of 
infection was observed (Figure 3C and D).  
 
 
Infectious properties of all DENV serotypes on epithelial cells 
 
Besides testing conditions of homotypic ADE, we pursued to investigate heterotypic enhancement conditions as 
well. Since the infectious properties of fully immature DENV-1, 3 and 4 have not been described before, we first 
examined and compared the specific infectivity of both std and fully immature DENV virions of all four serotypes. 
For this purpose, we analyzed virus particle production on C6/36 cells and LoVo cells 72 hpi by RT-PCR (van der 
Schaar et al., 2007) and immunofocus assay (Midgley et al., 2012) to measure genome-containing particles and 
infectious units, respectively. Table 1 shows that immature particles of all four serotypes have a very low specific 
infectivity on Vero-WHO cells. 
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Figure 3. imDCs do not support antibody-dependent enhancement of immature DENV infection.  ImDCs 
were infected with immature DENV-2  at MOG 1000 o 1,000 (A) and std DENV-2 at MOG 100 (B) as 
mentioned in the text. Data of one representative donor is shown. For each donor, experiments were 
performed at least in duplicate.  P388D1 cells were infected with immature (C) or std (D) DENV-2 at MOG 
1000 under similar conditions as in panel A and B. At least two independent experiments were performed in 
triplicate. Error bars represent standard deviation. N.d. denotes for “not detectable”.  
 
When compared to the std DENV preparations, the specific infectivity of immature DENV was about 700-fold 
reduced for DENV-4 and more than 80000-fold reduced for DENV-2. While the specific infectivity of immature 
DENV-1 and DENV-3 was at least 2000-fold and 300-fold reduced, respectively. The reduction in specific 
infectivity may be underestimated for DENV-1 and DENV-3 since we were not able to detect any infectivity (limit 
of detection of the immunofocus assay is 20 IU/ml). 
 
Antibody mediated enhancement of immature DENV-1, 2 and 4 infectivity on macrophage like cells 
 
Under laboratory conditions, enhancement of DENV infectivity can be detected using homotypic antibodies as long 
as the antibody concentration is lower than the threshold of neutralization (Beltramello et al., 2010; Boonnak et al., 
2011; da Silva Voorham et al., 2012; Rodenhuis-Zybert et al., 2010). However, during natural infection, severe 
disease is predominantly related with heterotypic secondary infection (Halstead, 1988; Halstead, 2007). Therefore, 
we also aimed to assess the influence of heterotypic human serum on the infectivity of different DENV serotypes. 
After titrating the virus preparations on Vero-WHO cells, we attempted to analyze the infectivity of DENV-1, 
DENV-3, and DENV-4 in imDCs. However, using std virus of these serotypes, only a viral output of about 10
3 
IU/ml was measured 43 hpi . Unfortunately, the low infectivity of std DENV-1, 3, and 4 in imDCs prevented further 
characterization of the infectious properties of immature DENV in these cells. In the macrophage cell line P388D1, 
however, the infectivity of std DENV-1, 3, and 4 was comparable to that of std DENV-2 (figure 3D, control 
condition) with the another serotypes (figure 4A and B). None of the immature DENV serotypes exhibited 
infectivity in the absence of serum following infection at MOG 1000. As expected, anti-DENV-2 serum stimulated 
viral infectivity of immature DENV-1 and DENV-4 to levels comparable to std DENV-1 and std DENV-4 infection 
(Figure 4A and B). We did not test immature DENV-3, since it was not possible to propagate this virus to  
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Figure 4. Immature DENV particles of different serotypes can be rendered infectious by heterotypic human 
serum. P388D1 cells were infected with MOG 1000 of std (grey bars) and pre-opsonized immature (black 
bars) DENV-1 (A) or DENV-4 (B) as described in the text. At least two independent experiments were 
performed in triplicate. Error bars represent standard deviation. N.d. denotes for “not detectable”.  
 
sufficiently high titers (Table 1). The enhancement profiles were similar for heterotypic and homotypic conditions, 




In summary, this study shows that immature DENV particles can infect imDCs via interaction with DC-SIGN. Viral 
infectivity of immature DENV on these cells is however low and cannot be stimulated by antibodies. In 
macrophages, antibodies do enhance infectivity of immature DENV, but no differences were found between 
homotypic and heterotypic serum.  
 
The DENV E glycoprotein is responsible for efficient interaction of the virus with host cells during primary 
infection. In immature particles, the E protein is obscured by prM, prohibiting efficient virus-receptor interaction (Li 
et al., 2008; Zheng et al., 2010). For this reason, immature particles are presumably scored non-infectious in 
numerous cell lines, like K562, U937, THP-1, and P388D1, and human PBMCs (Rodenhuis-Zybert et al., 2010; 
Tassaneetrithep et al., 2003; Zybert et al., 2008). However, and in line with recent results with WNV, we here show 
that immature DENV can bind to DC-SIGN expressed on imDCs. Binding is likely facilitated by sugar groups 
linked to position Asn
69
 in prM of DENV (Davis et al., 2006; Li et al., 2008; Mukherjee et al., 2011; Yu et al., 
2008). Upon binding, the virion enters imDCs via an as yet unknown pathway (Pierson & Diamond, 2012). For 
partially immature WNV particles, it has been shown that furin cleavage upon entry is not strictly required for WNV 
infection of DC-SIGN-bearing Raji B cells (Mukherjee et al., 2011). In contrast, several studies have shown that 
furin cleavage of fully immature DENV or WNV is essential for infection (da Silva Voorham et al., 2012; 
Rodenhuis-Zybert et al., 2010; Rodenhuis-Zybert et al., 2011). These studies indicate that some but not all prM 
molecules need to be cleaved upon cell entry to restore viral infectivity. The exact threshold for furin-independent 
infectivity of partially immature flavivirus particles has not been investigated yet. 
 
The infectious potential of immature DENV in imDCs may imply that these particles contribute - albeit limited - to 
the total viral load during primary infection. Furthermore, immature particles may be important in the initiation of 
infection as virus particles produced in mosquito cells are known to have high prM content (Junjhon et al., 2008; 
Junjhon et al., 2010). On the other hand, we previously showed that immature WNV particles do not cause disease 
in mice when injected through the intraperitoneal route (Colpitts et al., 2012; da Silva Voorham et al., 2012). 
Though, during natural infection, the virus is inoculated in the skin and directly encounters Langerhans cells (Wu et 
al., 2000). These cells express the C-type lectin Langerin, but no DC-SIGN (Geijtenbeek & Gringhuis, 2009). 
Whether Langerhans cells are permissive to immature DENV infection remains to be elucidated.  
 
 
Neither std DENV nor immature DENV exhibit ADE on imDCs during heterotypic re-infection. In line with 
previous observations (Boonnak et al., 2008), we propose that Fcγ-receptors expressed on imDCs do not have an 
additive effect on viral infectivity due to the high cell surface expression of DC-SIGN. It is, however, possible that 
  101  
 
the antibody–opsonized complexes are internalized through the Fcγ-receptor without net increase in viral infectivity. 
Furthermore, the observation that antibody-opsonized immature DENV has a lower infectivity than std DENV may 
suggest that immDCs are less efficient in promoting virus maturation upon entry than macrophages. Other target 
cells like monocyte or macrophage-like cell lines do support enhanced infection of antibody-opsonized immature 
and std DENV via  
Fcγ-receptor-mediated entry, thereby increasing total viral output (Boonnak et al., 2011; Rodenhuis-Zybert et al., 
2010). Our results suggest that imDCs generate a similar viral output during primary and secondary heterotypic 
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Immature dengue virus is a co-factor in disease pathogenesis 
_____________________________________ 
Julia M da Silva Voorham, Izabela Rodenhuis-Zybert, Silvia Torres, Denise Van de Pol, Simona Zompi, 
Eva Harris, Jan Wilschut, Jolanda M Smit 
 
Humoral immunity plays an important role in controlling dengue virus (DENV) infection. Antibodies developed 
during primary infection protect against sequential infection with the same dengue serotype, but can enhance the 
disease following heterologous re-infection. Moreover, to evade neutralization of infection DENV is thought to 
promote inefficient maturation of progeny virions. Indeed, DENV-infected cells are known to secrete particles with 
varying numbers of precursor membrane proteins (prM) in the viral membrane.   Furthermore, we and others 
observed that the historically regarded non-infectious prM-containing DENV become highly infectious in the 
presence of E- and prM-antibodies. Accordingly, we hypothesized that these virions can contribute to the 
exacerbation of disease during heterologous re-infection. To this end, we here investigated the ability of acute sera 
of 30 DENV-2 infected patients with different grades of disease severity, to bind, neutralize and/or enhance 
immature DENV-2 infection. We found that a large fraction of antibodies bind to immature DENV-2, but there is no 
significant difference between the disease severity groups. Furthermore, functional analysis of the antibodies did not 
underscore any specific correlation between the neutralizing/enhancing activity towards immature DENV-2 and the 
development of more severe disease. Based on our current results, we conclude that immature virions are not a 
discriminating factor but rather act as a co-factor in dengue pathogenesis. 
 
 











Dengue is the most prevalent mosquito-borne viral disease worldwide. Each year, 50-100 million infections occur 
mainly in the (sub) tropical regions of the world (Mackenzie, Gubler, & Petersen, 2004). Symptomatic infection 
with any of the four DENV serotypes can manifest as dengue fever (DF), a self-limiting febrile illness or lead to the 
more severe and potentially life-threatening dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS) 
(WHO, 1997). Pathogenesis of severe DENV infection is multifaceted (Rodenhuis-Zybert, Wilschut, & Smit, 2010), 
but sequential infection with a heterologous DENV strain as well as primary infection of infants with declining 
levels of maternal antibodies are considered major risk factors for severe disease. Accordingly, it has been 
hypothesized that antibodies generated during primary infection or passively acquired through DENV-immune 
mothers can exacerbate disease via so-called antibody-dependent enhancement (ADE) of infection. In ADE, cross-
reactive, non-neutralizing antibodies are thought to facilitate successful entry of virus-immune complexes in Fc-
receptor-bearing cells (Burke & Kliks, 2006; Halstead & O'Rourke, 1977; Kliks et al.,1989) ultimately leading to an 
increased viral load early in infection– one of the hallmarks of severe disease development (Balsitis et al., 2010). In 
vitro, ADE of DENV infection can be observed in many Fc-receptor-expressing cell lines, including K562, U937, 
P388D1 and in primary human cells like monocytes, macrophages and mature dendritic cells (Halstead & O'Rourke, 
1977; Morens et al.,1987).  
The viral surface of mature DENV is covered with 180 copies of 2 transmembrane glycoproteins: the membrane (M) 
and envelope (E) protein. The ectodomain of the E protein has three structurally distinct domains (DI, DII, DIII) and 
is responsible for the infectious cell entry of the virion (Modis et al., 2003; Nybakken et al., 2006; Rey et al.,1995; 
Y. Zhang et al.,2007). Immature virions, primary products of viral assembly, are structurally distinct from mature 
particles and contain 180 heterodimers of the E and precursor (pr)M protein in the viral membrane. Immature 
DENV matures during transit through the Golgi and trans-Golgi network, where the cellular protease furin cleaves 
prM to M and a “pr” peptide. The “pr” peptide is released upon secretion of the particle into the pH neutral 
extracellular milieu (Li et al., 2008). The prM protein inhibits the fusogenic activity of the E protein thereby 
protecting newly assembled virions from premature fusion within the mildly acidic compartments of the exocytotic 
pathway (Li et al., 2008). Importantly, the maturation process of DENV appears to be inefficient as infected cells 
release significant numbers of immature and partially mature virions. In fact, around 30-40% of the particles 
produced in mosquito cells still contain uncleaved prM protein (Junjhon et al 
., 2008; Zybert et al.,2008). 
The E protein is the principal target of neutralizing and enhancing antibodies developed in response to DENV 
infection (Beltramello et al., 2010; Dejnirattisai et al., 2010; Lai et al., 2008). The majority of antibodies are raised 
against EDII domain and in vitro analysis revealed that these antibodies often have weakly neutralizing properties 
and a high degree of serotype cross-reactivity (Beltramello et al., 2010; Crill et al.,2009; Lai et al., 2008). Only a 
small fraction of the total specific humoral response is directed against EDIII domain and these mostly represent 
potent neutralizing serotype-specific antibodies (Beltramello et al., 2010; Crill et al., 2009). Furthermore, and in line 
with the incomplete maturation status of standard (std) DENV preparations in vitro, prM-antibodies are generated 
during primary and secondary DENV infections (de Alwis et al., 2011; Dejnirattisai et al., 2010). Notably, several 
studies reported significantly higher levels of prM antibodies in secondary infection when compared to primary 
infections (Lai et al., 2008; Valdes et al., 2000). Antibodies directed against prM generally appear to poses non- or 
weakly neutralizing properties and are highly cross-reactive between DENV serotypes (Beltramello et al., 2010; de 
Alwis et al., 2011; Dejnirattisai et al., 2010). We and others have shown that in the presence of prM or E antibodies, 
the historically regarded non-infectious immature DENV particles become highly infectious (Chan et al., 2012; da 
Silva Voorham et al.,2012; Dejnirattisai et al., 2010; Rodenhuis-Zybert et al.,2010; Rodenhuis-Zybert et al.,,2011). 
Antibody-opsonized immature DENV binds to Fc-receptors and this interaction facilitates cell entry of the immune 
complex via an as yet unknown pathway. The acidic environment of endosomes/phagosomes subsequently triggers 
conformational changes in the virion allowing furin to cleave the prM protein (Rodenhuis-Zybert et al.,2010). 
Furthermore, the low pH conditions in the late endocytic/phagocytic pathway (to around 5.0) is thought to prompt 
the release of “pr” peptide thereby rescuing the fusion and infectious capacity of the virion (X. Zhang et al., 2003). 
Accordingly, in presence of antibodies, immature particles can expand the pool of infectious virus thereby likely 
contributing to the DENV pathogenesis (Chan et al., 2012; da Silva Voorham et al.,2012; Dejnirattisai et al., 2010; 
Rodenhuis-Zybert et al.,2010; Rodenhuis-Zybert et al.,2011).  
In this study we investigated the potential role of immature DENV in disease pathogenesis. First, we examined the 
antigen-specificity in patients with acute DENV-2 infection and compared the prM to E antibody ratio per disease 
severity (DF, DHF, DSS). Next, we tested the capacity of the sera to neutralize and/or enhance the current infecting 
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DENV serotype. We show that prM-antibodies were present in all immune sera tested. Moreover, immune sera from 
all severity groups were able to bind to and enhance infectivity of immature DENV-2 particles. Notably, antibody-
mediated enhancement of std DENV-2 infection by the sera partially relied on enzymatic activity of furin. Counter 
intuitively however, we found no significant difference between the 3 disease groups. This suggests that antibodies 
recognizing immature DENV cannot be used as a predisposing factor for severe disease development. Immature 
DENV particles act as a co-factor in dengue pathogeneses by enhancing the number of infectious virions circulating 





A significant fraction of human antibodies is directed against the prM protein 
 
First, we investigated if the prM antibody response is more abundant in patients with severe disease. To this end, we 
loaded immature DENV-2 virions on a SDS-PAGE gel and performed Western blot (WB) analysis using acute 
secondary DENV-2 sera. To rule out individual bias we pooled sera of 10 patients per disease group by triplicate. 
The specific antibody response and the ratio of prM and E antibodies was quantified by means of ImageQuant TL 
software, as described in Materials and Methods. The total prM and E antibody response was comparable between 
DF, DHF, and DSS patients (data not shown). Approximately 20-35% of the antibody response was directed to the 
prM protein (Fig. 1). The prM antibody response was slightly higher in the DF group albeit not statistically 
significant, indicating that a prM antibody response is not indicative for severe disease development.  
 
Dengue specific antibodies recognize immature virions 
 
Recent work showed that most of the antibodies generated against prM and E are conformation sensitive (Lai et al., 
2008; Roehrig et al.,1998), implying that the identification of certain IgG clones can be underestimated by means of 
WB technique (de Alwis et al., 2011). To rule out this possibility, we next analyzed the capacity of the human IgGs 
to react with immature and std DENV-2 preparation by means of indirect ELISA, as described in Material and 
Methods. Figure 2 depicts representative reciprocal end-point titers obtained from at least three independent 
experiments. Note that immune sera from all three disease severity groups contain antibodies that bind to immature 
(Fig. 2A) and std DENV-2 (Fig. 2B). Importantly however, in line with the WB results, we did not detect significant 
difference in the relative binding of immature and std DENV between the severity groups.  
 
Dengue-immune sera promotes infectivity of immature DENV-2 in a furin-dependent manner 
 
Having established that the quantity of immature-virus specific antibodies does not distinguish disease severity, we 
next evaluated the quality of these responses. We tested the capacity of the acute sera to neutralize and/or enhance 
DENV infection using the DENV serotype causing current infection. Viral infectivity was measured in murine 
macrophage-like P388D1 cells, which express three distinct Fc-γ-receptors (FcγR), FcγRIII [CD16], FcγRII [CD32], 
and FcγRI [CD64]) (Ochiai et al.,1988; Sung et al., 1985). Cells were infected with immature and std DENV-2 at 
MOG 500 in the absence or presence of increasing dilutions of pooled immune sera. After 1 round of infection, we 
harvested the supernatant and analyzed the infectious virus production. As shown in Figure 3, immune sera of all 
severity groups neutralized immature DENV-2 particles at a dilution of 400x or lower. Enhancement of infectivity 
was observed at higher dilutions 1600x-102400x (Fig. 3A, B and C). Importantly, at most enhancing conditions, the 
titers of immature DENV-immune complexes reached comparable levels as std DENV-2 in the absence of immune 
sera. These findings are consistent with previous studies, which demonstrated that immature DENV particles are 
infectious in the presence of polyclonal sera, anti-prM and anti-E (da Silva Voorham et al.,2012; Dejnirattisai et al., 
2010; Ochiai et al., 1988; Rodenhuis-Zybert et al.,2010; Rodenhuis-Zybert et al.,2011). Furthermore, and as 
expected, immune sera from all severity groups enhanced std DENV-2 infection (Fig. 3D, E and F), albeit with a 
lower power of enhancement when compared to that of immature particles. Interestingly, DHF sera was most 
efficient in neutralizing std DENV-2 infectivity at high sera concentrations and elicited significant ADE over a 
broadest range of sera dilutions (Fig. 3E).  
We previously demonstrated that antibody-opsonized immature viruses require enzymatic activity of furin in host 
cells to become infectious (da Silva Voorham et al.,2012; Dejnirattisai et al., 2010; Ochiai et al., 1988; Rodenhuis-
Zybert et al.,2010; Rodenhuis-Zybert et al.,2011). To investigate whether furin activity is also critical for the 
infectivity of immature particles opsonized with polyclonal sera,  




Figure 1. Specificity of human antibody response against DENV prM protein. Western Blot analysis of pooled 
immune sera from patients with DF, DHF and DSS binding to purified immature DENV-2. Student’s t-tests 
were used to determine significance, no significant difference was observed. 
 
we inhibited activity of cellular furin in P388D1 cells using a specific furin inhibitor decRRVKR-CMK (FI), as 
described previously (Rodenhuis-Zybert et al., 2010). Under the conditions used, FI did not affect maturation of 
newly assembled virions (control bars in Fig. 4A and 4B). Importantly, inhibition of furin activity in target cells 
abolished infectivity of immature virions opsonized with immune sera. These results substantiate our previous 
findings indicating that maturation upon entry is a prerequisite for rendering DENV-immune complexes infectious 
(Fig. 4A).  
 
ADE of std DENV-2 elicited by immune sera is partly dependent on furin activity 
 
The circulation of prM antibodies in patients sera is believed to mirror the existence of prM-containing (partially) 
immature virions in  vitro DENV preparations. Despite our limited understanding on the functional role of (partially) 
immature virions, it has been speculated that viral infectivity is inversely related to prM content (Rodenhuis-Zybert 
et al., 2011). Particles that have a high prM content being essentially non-infectious in multiple cells (Zybert et al., 
2008 da Silva Voorham et al., 2012; Rodenhuis-Zybert, et al., 2010). Interference with furin activity can therefore 
tell us which proportion of the ADE observed during std DENV infection is caused by immature particles that 
require maturation upon cell entry. Indeed, we previously reported up to 10-fold reduction in viral infectivity 
following infection of mAb opsonized-std DENV-2 in FI-treated cells (da Silva Voorham2012; Rodenhuis-Zybert et 
al.,2011). To assess the extent to which (partially) immature virions contribute to ADE in std DENV2 preparations, 
cells were treated with FI and tested for their ability to cause ADE of DENV2 opsonized with sera from DF, DHF 
and DSS patients. The sera dilution that gave the best ADE in non-treated cells was used for this experiment. Figure 
4B shows a significant reduction in viral infectivity in cells treated with FI, strengthening the hypothesis that ADE is 
also caused by (partially) immature particles present within standard virus preparatio 
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Figure 2. Capacity of immune sera to bind immature and std DENV-2. Presence of IgGs directed binding to 
Immature DENV-2 (A) and std DENV-2 (B) preparations were analyzed by means of indirect ELISA. Each 
dot represent reciprocal end point titer obtained in one of at least three independent experiments. The 
horizontal lines depict average of all experiments. No significant difference was found between the groups. 




























































In this study we investigated the potential involvement of immature DENV particles in dengue pathogenesis. We 
tested the ability of acute DENV-2 sera obtained from DF, DHF and DSS patients to bind and enhance infectivity of 
immature DENV-2. We found that a substantial fraction of antibodies is directed against the prM protein and 
immature virions, however no significant difference was observed between the distinct severity groups. 
Furthermore, similar ADE profiles were obtained following infection with immature virions pre-opsonized with sera 
from DF/DHF/DSS patients, suggesting that the presence of immature particles and the antibodies recognizing them 
cannot be seen as a predisposing factor for severe disease. Nevertheless, we demonstrated that prM-containing 
virions within std DENV-2 preparations significantly contribute to ADE, indicating that immature particles act as a 
co-factor in disease pathogenesis. Only a small fraction of the humoral response elicited during DENV infection 
appears to be responsible for protection (Beltramello et al., 2010; Crill et al., 2009; de Alwis et al., 2011; 
Dejnirattisai et al., 2010; Lai et al., 2008). The great majority of dengue specific antibodies being cross-reactive and 
weakly neutralizing. Accordingly these antibodies are thought to exacerbate disease during heterologous re-
infection. In line with earlier observations (Beltramello et al., 2010; de Alwis et al., 2011; Dejnirattisai et al., 2010), 
we found that a large fraction of antibodies are produced against the prM protein. Furthermore, and in agreement 
with Lai and co-workers, there was no significant difference in prM antibody levels between DF, DHF, DSS 
patients. This indicates that there is no direct correlation between the level of prM antibodies early in infection and 

















Figure 3. Immune sera neutralizes and enhances the immature and std DENV-2 infection. P388D1 cells were 
infected with immature or std DENV-2 at MOG 500 in the presence or absence of serially diluted pooled-
sera of DF patients (A and D), DHF (B and E)  patients and DSS patients (C and F). At 43 hpi supernatant 
was harvested and virus production was analyzed by plaque assay on BHK21-15 cells. Data are expressed as 
means of at least two independent experiments performed in triplicate. The error bars represent standard 
deviations (SD); (n.d.) denotes ‘‘not detectable’’. Student’s t-tests were used to determine significance; *, P < 
0.05; **, P < 0.01 
 
bind and enhance infectivity of immature virions (da Silva Voorham et al.,2012; Rodenhuis-Zybert et al.,2010), we 
also studied the capacity of immune sera to react with immature virions by means of ELISA. We demonstrated that 




















































































































































































































































































Figure 4. ADE of immature and std DENV-2 infection by immune sera can be influenced by furin activity. 
Non-treated P388D1 cells and the cells treated and with FI were infected with immature (A) and std (B) 
DENV-2 strain 16681 at MOG 500 in the absence or presence of pooled immune sera. Virus production was 
detected as described in the legend of Fig.1. The error bars represent standard deviation (SD) derived from 
at least two separate experiments performed in triplicate. Two-tailed Student’s t-tests were used to 
determine significance; *, P < 0.05; **, P < 0.01. 
 
the presence of such antibodies is not discriminative for severe disease development. Taken together, these findings 
suggest that antibodies recognizing immature virions cannot be used as a diagnostic tool to investigate if a patient is 
predisposed to severe disease. In vitro, DENV preparations comprises a mixture of mature, partially and fully 
immature particles (Junjhon et al., 2010). Importantly, the extent of virion maturation influences the capacity of 
antibodies to neutralize or enhance infection (Nelson et al., 2008). Accordingly, it has been speculated that 
“inefficient” cleavage of prM can serve as an immune evasion mechanism. This notion is supported by recent 
observations indicating that most prM and E antibodies that preferentially bind to immature virions are cross-
reactive and weakly or non-neutralizing (Dejnirattisai et al., 2010). An important remaining question is, how many 
prM-containing particles circulate in DENV-infected humans. We have attempted to answer this question by 
combinatory antigen capture ELISA/qPCR assay. Unfortunately, despite high viremia titers in acute sera of the 
patients, the numbers of ELISA captured virions were insufficient to reach the threshold necessary for reliable qPCR 
measurements. Instead we analyzed the overall contribution of (partially) immature virions to the ADE profile. We 
took advantage of the fact that fully and, probably also partially immature virions with a high prM content rely on 
enzymatic furin activity to become infectious (Mukherjee et al.,2011; Rodenhuis-Zybert et al.,2011; Rodenhuis-
Zybert,2011). Although no differences were found between disease severity groups, (partially) immature virions 
present within std DENV preparations significantly contributed to the overall ADE effect observed. These results 
strongly suggest that immature particles that depend on endosomal furin cleavage contribute to the total viral load 
observed during secondary dengue infection. Whether the remaining, furin-independent, ADE of infection is caused 
by partially immature virions or the fully mature particles remains to be elucidated. Multiple studies (Dejnirattisai et 
al., 2010; Huang et al., 2006; Rodenhuis-Zybert et al.,  2010) show that prM antibodies are more prone to initiate 
ADE rather than neutralization. Therefore one could argue that prM antibodies are detrimental for protection and 
should not be elicited by a DENV vaccine. Unexpectedly, although though no significant results were obtained 
between disease severity groups, sera from DF patients had relatively more prM antibodies and had a narrow 
spectrum of antibody neutralization. Moreover, sera of DHF patients neutralized the infecting serotype over the 
broadest range of dilutions. Noteworthy in this respect are the recent results from the Sanofi trail indicating that high 
antibody titers are not indicative for DENV-2 protection (Sabchareon et al., 2012). Clearly, these results show that 
we do not yet understand the correlate of protection against DENV disease. It is therefore imperative to better 
understand the immune response in vaccinated individuals and it would be of interest to determine the ratio of prM 
and E antibodies in this cohort. The unforeseen and disappointing results of the clinical trial indicate that more 
fundamental research is required to unravel which antibodies are most protective and should be elicited by a 
vaccine. What then determines the development of severe disease? At present, we cannot answer this question but it 
is clear from this and many other studies that dengue virus pathogenesis is very complex and involves multiple virus 
and host factors (Halstead, 2007; Martina et al., 2009; Rodenhuis-Zybert et al., 2010). The infection history of the 
patient in combination with the current infecting DENV genotype will determine the balance between neutralizing 
and enhancing antibodies. These together with yet unspecified host factors will likely predispose to more severe 
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disease. Evidently, it remains an enormous challenge to fully understand why some individuals develop severe 
disease whereas others do not.  
Materials and Methods 
Patients.  
 
Immune sera was obtained from the ongoing Pediatric Dengue Cohort Study in Nicaragua. DF, DHF and DSS were 
diagnosed according to WHO case definitions (WHO, 1997). All patients had an acute secondary DENV-2 
infection, defined by an antibody titer by inhibition ELISA ≥ 20 (equivalent to an HI titer ≥ 10) (Harris et al., 2000; 
Nogueira et al., 1993). The sera used in this study was taken 2 to 4 days after the onset of fever. In total 30 patients: 





Aedes albopictus C6/36 cells were maintained in minimal essential medium (Life Technologies) supplemented with 
10% fetal bovine serum (FBS), 25 mM HEPES, 7.5 % sodium bicarbonate, penicillin (100 U/ml), streptomycin 
(100 μg/ml), 200 mM glutamine and 100 µM nonessential amino acids at 30°C, 5 % CO2. Baby hamster Kidney 
clone 15 cells (BHK21-15) cells were cultured in DMEM (Life Technologies) containing 10% FBS, penicillin (100 
U/ml), streptomycin (100 μg/ml), 10 mM HEPES, and 200 mM glutamine. Human adenocarcinoma LoVo cells 
were cultured in Ham’s medium (Invitrogen) supplemented with 20% FBS at 37°C, 5% CO2. Mouse macrophage 
P388D1 cells were maintained in DMEM supplemented with 10% FBS, penicillin (100 U/ml), and streptomycin 
(100 μg/ml), sodium bicarbonate (Invitrogen, 7,5% solution) and 1.0 mM sodium pyruvate (GIBCO) at 37°C, 5% 
CO2. 
 
Virus growth.  
 
DENV-2 strain 16681 was propagated on C6/36 cells, as described before (Zybert et al., 2008) Immature DENV-2 
was produced on LoVo cells, as described previously (Zybert et al., 2008). Briefly, LoVo cells were infected at 
MOI 5, 1.5 h post-infection (hpi) the virus inoculum was removed, cells were washed three times with PBS, and 
fresh medium was added. At 72 hpi, the medium containing the virus particles was harvested, cleared from cellular 
debris by low-speed centrifugation, aliquoted, and stored at -80ºC. The specific infectivity was determined by 
measuring the number of infectious units by plaque assay on BHK21-15 cells and the number of GCPs by 
quantitative PCR (qPCR) analysis, as described previously (van der Schaar et al., 2007).  
 
Western Blot.  
 
For Western blot analysis, 1.0x10
9
 GCPs of purified immature DENV-2 were loaded on 12.5% SDS 
polyacryramide gels under non-reducing conditions. The blot was incubated with serial dilutions of pooled immune 
sera from DF, DHF and DSS patients. A human monoclonal prM antibody hmAb 27.2 (kind gift from A. 
Lanzavecchia, Institute for Research in Biomedicine, Bellinzona, Switzerland) was used as a positive control. The 
antibody response against the E and prM protein was analyzed with ImageQuant TL. The percentage of prM is 
calculated by relating the intensity of the prM protein band to the total intensity of prM and E. Values obtained 




The binding properties of dengue-immune sera to immature virus particles was assessed with a three-layer ELISA. 
Briefly, microtiter ELISA plates (Greiner bio-one) were coated overnight with 1x10
8
 GCPs of purified virus per 
well in 100 µl coating buffer. After blocking with 2% milk in coating buffer for 120 min, 100 µl of two-fold serial 
dilutions of control and pooled dengue-immune sera from patients with DF, DHF and DSS were applied to the 
wells and incubated for 1.5 h. Subsequently, upon extensive washing, 100 µl of horseradish peroxidase-conjugated 
mouse anti-human IgG antibody (Southern Biotech 9040-05) was applied for 1 h. All incubations were performed 
at 37°C. Staining was performed using o-phenylene-diamine (OPD) (Eastman Kodak Company) and absorbance 
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was read at 492 nm (A492) with an ELISA reader (Bio-tek Instruments, Inc.). The highest positive (cut off = mean 
control sample OD + 3xSTDEV of control) in the assay was defined as the endpoint titer.  
 
Infectivity assays.  
 
Virus or virus-immune sera complexes were added to a monolayer of P388D1 cells (2 × 10
5
) in 24 wells plates 
(Costar), at a multiplicity of genome-containing particles (MOG) per cell of 500. At 1.5 hpi, fresh medium was 
added to the cells. At 43 hpi, the medium was harvested and virus production was analyzed by plaque assay on 
BHK21-15 cells, as described previously (Diamond & Harris, 2001). The limit of detection in the plaque assay is 
20 PFU/ml. In furin inhibitor experiments, cells were treated with 25 µM of furin-specific inhibitor, decanoyl-L-
arginyl-L-valyl-L-lysyl-L-arginyl-chloromethylketone (decRRVKR-CMK) (Calbiochem) prior to and during virus 
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Dengue is the most prevalent mosquito-borne viral disease in the world. Previously dengue was confined to tropical 
regions but in recent years it has spread to areas with sub-tropical and moderate climates (Hayes et al., 2006; Moi et 
al., 2010; WHO, 1997). In fact, in 2012 the first dengue outbreak was observed within Europe (Sousa et al., 2012; 
WHO, 2013). An estimated 400 million infections occur annually (Bhatt et al., 2013). Infection with dengue virus 
(DENV) can induce multiple clinical manifestations ranging from a self-limited fever called dengue fever (DF) to 
life-threatening manifestations, such as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) (WHO, 
1997). There are 5 antigenically distinct serotypes (DENV-1 to DENV-5), the fifth one was only recently discovered 
in Malaysia (ScienceInsider, 2013). 
 
All DENV serotypes are human pathogens. The immune response generated during a primary DENV infection 
appears to have a dual role upon re-infection (van der Schaar et al., 2009).  During homotypic re-infection it controls 
viral infection and no disease symptoms develop. In approximately 2% to 4% of the individuals re-infected with a 
heterologous DENV serotype, however, the immune response is believed to underlie the development of severe 
disease. Indeed, exacerbation of disease during heterologous re-infection has been linked to the phenomenon of 
original antigenic sin of T cells and antibodies (Halstead & O'Rourke, 1977; Halstead, 2003; Mongkolsapaya et al., 
2003). This implies that the antibody and T cell response is skewed towards the primary infecting DENV serotype 
and as a consequence high numbers of cross-reactive antibodies and low avidity T cells are generated during 
secondary infection. Cross-reactive antibodies have been shown to facilitate enhancement of infection thereby 
increasing the infected cell mass and viral burden. Imbalanced secretion of cytokines by T lymphocytes 
subsequently increases vascular permeability, which appears to be the principal factor that gives rise to the 
development of severe disease. Pre-existing antibodies appear to represent an essential trigger as infants, with 
waning maternal dengue antibodies have an increased risk to develop severe disease during primary infection 
(Simmons et al., 2007). 
 
During primary DENV infection, the three major phagocytic cell types of the innate immune system, monocytes, 
macrophages, and dendritic cells (DCs) have been found to be preferentially infected (Blackley et al., 2007; 
Marovich et al., 2001; Wu et al., 2000). During secondary infection, antibodies from a prior infection facilitate viral 
entry into Fc receptor (FcR) bearing cells, such as monocytes, macrophages, and DCs. In case of a homotypic re-
infection, most virus-antibody complexes will be degraded upon FcR-mediated phagocytosis (Heusser et al., 1977). 
In case of a heterologous re-infection leading to severe disease, the virus-antibody complexes escape from the 
degradative pathway and induce a productive infection. Thus, during primary and secondary infection, immune cells 
are the predominant infecting cell types. Infection of immune cells by DENV may significantly impact the 
development of the immune response, because these cells are essential for the initiation and polarization of adaptive 
immune response. To recognize the intruders, these cells are equipped with a set of phylogenetically conserved 
pattern recognition receptors (PRRs), such as Toll-like Receptors (TLRs) [revised in chapter 2] (Torres-Pedraza et 
al., 2010). TLRs recognize pathogen-associated molecular patterns  (PAMPs) and danger associated molecular 
patterns (DAMPs) and in DCs, their activation leads to a positive regulation of co-stimulatory molecules, HLA 
molecules, cytokines, chemokines, and other soluble mediators. These signals are required to establish a cellular 
immune response (Banchereau & Steinman, 1998) and an antiviral state. However, many viruses, including DENV, 
exert mechanisms that aim to evade innate signaling and sustain an efficient DENV  replication [revised in chapter 
1]. The characterization of these early events that lead to either protection or the virus spreading is essential to 
understand dengue pathogenesis and is the central focus of this thesis. 
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In chapter 4, we explored the activation of TLRs in monocytes, myeloid, and plasmacytoid DCs (mDCs and pDCs, 
respectively) from individuals who developed different manifestations of the disease. We found differences in TLRs 
expression and activation status of DCs from DF and DHF patients. A higher expression of TLR2 in pDCs was 
observed in individuals with DHF when compared to DF patients. In addition, we found that mDCs from DHF 
patients had a significant lower expression of TLR3 and TLR9 compared to DF patients. Furthermore, DCs from 
patients with hemorrhagic manifestations expressed lower levels of the maturation markers CD80 and CD86 than 
DF patients. These results show that during dengue disease progression, the expression profile of TLRs changes 
depending on the severity of the disease. Alteration in TLRs signaling could also directly affect DC activation, 
thereby influencing the innate immune response. In order to validate our ex vivo study, we also assessed TLRs 
functionality in vitro. We evaluated the capability of DENV infected peripheral blood mononuclear cells to produce 
IFN in response to the stimuli and in presence of  several TLRs agonists. We found that there was a poor stimulation 
of IFN production via TLR9, suggesting that DENV alters IFN response through this signaling pathway.  
 
In chapter 5, we characterized the phenotypical and functional changes that immDCs undergo after DENV 
infection in the absence or the presence of antibodies. We demonstrated that direct DENV infection - unaided by 
antibodies - blocked maturation and cytokine production of immDCs. ImmDCs directly infected with DENV did not 
up-regulate the expression of maturations makers such as CD83, CD86 and HLA-DR. In contrast, we observed that 
exposure of DCs with DENV opsonized with neutralizing concentrations of antibodies stimulated full DC 
maturation and triggered a cytokine response. At these conditions we found a balanced pro- inflammatory (IL-6 and 
TNF-alpha) and anti-inflammatory (IL-4, and IL-10) response. The increased cytokine production was strictly 
dependent on the interaction of the immune-complex with FcγRIIa. Interestingly, despite a similar level of infection 
was seen following infection at non-neutralizing serum conditions and direct infection (virus unaided to antibodies), 
only non-neutralizing conditions lead to an increase in HLA-DR expression and cytokine production. These findings 
show that the presence of immune-complexes modulate the signaling pathways that lead to activation of DCs. 
  
In order to expand our knowledge on the role of DCs in DENV dissemination [chapter 6], we evaluated the 
infectious properties of the particles produced by immature and mature DCs in the absence and presence of DENV-
immune serum. A higher specific infectivity of the viral progenies generated by matDCs was found when compared 
to the particles produced by immDCs. We found that the frequency of DENV positive cells in immDCs was 
approximately 3 times higher than DENV positive cells in matDCs. This high susceptibility of immDCs to DENV 
infection can be explained by its high content of the dendritic-dells specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN) receptor (Boonnak et al., 2008; Sun et al., 2009). We also infected immDCs and 
matDCs in the presence of a DENV-2 immune-serum. Our results reveal that DENV-immune serum enhances viral 
infection in matDCs but not in immDCs. Taken together, the findings from chapters 5 and 6 suggest that, even 
though immDCs are slightly more permissive to DENV infection than matDCs, their contribution to virus 
dissemination might not be as significant as initially thought. In fact, immDCs and matDCS may be equally 
important during primary DENV infection. During secondary heterotypic infection, matDCs are likely to become 
the main viral factories contributing to increased viremia that often preludes disease exacerbation. 
   
Furthermore, the statement that DENV-infected cells produce heterogeneous populations of virions that vary in their 
maturation state prompted us to investigate whether immDCs are susceptible to immature DENV particles. The 
variation in virion maturation is due to incomplete cleavage of the viral precursor membrane (prM) protein during 
the process of exocytosis. Immature prM-containing particles are considered non-infectious as the prM protein caps 
the receptor binding envelope (E) glycoprotein (Li et al., 2008). The cleavage of PrM to the Pr and M fragments is 
performed by the Golgi resident protease furin. This process is required for the complete maturation of DENV 
particles and for the conversion of the viral particles into infectious virions. Rodenhuis-Zybert and co-workers have 
demonstrated that antibody-mediated entry of immature viral particles facilitates the intra-endosomal cleavage of 
prM by furin and leads to the conversion of immature-non-infective particles to infectious particles (Rodenhuis-
Zybert et al., 2010). This indicates that, in the presence of antibodies, immature DENV particles may contribute to 
the viral load observed in secondary infections. In chapter 7, however, we demonstrated that immature DENV is 
infectious in immDCs via the receptor molecule DC-SIGN, albeit with a low infectivity. In order to elucidate 
whether ADE can take place in immDCs, immDCs were infected with immature DENV in the presence of 
increasing dilutions of dengue- immune serum. We found that, immDCs did not display ADE in the presence of 
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serial dilutions of homotypic DENV-immune serum, thus as in the case of wild type virus (evaluated in chapter 6), 
immDCs did not contribute to ADE after infection with immature particles.  
In chapter 8, we evaluated the role of immature dengue virus in disease pathogenesis. Initially, we evaluated the 
capacity of IgG antibodies recovered from sera of patients with different severity of dengue to react to prM and E 
proteins. No significant differences were found in the relative binding of immature and wild type DENV particles to 
the antibodies present in the different severity groups; indicating that the prM response is not contributory to 
severity. In light of the fact that there were no quantitative differences in the content of anti-prM antibodies between 
severities of the disease, and that DCs did not exhibit and important participation in ADE, we focused on the quality 
of the response generated by the sera from different severities in the macrophage cell line P388D1. High 
concentrations of the polyclonal sera from all the severities of dengue neutralized the infection. Nonetheless, 
enhancement of the infectivity was observed in the presence of high dilutions of polyclonal sera. In addition, it was 
observed that ADE of immature and standard DENV in macrophages was influenced by endosomal furin. Taken 
together, these findings demonstrate that prM antibodies indeed play a role in the entry of immature DENV particles 
in cells and are consistent with a prior publication of our group demonstrated that antibody-opsonized immature 
virus requires endosomal furin to become infectious (Rodenhuis-Zybert et al., 2010). 
 
Role of dendritic cells in DENV infection  
 
Dendritic cells vs DENV 
 
Dendritic cells are essential in the detection and response to pathogens, such as viruses. Recognition of the antigens 
occurs via a set of PRRs including TLRs that activate DC maturation and production of soluble factors including 
cytokines. These phenotypical and functional changes are required for DCs to become professional antigen 
presenting cells (APCs).  Accordingly, alteration in TLRs signaling can directly affect DC activation, and ultimately 
lead to aberrant immune responses. We and others have shown that DENV infection can indeed modulate TLR2, 
TLR3, , TLR4, TLR7 (Modhiran et al., 2010) and TLR9 expression and signaling (Azeredo et al., 2010; Modhiran 
et al., 2010; Torres et al., 2013; Tsai et al., 2009; Wang et al., 2006) and that this modulation can be associated with 
different disease presentation. It is thus clear that DCs activation plays an important role in dengue pathogenesis. 
Importantly, DENV replicates in DCs and although the major targets of DENV infection in vivo is still under 
investigation, DCs are considered to be one of the most important susceptible cell-types. Thus, it seems that DENV 
infection will be like a battle of 2 giants, one fights the infection and the other exerting mechanisms to block these 
processes. Since the presence of dengue-specific antibodies during infection may become a sword of each of the two 
giants, the following part of the discussion is dedicated to the immune responses that might be initiated by DCs 




DCs in primary DENV infections 
 
The typical clinical manifestation of dengue, DF, is characterized by high fever, severe retro-orbital headache, 
myalgias, and other signs that are thought to result from exaggerated proinflammatory responses. However, 
epidemiological evidence has demonstrated that a significant number of primary DENV infections are in-apparent or 
subclinical. Thus, in the majority of primary infections the immune system is able to control the infection. IFN type 
1 has been shown to be crucial for the containment of DENV infection (Samuel, 2001). Differential activation of 
endosomal TLR3, TLR7, TLR8, and TLR9, can thus lead to high or low antiviral responses (Kawai et al., 2004; 
Okahira et al., 2005) . Indeed, it has been shown  in vitro that over-expression of TLR3 inhibited DENV replication 
through IFN production (Tsai et al., 2009). The specific expression of TLRs and likely other PRRs that recognize 
DENV exhibited by an infected individual may contribute or even predispose to a distinct disease presentation. 
In addition, we demonstrated that DENV infection did not induce maturation of DCs or production of fever-inducing 
cytokines like Il-6 and TNF-alpha, suggesting that DCs were able to abort infection without inducing strong immune 
responses. This immune-modulatory effect of DENV infection is in line with previous publications (Chase et al., 
2011; Jones et al., 2005) and in contrast to others (Ho et al., 2001; Libraty et al., 2001; Nightingale et al., 2008).The 
lack of unanimity between the studies, although likely reflecting different DENV strains and genetic background of 
the donors tested in vitro, also perhaps mirrors the variety of the disease presentations.  
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What role will DCs play as DENV factory during primary infection?  We showed that immDCs might not be as 
susceptible to DENV as previously thought. In fact, the majority of immDCs were able to block infection of 
internalized DENV. Moreover, immDCs that did replicate the virus produced virions having a very low specific 
infectivity when compared to mosquito cell line- or matDCs-derived viruses. It has been previously reported that in 
the process of DC maturation, there is up-regulation of N-glycosyltrasferases enzymes. Importantly, during the 
replication cycle of DENV, these enzymes are responsible for N-glycosylation of Asn-67 and Asn-153 on DENV 
envelope (E), and both glycosylations are related to higher infectivity of the released viral particles. Whether 
inefficient glycosylation is the underlining mechanism of the low specific infectivity of immDCs-derived virus 
remains to be investigated.  
In summary, in our studies DENV infection of immDCs did not induce production of pyrogenic cytokines and led to 
production of poorly infectious virus.  Accordingly, during primary infections immDCs  are more likely to 
contribute to the containment of DENV infection  rather than to its dissemination. Since our data at least in part 
corroborated previous studies, we propose that these observations could explain how certain individuals contract the 
infection without any noticeable signs of disease. Whether this phenomenon does indeed contribute to the resolution 
of the infection rather than spreading the virus requires further investigation. 
 
On the other hand, matDCs, which produce virus with relatively high specific infectivity, may play important role 
dengue pathogenesis. Accordingly, it may suggest that primary DENV infection of an individual with ongoing 
inflammation may confer a risk for more symptomatic or maybe even enhanced infection presentation.  
 
DCs in secondary infections 
 
The vast majority of secondary infections are resolved, signifying that antibodies also confer protection. In this 
study, we found that in the presence of high concentrations, dengue immune serum neutralized infection in DCs. 
Under neutralizing conditions, immDCs not only blocked infection but also up-regulated HLA-DR, costimulatory 
molecules, and secreted inflammatory cytokines suggesting a transition to fully functional APCs. Interestingly, the 
activation of  DCs was found to depend on the ligation of the DENV immune complexes with FcRyIIa and occurred 
irrespectively of neutralization. A study performed by Den Dunnen and Co-workers revealed that the presence of 
immune-complexes formed by IgG and Staphylococcus aureus triggers maturation and cytokine production by 
immDCs (den Dunnen et al., 2012). When we evaluated the immunological effects of  antibodies during DENV 
infection of immDCs, we found that immDCs at neutralizing as well as non-neutralizing antibody conditions up-
regulated IL-4, IL-6, and TNF-alpha production. At neutralizing conditions, the DENV antigen-positive cells also 
exhibited a mature phenotype when compared to cells exposed to virus unaided by antibodies. These findings 
suggest that, during secondary infections, the presence of high concentrations of antibodies not only favors 
neutralization of the virus but also induces a stronger immune response. 
Heterologous secondary DENV infections are mainly interpreted as a risk factor for the development of DHF/DSS. 
This has been linked to the presence of sub-neutralizing levels of heterotypic antibodies which facilitate ADE  and 
thereby increase the titers of circulating virus. Here we have shown that matDCs likely to contribute to the ADE 
phenomenon in the presence of sub-neutralizing levels of dengue-specific antibodies. Interestingly, at the same 
antibody dilution, immDC maturation was affected and a mainly pro-inflammatory response was seen. 
High viremic titers often prelude severe disease development. The increased viral burden subsequently triggers an 
imbalanced immune response which leads to a so called cytokine stormby T lymphocytes (Green & Rothman, 2006; 
Navarro-Sanchez et al., 2005). Indeed, elevated cytokine levels are seen in patients with DHF/DSS .  It has been 
reported that DENV infection of DCs activates T cells to produce a mixed TH1, TH2 cytokine profile (Chaturvedi et 
al., 1999). Since TLRs are directly related to cytokine production and maturation of DCs, we sought to find 
differences in TLR expression profile according to the severity of the disease.  Indeed, we found that there is a 
differential profile in the expression of TLRs in DCs from DHF patients when compared to the DF patients.  DCs 
from severe dengue cases exhibit high expression of the surface-expressed TLR2 and down-regulated expression of 
the intracellular receptors TLR3 and TLR9.  Since TLR2 is known to recognize bacterial products such as 
peptidoglycans, and lipoarabinomannan its increased expression pDCs from DHF patients is puzzling.  It has been 
reported that the activation of  TLR2 is mainly related to the induction of a TH-2 biased cytokine profile, which 
drives proliferation of the regulatory T lymphocytes (T-regs) (Redecke et al., 2004). This assertion draws us to the 
conclusion that the activation of TLRs and the induction of a TH2 profile may have two implications regarding the 
dengue disease. On one hand, a TH2 biased cytokine profile represented mainly by IL-10 may be a regulatory 
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response to the exacerbated inflammatory environment generated by T lymphocytes during secondary infections. On 
the other hand, since high levels  of IL-10 has been recognized as a severity marker in dengue, it may signify that 
TH2 skewed cytokine profile contributes to the pathogenesis of dengue by the abrogation of the antiviral response 
(Redecke et al., 2004). Future studies should elaborate the role of TH2 immunity. 
In summary, we propose that there is a direct link between DC activation, antibodies, and T-cell-mediated responses 
and protection during secondary DENV infections and that this effect is contingent on the concentration of 
antibodies present during the infection. 
Immature DENV particles: Their contribution in disease  
DENV-infected cells secrete a heterogeneous population of particles with regard to the number of precursor 
membrane (prM) molecules per individual particle. Within infected cells, the prM protein acts as a chaperone and 
blocks the envelope (E) glycoprotein from undergoing pre-mature pH-induced conformational changes during 
transit through the acidic secretory pathway (Elshuber et al., 2003).  Indeed, structural studies revealed that the prM 
protein caps the E protein. Prior to secretion, the prM protein is cleaved into a membrane (M) protein and a pr 
peptide, the latter dissociates after the release of the particle to the extracellular milieu. This cleavage event is, 
however, not efficient as almost all particles contain residual prM. Indeed, approximately 90% of mosquito cell-
derived DENV appears to contain prM molecules, indicating that during viral transmission many prM-containing 
immature particles are released into the skin (Junjhon et al., 2010). The functional properties of immature DENV 




We and others showed before that immature DENV particles are non-infectious in cell lines because they fail to bind 
to receptors expressed at the cell surface (Guirakhoo et al., 1991; Junjhon et al., 2010). We argued that prM caps the 
receptor binding motif of the E protein thereby rendering them non-infectious. This implied that these particles 
would not contribute to disease pathogenesis (Elshuber et al., 2003; Moesker et al., 2010; Randolph et al., 1990; Yu 
et al., 2008; Zybert et al., 2008). Recently, however, another study revealed that immature particles of West Nile 
Virus (WNV), which is closely related to DENV, is infectious in cells expressing DC-SIGN   (Mukherjee et al., 
2011). DC-SIGN is abundantly expressed at the cell surface of DCs, cells that are known to be permissive to DENV 
infection. Therefore, in chapter 7, we addressed the question of whether immature DENV particles can use DC-
SIGN to enter immDCs. Indeed, we demonstrated that immDCs can be infected with immature DENV particles due 
to interaction with DC-SIGN. This suggests that immature DENV particles can also contribute to the viral load in 
patients experiencing a primary infection. I do however think that mature M-containing particles are more important 
in disease development as the level of infectivity of immature particles was much lower than that of standard virus 
preparations. Furthermore, in contrast to mature virions, immature particles will be non-infectious in cells lacking or 
expressing very low levels of DC-SIGN. Indeed, immature particles were   found to be non-infectious on murine 
macrophage cells, which express low levels of DC-SIGN whereas  multiplication of standard virus preparations was 
seen in these cells ((Boonnak et al., 2008). Taken together, although immature particles were found infectious in 
immDCs, I believe their role in disease pathogenesis during primary infection is rather limited.       
Secondary infection  
Previous studies performed by our group have revealed that in cell lines, antibodies directed against prM and E can 
rescue the infectivity of immature DENV2 particles. Infectivity is rescued by: 1) antibody-Fc receptor interaction, 
and 2) prM to M cleavage upon entry due to the host protease furin. Intriguingly, the infectious properties of 
immature DENV particles in presence of antibodies are almost as high as standard preparations. This suggests that 
during secondary infection immature particles can play an important role in disease pathogenesis.  In chapter 7 we 
aimed to decipher whether immature DENV particles from DENV-1, 3, and 4 also recover their infectivity after 
opsonization with DENV-antibodies. Indeed, in macrophages, enhanced infectivity of immature DENV1, 2, 3, and 4 
was seen in presence of antibodies. In immDCs, however, no enhanced infectivity was observed following immature 
DENV-2 infection in presence of antibodies. The experiments could not be performed with immature DENV1, 3, or 
4 due to too low infectivity of these virus preparations. However, the data obtained with immature DENV-2 is in 
agreement with our data with standard dengue preparations and suggest that the efficient DENVE/prM-DC-SIGN 
interaction overrules the additive role of FcR-mediated entry of DENV in the presence of non-neutralizing 
antibodies. One could also speculate that the intracellular network of  PRRs  displayed by DCs, such as TLRs, play 
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an important role in the abrogation of ADE by the activation of antiviral products such as interferon and  TH1 
profile cytokines. Furthermore, immature particles appear to be less infectious in immDCs than mature virions as we 
did not -despite the moderate infectivity of immature virions in the absence of antibodies – observe ADE. Also, 
immature DENV infectivity in the presence of antibodies is less efficient in immDCs than in macrophages. This 
observation may imply that immDCs do not allow viral maturation upon entry to the cells in the same way as 
macrophages do. Given the high infectivity of immature particles opsonized with antibodies in macrophages, we 
wondered whether these particles and the antibodies that recognize them are crucial for severe disease development. 
As described in chapter 8, we found that antibodies from all severities are capable to bind to immature DENV 
particles without differences. Furthermore, we also corroborate that immDCs are not susceptible to undergo ADE 
neither in the presence of standard DENV nor immature DENV particles.  In macrophages, the immature DENV 
particles present within the standard virus preparations contributed to the total viral output under ADE conditions 
but no differences were observed between disease severities. Taken together, antibody-opsonized immature particles 
are not the sole trigger but act as a co-factor in disease pathogenesis. The heterogeneity of DENV particles thus adds 
another layer of complexity to dengue pathogenesis.  
All neutralizing anti-DENV antibodies analyzed to date caused ADE once the antibody concentration is below the 
threshold that is required for virus neutralization (Pierson et al., 2007). But which antibodies recognizing immature 
and mature particles then protect during homotypic re-infection and enhance disease during heterotypic re-
infection?.    
 Interestingly, the most potent neutralizing antibodies are type specific and directed against the domain III of the E 
glycoprotein. These represent however a minority of the total anti-E response as more than 90% of the antibodies are 
generated towards the highly conserved fusion loop in domain II.   Antibodies against prM have been shown to be 
weakly neutralizing and are highly cross-reactive to other serotypes.  In homotypic re-infection, the high affinity 
type specific antibodies likely neutralize the newly infecting virus. It is possible however that at the same time prM 
antibodies and non-neutralizing E antibodies facilitate successful infection of mature and immature particles during 
homotypic re-infection. But given the presence of the type specific highly neutralizing antibodies the overall balance 
is oriented towards neutralization of infection.   In case of heterotypic re-infections, only the cross-reactive 
antibodies can bind and these generally have weakly neutralizing properties. The weakly neutralizing properties of E 
domain II antibodies plus the ability of antibodies to render immature virions infectious therefore sets the stage to 
antibody-dependent enhancement of infection. Importantly, however, only 2-4% of the individuals experiencing a 
heterologous re-infection develop severe disease demonstrating that besides antibodies other unknown factors are 
also involved in disease pathogenesis.  
Concluding remarks and future perspectives  
In this thesis, we have demonstrated that immDCs play a dual role in DENV infection. They can confer protection 
against the infection or contribute to the pathogenesis depending on history of previous DENV infection and the 
maturation state of the DCs upon infection. We demonstrated that immDCs, despite being relatively higher 
permissive to viral entry than mat DCs, produced viral particles with low infectivity. In addition, we observed that 
DENV, when unaided by antibodies, did not induce either the maturation of the cells or cytokine production. We 
therefore infer that during primary infections, the infection of immDCs does not contribute to the high viral output, 
nor does contribute to the increasing of the levels of cytokines observed in hemorrhagic manifestations. These 
observations could at least in part explain the fact that high proportion of primary infections are asymptomatic or do 
not lead the development of a pro-inflammatory response. 
Interestingly, infection of immDCs in the presence of neutralizing concentration of antibodies induced maturation of 
the cells and cytokine production in a FcRyIIa-dependent manner. Immune complexes at non-neutralizing serum 
titers, however, were still infectious and led to partial DCs maturation and a distinct more pro-inflammatory 
cytokine response. Consequently, we propose that during homotypic re-infection, high antibody titers induce the 
induction of pro-inflammatory cytokines and the generation of DCs capable of initiation of adaptive responses. On 
the other hand, during heterotypic infection, in the presence of non-neutralizing cross-reactive antibodies, immDCs 
may acquire a phenotype that is impaired in their ability to initiate adaptive immunity. Subsequently, the pro-
inflammatory cytokines released by these cells may increase the number of circulating matDCs. These cells support 
ADE of infection and release highly infectious particles. Therefore, matDCs may contribute to the development of 
severe dengue. Does the presence of immune complexes that ligate FcyIIa on DCs lead to the development of an 
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effective antiviral immune response that contributes to disease containment?  If so, we could use this knowledge for 
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